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Abstract
This thesis describes the successful isolation and characterisation of novel phages with
applications in the medical/veterinary sector and also in the food and beverage industry.
This thesis begins with a comprehensive literature review on the biocontrol applications
of phages which will appear as a book chapter in “Phage therapy; Current research and
applications” edited by Andrzej Gorski in the Hirszfeld Institute of Immunology and
Experimental therapy, Wroclaw, Poland.
Chapters 2 to 5 encompass the technical part of the thesis work, which begins with the
isolation and characterization of phages of Lactobacillus and Pediococcus which cause
spoilage in the brewing industry'. Genome sequencing of one of these phages revealed its
unique nature and unusual genome organisation. This Pediococcus phage, clPl had no
close homologues in the genomic databases. Its closest relative was a Lactobacillus
plantarum phage, OJL-1, which showed some homology in 22 ORFs.
The second part of the technical work investigated phage K resistance mechanisms in
the medically important pathogen S. aureus, and on this basis led to the devclopiuent of
modified derivatives of this phage with broader host ranges. Combination of six of these
modified derivatives into a phage mixture with the parent phage K resulted in the
generation of a potent anti- staphylococcal cocktail for biocontrol applications.
Subsequently, this phage mixture was exploited for the successful prevention of S.
aureus biofilms and also removal of established biofilm biomass. In addition,
inflammatory immune response assays using primary human umbilical vascular
endothelial cells (HUVECs) indicated that stimulation of these cells with phage K did
not induce expression of adhesion molecules, transcriptional activators, or cytokines
suggesting a lack of an immune response to phage K in these cells.
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Chapter 1
Literature Review
Overview of therapeutic applications of bacteriophages

Phage therapy: Current research and applications. Caister Academic
Press, NorfoIk, UK. (2011). In Press.

Abstract
This chapter will give an overview of the different applieations of bacteriophages (phages).
These include the use of whole virulent phages as antibacterials, recent advances in the
development and applications of genetically modified phages, the use of phages as delivery
vehicles and vaccines, and recent developments in the study and use of purified endolysins.
Generally, it is clear that phages have a considerable array of potential applications as
therapeutics in the modern medical and veterinary fields. In particular, the continued antibiotic
resistance problem in clinically relevant micro-organisms calls for the exploitation of cheap,
natural, readily-available, safe and efficient therapeutic agents. Phages exhibit characteristics
which satisfy all of these criteria and their reintroduction as medical treatment options is worthy
of strong consideration.

The use of unmodified lytic phages
Introduction
Phages are viruses which are specifically parasitic to bacteria and do not infect eukaryotic or
mammalian cells. The specificity of phages is usually limited to the species or sometimes even
the strain level of their host bacteria. They utilize the metabolic resources of the bacterial cell for
their own replication. Phages are considered ubiquitous, infecting more than 150 bacterial genera
(Ackermann 2007), and are estimated to be ten times more numerous than bacteria in the
environment, making them the most abundant biological life forms known, with a reported 10^'
phage particles on the planet (Hanlon 2007). Phages are generally found wherever their host
bacteria reside and they have constantly co-evolved with bacteria over billions of years.
Compared with higher organisms, they are both structurally and genetically simple, consisting of
either DNA or RNA as their genetic material, which is encapsulated by a protein coat. More than
90% of phages examined by electron microscopy (HM) are of the order Caudovirales, consisting
of tails of varying lengths and double-stranded DNA genomes within icosahedral heads
(Ackermann 2001; 2007). These arc classified into three major families based on morphological
features, the Myoviridae (long, rigid, contractile tails), the Podoviridae (short, non-contractile
tails) and the Siphoviridae (long, flexibile, non-contractile tails). There is considerable variation
in genetic material and morphology of the remaining phage families (Ackermann 2001; 2007;
Matsuzaki et ai, 2005; Bcrgh et al., 1989; Whitman et al, 1998; Brussow and Kutter 2005;
Hanlon 2007; Pal et al., 2007; Monk et ai, 2010).

The discovery of phages came about around twenty years before penicillin, the first antibiotic,
was used for practical applications. This discovery is attributed to two scientists, Frederick Twort
(1915) and Felix d’Herelle (1917), with the latter credited as the one to have thoroughly
investigated, recognized and named them. However antibacterial activity, thought now to be
associated with bacteriophages, had also been recognized by Ilankin and Gamaleya (Fig. 1) as
far back as 1896 and 1898 respectively (Sulakvelidze et al, 2001). D’Herelle worked and
published extensively on phage after their discovery and helped in the establishment of the
International Bacteriophage Institute in Tbilisi, Georgia in 1923 (Summers 1999; Sulakvelidze et
al., 2001). Several reviews describe the history of phage therapy, including early uses for human
applications (Summers 1999; 2001; Sulakvelidze and Kutter 2005; Dublanchet and Bourne
2007; and O’Flaherty et al., 2009). In addition, a review of former USSR research on the use of
phages in medical trials in infants and adults has been translated into English and published in a
monograph by the Elivia Institute (Chanishvili, 2009). Results of many of the earlier phage
therapy experiments were inconsistent, with reports of both success and failure. Failures were
generally attributed to several factors including (1) a poor understanding of general phage
biology, (2) poor quality experimental techniques (3) low quality phage preparations and (4) a
lack of understanding of the illnesses being treated. The emergence of the antibiotic era in the
1940’s led to a decline in the use of phages in the West. However in the former Soviet Union,
significant use of phages either as stand-alone treatments, or in combination with antibiotics
continued (Sulakvelidze et al., 2001). The history of phage therapy in the West has been viewed
as composing four periods (1) early enthusiasm (2) crucial scepticism (3) abandonment and (4)
recent interest and reappraisal (Summers 2001). This recent reappraisal of phages as viable
options in treating bacterial infections has no doubt arisen due to the widespread problem of

antibiotic resistance among several bacterial pathogens. A recent review lists a plethora of
bacterial pathogens amongst which antibiotic resistance has become common (O’Flaherty et al,
2009). The emergence of pathogenic bacteria which are resistant to the majority of currently
available antimicrobial therapies, along with the increase in numbers of immunosuppressed
hospital patients has become a major problem in the modem medical world (Abhlilash et al,
2009). In recent years, pharmaceutical companies have been investing less in the discovery and
development of novel antibiotics, due to poor investment returns (Projan and Shales, 2004;
NoiTby et al, 2005). This trend of increasing antibiotic resistance, combined with the financial
burden on health systems has led to a renewed interest in the use of alternative antibacterial
agents, including phages (Shasha et al, 2004; Gorski et al, 2009).

Phage therapy and unmodified lytic phages
The aforementioned ability of phages to infect a specific bacterial culture, replicate exponentially
within the culture, and ultimately kill them, is the cornerstone of their use as antibacterial agents
for phage therapy. Phage therapy itself can be described as the application of phages to control or
eliminate bacterial infections and it is a very promising means of complementing the use of
chemical antibiotics to treat infections, particularly where antibiotic resistance is prevalent
(Abedon, 2010). A critical step in phage therapy is the choice of phage and this requires
knowledge of the life cycles of phages whether virulent or temperate (Kropinski 2006; Hanlon
2007). The latter persist as prophages, quiescent in the host and only replicate along with the host
genome. These are poor candidates for phage therapy and are usually avoided for a number of
reasons: (1) They do not kill 100% of the bacteria which they infect; (2) They may harbor genes
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that render the bacterium more virulent, a process known as lysogenic conversion; (3) The
establishment of lysogeny leads to super-infection immunity, where the lysogen becomes
impervious to infection by the same or related phages; (4) Temperate phages may also carry out
generalized transduction, and this may increase the disease-causing ability of host bacteria
(Kropinski 2006; Deresinski 2009; Gill and Hyman 2010). Virulent phages on the other hand
directly exploit the bacterial cell’s replication machinery, and having replicated and assembled
into complete virions, cause lysis and cell death of the bacterium, with concomitant release of
10-100 progeny phage, which subsequently go on to infect additional bacteria. These
characteristics of lytic phages, (1) their target specificity, (2) their rapid lysis and killing of
bacterial hosts independent of their antibiotic resistance profile, and (3) their ability to amplify at
the site of the bacterial infection make them good candidates as therapeutic agents for treatment
of bacterial infections.
The development of an effective phage therapy protocol is a multistep process, namely (1) phage
isolation against the target bacterial strain; (2) activity testing against this strain and also against
other related strains; (3) screening for negative traits such as the ability to enhance bacterial
virulence; (4) propagation and growth to high titres; (5) removal of any bacterial toxins present
in phage lysates by purification, (6) stabilization of phages for storage, (7) efficient delivery of
viable phages to target bacteria in the site of infection. Once phages have been delivered it is
then desirable that they will sur\dve, adsorb to and kill bacteria, while not significantly
stimulating an immune response from the organism to which it was delivered (Abedon 2010). It
is generally agreed that all newly isolated phages which are to be used for therapy should be
characterized in detail prior to use and this should include: genome sequencing, structural
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studies, and bioinformatic analysis. The phages should also be put through a proof of application
process for their intended use (Carlton et al., 2005).
In addition to developing the above protocol and defining desirable phage characteristics, the
choice of phage strain and the methods of phage preparation and purification are also an
important consideration for the success of phage therapy trials. The requirements for isolation,
preparation and purification of phages to maximize their therapeutic potential has been reviewed
recently by Gill and Hyman (2010).
After taking the above into consideration, it is still necessaiy' to outline the prerequisites which
must be met before phage therapy itself is initiated: (1) the biology of the therapeutic phage(s)
must be well understood as phage-host systems tend to be extremely complicated; (2) therapeutic
phage preparations should comply to all safety requirements, and be free of bacteria and their
toxic components; (3) phage preparations should contain infective particles; (4) the phage
receptor should be known; (5) the efficacy of phage therapy should be tested in an animal model
of infection as each phage may behave differently in vivo compared to in vitro (Levin and Bull,
2004).

Another critical step is the choice of route of administration of therapeutic phage to the patient.
There are many potential routes including oral, rectal, parenteral, intra-pleural, bladder irrigation,
and topical. Topical administration to wounds in chronic infections is the most commonly used
route and by this route phages can be administered by sprays, aerosols, lozenges, mouthwash,
suppositories, bandages, eye drops and tampons (Deresinski 2009). Since phages are considered
self-replicating particles, administration of phages to the systemic circulation therefore not only
involves a choice of many modes of administration, but also necessitates knowledge of the
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pharmacokinetics and pharmacodynamics of each phage and these are considered to be complex
due to the fact that both phage and bacterium are replicating at the site of infection, while the
latter are also undergoing lysis (Cairns and Payne 2008). Pharmacokinetics can be described as
the impact of a body on a specific drug, while pharmacodynamics is a description of a drugs
impact on a body (Abedon and Thomas-Abedon 2010). It is clear therefore that while phage
therapy is a two- step process, involving phage penetration to reach their target bacteria,
followed by bacterial cell killing, that analysis of both steps also needs to take into account
phage environmental interactions. This indicates that the interactions between phages and body
tissues, as well as between phages and their target bacteria need to be considered during phage
therapy treatments (Abedon and Thomas-Abedon, 2010). It is noteworthy that endogenous
phages already present in the human body may play a crucial role in the pathology and
physiology of the body system (Gorski and Weber-Dabrowska 2005; Gorski et ai, 2006; Letarov
and Kulikov 2009; Kurzepa et al 2009). fhese studies suggest that endogenous phages may
undergo translocation through the gut wall and play an important role in eliminating bacteria,
regulating the body ecosystem, and stimulating the immune system, in the process helping to
control local inflammatory and autoimmune reactions (Gorski and Weber-Dabrowska 2005;
Gorski et al., 2006; Letarov and Kulikov 2009; Kurzepa et al 2009). The significance of these
interactions may be crucial for the further development of phage therapy, as increased
knowledge of human-phage associated interactions may lead to fewer restrictions and obstacles
in initiating phage therapy treatments. Indeed, the finite amount of data published on these
interactions to date, coupled with the increasing significance of phages in modem contemporary
medicine is a problem which needs to be addressed. Despite these studies it is thought that the
process of phage therapy may be improved through a more detailed understanding of its
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pharmacodynamics and pharmacokinetics. Basically a drug’s pharmacodynamics lead to two
important concerns, its therapeutic effects versus its toxic effects along with associated dosing
considerations. For phages, which can be considered self-amplifying drugs, proper dosing by
clinicians and doctors may be less crucial than for other administered drugs since the phage itself
is responsible for multiplying and attaining therapeutic levels at the site of infection. As a
consequence of this, it may be quite safe to apply high litres of phage with no significant side
effects. Phage therapy may indeed be successful due to two key phage properties, their selfamplification and their safety, which suggest that there may be less reason for concern about the
pharmacodynamics. Phages undergo degradation by the immune system and due to their DNA
and protein composition this does not result in the release of toxic byproducts, unlike the
metabolic decay of many other drugs. Phages do not bind to or manipulate body tissues; the
human body is routinely exposed to phages and hence therapeutic application of phages is not an
entirely foreign experience for the body. The ability of phages to multiply in situ in addition to
the possibility of applying them at high litre is an important aspect of phage therapy as achieving
o

bacterial lysis and death in the scale required often requires high litres of phages (> 10 PFU/ml),
which would not be feasible with many other antimicrobial agents. It may be suggested therefore
that some phage therapy failures, both past and present may be considered pharmacodynamic
failures, resulting from the supply of insufficient phages to the site of infection to cause effective
bacterial killing (Gorski and Weber-Dabrowska 2005; Waldor et ai, 2005; Merril 2008; Abedon
and Thomas-Abedon 2010; Gill and Hyman 2010). Pharmacokinetics of phages must also be
taken into account, and it has been noted that the in vitro growth data for any given phage cannot
be applied to the in vivo situation, while likewise the in vivo data for any one phage cannot be
considered as standard for another phage. Hence the therapeutic use of phages as drugs tends to
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differ significantly from pharmaceuticals due to the pharmacokinetic differences (Payne and
Jansen 2003). These authors reported that the critical parameters affecting phage therapy in this
context are: initial phage dose, phage adsorption rate, burst size, latent period, densitydependant thresholds and associated critical times, and phage clearance from body fluids by the
reticuloendothelial system (Payne and Jansen, 2001). Phages thus can be considered a unique
medicine, which challenge current pharmacokinetic concepts. In the absence of target bacteria,
phages are quickly diluted, minimizing adverse effects, while in the presence of the target
pathogen, they represent a biologically amplifiable drug. When the host bacterial population is
exhausted, the phages are quickly eliminated from the body. Overall a better understanding of
phage therapy pharmacodynamics and pharmacokinetics will likely lead to improvements and
innovative phage therapy protocols, and also it may be possible, using relatively basic
mathematical tools, to estimate phage densities which may be appropriate for both in vitro and in
vivo bacterial killing. This may see a decrease in phage therapy failures due to protocols
attempted w ithout prior knowledge of phage killing potential (Abedon and Thomas-Abedon,
2010). In general, like any medical treatment option, phage therapy has its perceived advantages
and disadvantages and these can be summarized in Table 1 (Loc-Carrillo and Abedon, 2010).
These also need to be taken into consideration before the initiation of any phage therapy
treatments.
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Use of virulent phages as antimicrobial agents in humans
Several reviews published over the last decade in the Soviet Union and Poland have documented
work on the application of lytic phage therapy in humans (Carlton 1999; Weber-Dabrowska et
al, 2000; Chanishvili et al, 2001; Sulakvelidze and Morris 2001; Summers 2001). In addition to
the above reviews, the most prominent and comprehensive research in recent years has been
carried out and also reviewed by the polish group of Gorksi and Weber-Dabrowska at the
Institute of Immunology and Experimental Therapy in Wroclaw, Poland (Slopek et al, 1983,
1987; Weber-Dabrowska et al., 2000; Gorski et al., 2007; Fortuna et al., 2008) and also by the
phage group at the Bacteriophage Institute in Tbilisi, Georgia (Chanishvili et al., 2001). Today
phage therapy is considered to be an experimental treatment in Poland, and it is administered to
patients in whom antibiotic therapy has generally failed (Gorksi et al., 2007). The average
success rate of phage therapy has been reported to be 85% and even though these trials were not
set up to be randomized clinical trials, they still clearly indicate a high capability of phage
therapy to eliminate bacterial infections in cases where antibiotic treatment was not effective.
This work details the use of phages against several pathogens including Staphylococcus,
Klebsiella, E. coli, Proteus, and Pseudomonas, and in the treatment of illnesses such as
osteomyelitis, prosthetic joint infections, lower respiratory tract infections, skin and soft tissue
infections, and significantly the Polish Institute was the first Institute to use phage lysates for the
treatment of chronic bacterial prostatitis where other treatments had failed (Gorski et al., 2009;
Letwkiewicz et al. 2009, 2010).
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Other notable work was carried out in the former Soviet Union at the Eliava Institute for
Bacteriophage, Microbiology and Virology in Tbilisi, Georgia (Chanishvili at el., 2001;
Sulakvelidze and Kutter 2005). Phages were mass produced at the Eliava Institute and used for
therapy throughout the entire former Soviet Union. Recent screening at the institute was
undertaken for phages against antibiotic resistant bacteria including methicillin resistant S.
aureus (MRSA) and vancomycin resistant Enterococcus (VRE) (Chanishvili at el., 2001). Phage
therapy experience itself at the Eliava Institute was recently published as a short communication
(Kutateladze and Adamia 2008), and describes a brief history of the institute, and examples of
preparations used there, of which the most prominent are Pyophage: a cocktail of five phages
against purulent septic infections, Intestiphage; a phage preparation used against pathogens
which cause intestinal problems, staphylococcal bacteriophage: used against various
staphylococcal infections, and Phage Bioderm- a biodegradable, non-toxic polymer impregnated
with pyophage and different phage components for treatment of P. aeruginosa, S. aureus and
Streptococcus wound infections. A review by Kutter et al. (2010) focuses on lessons learned
from the experience of practitioners which was obtained from both personal communications and
publications. Discussion of therapeutic phage use in Georgia focused on two main areas of
application: the use of phages for the treatment of wounds and surgical infections, and their use
in the treatment and prophylaxis of enteric infections. The authors also discussed specific phage
therapy approaches which are applied at the Hirszfeld Institute in Poland, and concluded that the
results reviewed are highly suggestive that the Institutes approach to phage therapy has the
potential for substantial efficacy, although the protocols employed would require rigorous double
blind clinical testing (Kutter et al., 2010).
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However despite these strongholds of phage therapy practice in Eastern Europe, little work on
phage therapy has been undertaken in the Western world, and commercial phage preparations
had not been available since the early phage products of companies like Eli Eilly and L’Oreal
went into decline after the advent of antibiotics. A number of trials have been carried out in the
west by commercial phage companies as discussed later. Indeed several companies are now
active in the commercialization of phage products as the interest in phage as an alternative
therapy gathers pace in other countries including the LIK, Canada, The Netherlands, India, USA,
Portugal, Israel, and Australia (Ilousby and Mann 2009; Monk et ai, 2010). These companies
utilize phage technologies ranging from whole phage to phage DNA and peptides, and have
identified the large niche markets for antibacterial products against the common antibiotic
resistant infectious bacteria. Two companies, Novolytics limited (UK), and Phico therapeutics
(UK) (Eairhead, 2009), are at the stage of clinical trials, with Phico therapeutics now engaged in
phase II trials. Phage nasal decolonization

Staphylococcus aureus is an area which is currently

under investigation and the fact that a product for this type of medical problem would not require
intravenous use will potentially get products to market far more quickly due to there being fewer
regulatory hurdles to overcome (Eairhead 2009; Ilousby and Mann 2009).
Human safety trials have been carried out with increasing frequency in recent times including the
administration of coliphage T4 to patients (Bruttin and Brussow 2005) and those with Staphage
lysate (Delmont Laboratories in the USA) which was administered to human volunteers by a
variety of routes. Results indicate that in over 12 years of use in humans, only minor side effects
have been noted (Sulakvelidze and Barrow 2005). An FDA- approved phase I physician-led trial
has also been carried out at a wound centre in Lubbock, Texas using a mixture of phages
targeting P. aeruginosa, S. aureus, and E. coli, and no ill effects were noted (Rhoads et ai.
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2009). A laboratory based quality control experiment with phages prepared at the Eliava Institute
has been conducted at the Queen Astrid Military Hospital in Brussels, Belgium. This study
confirmed the absence of temperate phages and also determined the stability, pyrogenicity,
cytotoxicity and sterility of the phages (Merabishvili et al, 2009). The phage mixture was
evaluated by all stringent safety measures and it was also evaluated for therapeutics in that it was
applied topically to bum wounds of eight patients. No adverse reactions were reported and the
experiment was seen as an important step in the promotion of phage treatment in Western
Europe, at the same time creating a discussion platfonn for a regulatory framework for the
approval of phage therapy. Other notable trials carried out in the west include a clinical trial of
topical administration of two phages for the treatment of nasal carriage of MRS A by Novolytics,
and also a trial by Intralytix with WPP-2()1, a topical preparation of eight lytic phages against P.
aeruginosa, S. aureus and E. coli, for treatment of patients with leg ulcers, and also an antistaphylococcal phage lysate, Stafal which is registered for the treatment of staphylococcal
infections by topical application in the Czech Republic and Slovakia. The latter product could be
used for the elimination of skin infections, as well as in potential reservoirs of infection such as
the nasal passage and the intestinal and urinary tracts. It may also be used as a preventive agent
to prevent pyogenic infections in operation wounds. These have been reviewed by Gorski el al
(2009). In the UK, Wright et al (2009) described a fully regulated, placebo controlled, double
blind, randomized phase II clinical trial of the efficacy of a bacteriophage therapeutic against
chronic otitis involving the private company Biocontrol Limited in 2009. This study involved a
series of clinical trials with 24 volunteer patients suffering from the infection, and several
outcomes were noted: phages were not present in the organism after elimination of the target
bacteria, the phage therapy only required the administration of a single dose to be effective, and
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the phage effects lasted several weeks. In three previously untreatable cases, phage treatment
resulted in a complete cure (Wright et al., 2009). Human clinical trials with phages have also
been initiated by various phage companies in the treatment of leg ulcers, bum wounds, and ear
infections (Fortuna et al, 2008). Borysowski and Gorski (2008) summarized four clinical trials
which were carried out to evaluate the therapeutic efficacy of phage therapy in
immunocompromised patients suffering from cancer, leukemia and chronic urinary tract
infections. It is also worth noting that a large phase 1 and II trial of 450 patients evaluating the
efficacy of multiple phage products against diarrhea caused by E. coli is currently being carried
out in Bangladesh by Nestle (Monk et al, 2010). It is clear from the above that phage products
against human infections are now being taken through fully regulated human trials. Rigorous
assessments of safety and efficacy are being included. The majority of the activity involves small
companies established over the last twenty years and the area is set to grow in the future (ilousby
and Mann 2009; Loc Carrillo and Abedon 2010; Monk et al, 2010; Pirnay et al, 2010).

The use ofphages as antibacterial agents in animal models of human infection
Before any new potential drug or antimicrobial agent is considered for use as a human
therapeutic, its efficacy and safety are generally evaluated in animal models of infection and this
has certainly been the case with phages as antimicrobials, where numerous studies have focused
on animal models of infection. Interestingly, in the past, several studies were carried out in
an:mals which indicated that phage can appear in the urine after administration. One study
reported that phages could accumulate in dog kidneys after intravenous administration (Keller
and Zatzman, 1959). In a more detailed study, published six years later, it was reported that
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phages were detectable in the urine of mice and rats when serum levels exceeded 10^ PFU/ml.
I'his work also found that urine analysis did not show any changes, while no detrimental
histological changes were seen in the urinary tract. Also, phage activity was not compromised in
urine (Schultz and Neva 1965). A similar study in sharks, demonstrated that phages were
detected in the kidneys for as long as 1 month after administration (Russell et ai, 1976). Early
phage studies in animals also gave an indication of the effectiveness of different routes of
administration. Rectal administration in rabbits and mice resulted in penetration through the wall
of the intestine to the circulatory system within a few minutes (Hoffmann 1965; Sechter et al,
1989). Hoffmann’s study also found that the blood phage level was as much as two orders of
magnitude higher by rectal administration than by oral feeding possibly due to the lack of
inactivation of phage particles by gastric juice (Hoffmann 1965). More recently, it has been
reported that E. coli phage T4 and phages of enterococci are capable of penetrating rat prostate
tissue after administration (Miedzybrodzki et al., 2008). Data also indicates that therapeutic
phages could be isolated from rodent prostate tissue and urine after rectal application
(Letkiewicz et al., 2010). Although one study in 1928 showed the presence of phages in the urine
of human patients with urinary tract infections (Caldwell 1928), other early data on humans is
scarce, and hence the previously mentioned animal studies were likely to have been important in
encouraging the persistence of researchers with phage in vivo studies and the development of
phage therapy itself. Soothill (1992) highlighted the use of phages for the elimination of
Acinetobacter, Pseudomonas and S. aureus infections in murine models of infection and
concluded that phages could be useful in the treatment of antibiotic resistant human infections.
Recently, O Flaherty et al. (2009) reviewed the in vivo and in situ studies carried out in animal
models of human infection. Animal models used included mice, rabbits, guinea pigs and
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hamsters, and phage efficacy against many significant human pathogens including E. coli,
Salmonella, Enterococcus, Pseudomonas, S. aureus, C. difficile, Klebsiella, and Vibrio was
discussed (O Flaherty et al, 2009). Several additional animal studies have been reported since
then. Antibiotic resistant S. aureus in particular is now considered one of the most common
causes of both community-acquired and nosocomial infections which are difficult to eliminate
(O’ Flaherty et al, 2005; Mann 2008). Capparelli et al. (2007) examined the potential use of the
phage

as a therapeutic agent against S. aureus, including methicillin resistant strains. In this

study the phage, when administered intraperitoneally (10^ PFU/ml), was shown to prevent
abscess formation and reduce the bacterial load and weight of abscesses in the flanks of mice.
Q

The phage rescued 97% of mice when they were inoculated with lethal (10 CFU/mouse) and
nonlethal (10^ CFU/mouse) doses of 5'. aureus. Also, interestingly, phage

delivered inside

macrophages was found to kill intracellular staphylococci, which are often protected from the
defences of the immune system (Capparelli et al.,20{)l). More recently Gupta and Prasad (2011)
showed that the broad host range phage P-27/HP protected mice from S. aureus bacteremia and
subsequent death when a single subcutaneous injection was given, llsieh et al. (2002) also
isolated a broad host range phage, Stau2, whose host range against S. aureus isolates was wider
than the well recognised polyvalent phage K (Kelly et al, 2011). This phage provided 100%
protection against lethal doses of 5. aureus strain S23 in mice (Flsieh et al, 2011). Elimination of
P. aeruginosa has also been evaluated in canine models by Marza et al. (2006), focusing on
chronic bacterial otitis. This infection had failed to be treated effectively by topical and systemic
administration of antibiotics, however inoculation of 4 x 10 PFU/ml of phage into the auditory
canal, resulted in a significant clinical improvement only 27 hours after the treatment was
initiated (Marza et al., 2006). Watanabe et al. (2007) examined the efficacy of phage therapy
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against gut derived sepsis caused by P. aeruginosa in a murine model. Oral administration of the
lytic phage KPPIO resulted in survival of almost 67% of mice, in comparison to a survival rate of
0% for a saline treated control group. The study provided a sound basis for the possible oral
treatment of gut derived sepsis (Watanabe et al, 2007). Interestingly, phage therapy has also
been used in Drosophila melanogaster to effectively eliminate infections caused by P.
aeruginosa. Phages MPKl and MPK6 were fed to the fruit flies, and both significantly delayed
the killing of Drosophila by the bacterium (Ileo et al., 2009). The phages used in this study also
protected mice from peritonitis sepsis induced by Pseudomonas, and phage treated mice had
lower bacterial numbers in the lungs, liver and spleen. The insect model of infection may
perhaps prove attractive to researchers not in favour of animal trials. Two recent studies report
the use of phages against Klebsiella pneumoniae, a major causative agent of nosocomial
infections, particularly in patients with burns. Malik and Chhibber (2007) examined the potential
use of the phage K01 against K. pneumoniae induced burn wound infection in mice. They found
that 100% of the animals survived when treated with phage alone, in comparison to 100%
mortality for the untreated animals. Analysis of bacterial titres in the blood, lungs and
peritoneum indicated a substantial decrease in all areas following phage administration. This
study also detennined that the intra-peritoneal route of phage administration was superior to the
subcutaneous route. Kumari et al. (2011) demonstrated the superiority of phage therapy over
silver nitrate and gentamicin in the treatment of bum wound infection by K. pneumoniae. One
single dose of phage Kpn5 applied topically eliminated the infection, while multiple applications
of silver nitrate and gentamicin were necessary. Hagens et al. (2006) investigated the use of
phage treatment to augment antibiotics. In this study the Pseudomonas phage Pfl, when used in
combination with low concentrations of gentamicin rescued mice from lethal P. aeruginosa
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infections. Interestingly, neither treatment when administered alone was capable of curing the
infection. In addition, P. aeruginosa K strains which harboured a plasmid-bome gentamicin
resistance gene could be re-sensitized to this antibiotic upon infection with phage Pfl. In another
recent study. Hung and colleagues (2011) showed that a very low dose of phage NK5 was
potentially an effective therapeutic agent for K. pneumonias induced liver infection in an intragastric murine infection model. Another recent mouse study reported successful phage therapy
against B. cenocepacia lung infection (Carmody et al., 2010). The authors demonstrated that
systemic administration of phages was more effective than administration by inhalation,
indicating that circulating phages can gain better access to bacteria in the lungs than phages
administered topically (Carmody et al., 2010). In a fresh appraisal of phage therapy, Cappareli et
al. (2010) carried out an important murine infection study which explored anti-phage antibodies
and the persistence of .S. enterica in the circulatory system. These authors found that the phageinduced antibodies were non-neutralizing, were active 2 weeks after experimental inoculation
into mice, and also that phage - resistant bacteria were avirulent and short lived in vivo and they
also made excellent vaccines (Capparelli et al., 2010).
Also, in the context of immunology, Merril et al. (1996) demonstrated that long circulating
phage mutants of^". coli phage lambda and S. typhimurium phage P22 could be isolated by a
serial passage technique. Subsequent experiments confirmed that a substitution of the amino acid
lysine for glutamic acid in the major phage capsid protein, was sufficient to confer a long
circulating phenotype on phage lambda mutants (Vitiello et al., 2005). While a considerable
body of evidence has been published on the safety and efficacy of phage therapy in
immunocompetent patients, data remains scarce with regard to its use in immunocompromised
patients. The group of Gorski has been active in addressing this knowledge deficit and recently
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published an article summarizing the findings of a range of experimental and clinical studies
which could be of relevance in the utilization of phage therapy in immunocompromised human
patients. In this article they investigated whether the immunostimulatory activity of some phages,
which enhances the use of phage therapy in immunocompetent individuals may be suppressed in
immunocompromised patients. They found that the direct killing of target bacteria by the phages
was the major mechanism by which the in vivo therapeutic effect was mediated and not by any
immune stimulated activity. In addition it was found that in immunosuppressed subjects, phage
clearance by the circulatory system may be slowed down, enhancing their survival, and
availability to host bacteria in the bloodstream for longer periods in these subjects (Borysowski
and Gorski, 2008). In other work by this group, the beneficial effect of prophylactic
administration of phages to .S', aureus infected immunosuppressed mice was also demonstrated.
Bacterial counts in the organs, as well as tumor necrosis factor and interleukin serum
concentrations were significantly lowered after phage application. This thus supports the
application of phage therapy for bacterial infections in immunocompromised patients (Zimecki
et al, 2009). These authors also found that in bone marrow transplant murine models, phage
treatment increased leukocyte and neutrophil content in the blood and myelocytic cell lineage in
the bone marrow, thus enhancing protective effects on many levels (Zimecki et al., 2010).
Animal models of infection are an essential prelude to phage clinical trials in human patients, as
they give an indication of the optimum conditions necessary to effect the maxium benefical
outcome.
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Phages for veterinary applications
In addition to the use of phages in animal models of human infections, phages have been widely
researched for veterinary applications. The important work of Smith and ff uggins at the Institute
for Animal Disease Research in Cambridgeshire in the 1980s may have been a catalyst for the
reinvestigation of phage therapy for medical treatments in general, including those for veterinary
applications (Smith and Muggins 1982, 1983; Smith et ai, 1987a, b). O’ Flaherty et al. (2009)
comprehensively reviewed the literature on the veterinary applications of phages against a range
of pathogens and in a range of animals. In addition to those discussed in that review, a number of
additional examples have been published in recent years involving E. coli, Salmonella,
Clostridium, and Campylobacter. Oliveira et al. (2009, 2010) investigated the effect of the mode
of administration of three phages (phi F78E, phi F258Ii, and phi F61F) on their dissemination in
chickens, and also the efficacy of a cocktail of these three phages in the control of colibacillosis
in poultry whether delivered orally or by aerosol. Subsequently, the authors found that the
success of phage treatment was dosage dependent, and indicated that 10*^ PFU/ml of phage phi
F78E was more effective than 10^ PFU/ml for elimination of infection (Oliveira et al., 2009).
They also indicated that a three phage cocktail was more effective than individual phages
(Oliveira et ai, 2010). In treating the same disease in poultry. Fluff and colleagues (2010)
investigated the effect of prior exposure to phages on the ability of that same phage to treat
chicken E. coli infection. The study found that mortality in untreated chickens was 55% and this
was reduced to 8% following phage treatment, but interestingly pretreatment by the same phage
reduced the efficacy of phage therapy in that mortality was 33%. The authors reported that serum
IgG levels against the phages were present at high levels when phage pretreatment was
employed. Thus, prior exposure to phage can limit the efficacy of phage therapy (Huff et al.
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2010). Control of E. coli 0157 carriage in beef cattle using phages has been exploited by a
number of authors (Rivas et al. 2010, Coffey et al, 2011). Recently, Rozema et al. (2009)
compared the efficacy of oral and rectal administration of anti-0157 phages and reported that the
latter gave rise to improved reduction of 0157 levels. Phages have also been employed to help
eliminate Salmonella in chickens (Andreatti et al, 2007; Borie et al., 2008; 2009). In all cases
phages were shown to be effective. An interesting study by Waseh et al. (2010) demonstrated
that truncated and functionally equivalent versions of phage P22 tailspike proteins (Tsp)
significantly reduced S. enterica colonization in the chicken gut. Significantly, they indicated
that the proteins were not degraded by chicken gastro-intestinal tluids. Campylobacter carnage
in chickens has also been an important focus for phage therapy research as reviewed by
O’Flaherty et al. (2009). More recently Carvalho et al. (2010) investigated phage administration
in feed and oral gavage and found that the former gave a more sustainable reduction in
Campylobacter numbers. Miller et al. (2010) utilized a phage cocktail for treatment of Necrotic
enteritis (NF7) caused by C. perfringens in broiler chickens and found that administration via feed
or drinking water was effective in the control of this pathogen. The company Biocontrol Ltd
(UK) has been active in the therapeutic treatment of Pseudomonas aeruginosa otitis infections in
humans and animals, and recently carried out the first animal phage clinical trial (Soothill et al.,
2004; Hawkins et al., 2010). Phage therapy was also investigated for use as a low environmental
impact option to treat and inactivate bacteria in fish farming plants (Almeida et al. 2009). These
authors reported success with phages against L. garvieae, P. plecoglossicida, V. harveyi, and A.
salmonicida. Johnson et al. (2008) discussed the literature on the use of phages for both
prophylaxis and therapy in cattle, pigs and poultry. These authors indicated that the most
promising animal health applications of phage therapy are for acute intestinal, systemic and
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respiratory infections of the above animals. They also suggested that phage therapy for animal
diseases needs to be developed further, although its progression may be held back by improved
management practices, vaccines, and prophylactic use of various antimicrobial drugs. However
they also stressed that the limitations of phage therapy itself must be considered, and these
included knowledge of the epidemiology of the disease agent, the efficacy of phages in fluid as
opposed to other matrices, and the timing and mode of administration. In general these authors
postulate that if phage therapy is to realize its potential, it may depend on its complementarity
with other treatment approaches (Johnson et ai, 2008).

The use ofphases in the treatment of hiofilms
Biofilms are agglomerations of bacterial cells and their excreted products attached to both living
and inert surfaces. Secreted products include exopolysaccharidc (KPS), enzymes, bacteriocins,
low molecular mass solutes and nucleic acid. Several bacteria have been implemented in biofllm
formation including staphylococci, enterococci, E. coli, Proteus, klebsiellae, streptococci,
pseudomonads, and acinetobacters (Donlan 2009). Many of these are associated with a range of
pathologies in humans including bum infections, chronic otitis media, chronic bacterial
prostatitis, periodontitis, respiratory infections, urinary tract infections, and endocarditis.
Biofilms can also be formed on indwelling and subcutaneous medical implants such as
pacemakers, heart valves, catheters, grafts and stents, and joint prostheses which may lead to
persistent infections (Costerton et al, 1999; Davey and O’Toole 2000). The multi-species nature
of natural biofilms makes their elimination difficult. Interestingly, some phages have been shown
to produce enzymes which can degrade the EPS matrix of a biofllm (Hughes et al, 1998; flanlon
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et al, 2001). Sutherland et al. (2004), Azeredo and Sutherland (2008), and Donlan (2009)
reviewed a range of studies, each of which illustrated the successful removal of biofilms with
phages. The applications of phages vary among studies, for example Curtin and Donelan (2006)
used pre-treatement with phages to eliminate S. epidermidis from a hydrogel-coated cathether
whereas Carson et al. (2010) successfully used phages to remove established biofilms of P.
mirabilis and E. call from indwelling urological devices and urinary tract catheters. Goldman et
al. (2009) suggested that a combination of several phage types may be used to prevent adhesion
and biofilm formation and successfuly utilized phages to control biofilm fouling of ultrafiltration
membranes resulting in significantly improved membrane permeability of effluent treatments.
Other authors have also used phage mixtures for biofilm treatment. A cocktail composed of five
P.seudomonas phages was used to pretreat catheters prior to inoculation with biofilm forming P.
aerugino.sa strains. In this case biofilm density was significantly reduced. Phage treatment post
inoculation was also successful in reducing biofilm counts, although supplemental inoculation
was required to address biofilm regrowth. This study also demonstrated that fewer resistant cells
were isolated when treated with this phage cocktail than when treated with an individual
Pseudomonas phage (M4) (Fu et al., 2010). Lu and Collins (2007) designed an enzymatic phage
T7 derivative, which expressed Dispersin B, a polysaccharide degrading enzyme. This
engineered phage was subsequently found to have a biofilm dispersing ability two orders of
magnitude higher than that of the non-engineered phage and it reduced E. coli biofilm counts by
over 99%. Another adaptation is the combination of phage endolysin with whole phages for
removal of biofilm-forming S. aureus strains (Son et al, 2010). The above selection of studies
provide clear evidence for the potential of phages in the removal of problematic biofilms, and
also emphasize the need for continued research into the improvement of this application.
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Additional applications ofphages

In addition to the above, phages have also been used for the control of disease-causing
phytobacteria, as reviewed by Balogh et al. (2010). Withey et al. (2005) discussed the use of
phages for improvement of the quality of effluent in wastewater treatment processes and
Cherwonogrodzky (2005) has reviewed their possible role in defence against biothreats. Hagens
and Loessner (2007; 2010) have described the application of phages for both the detection and
control of pathogens in food systems, a topic which was also reviewed by the European Food
Safety Authority (Anonymous 2009), Coffey et al. (2010), and Mahony et al. (2010).
Interestingly, recent observations by Budynek et al. (2010) and Dabrowska et al. (2010) suggest
that phages can mediate changes in a tumour microenvironment making it more suitable for anti
cancer treatment. These authors discuss the innucnce of phages on cancer processes, which may
have implications for phage therapy in cancer patients. Miedzybrodzki et al. (2005) explored
three mechanisms whereby phages could be exploited to inhibit human virus infections. These
were (1) interferon induction by phage nucleic acid causing prevention of pathogenic virus
infection (2) direct competition of phages and viruses for cellular receptors; and (3) phagemediated display or induction of antibodies, which may have subsequent antiviral action. These
authors postulated that these antiviral applications may be a cost-effective alternative to
conventional antiviral drugs. Phage genome analysis has also been exploited with the aim of
discovering novel antimicrobial agents (Liu et al., 2004). In this study several S. aureus phages
were sequenced and phage proteins that inhibited cellular growth upon expression in S. aureus
host cells were identified. Cellular targets for many of these proteins were subsequently
identified in these bacteria, and were shown to be essential components of host DNA replication
and transcription machineries. Interaction between a phage protein and a putative helicase loader
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was then used to screen for inhibitory molecules, and several were identified which inhibited
bacterial growth and DNA synthesis. This suggested that mimicking the inhibitory effect of
phage polypeptides on bacterial growth by chemical compounds may yield novel antimicrobials
to combat disease causing pathogens.

The therapeutic use of phage lysins
The work cited above concentrates on the use of whole phages as antibacterial agents. Recent
research on phage genomes has increased our knowledge of the mechanisms by which phages
infect host cells and carry out their own replication, and has created opportunities to scan the
genomes of therapeutic phages for possible novel antibacterials. The best example of such work
is the utilization of the lytic enzymes of phages, which mediate bacterial cell death. These
enzymes, also known as virolysins, endolysins, or simply lysins, have been extensively evaluated
for therapeutic applications since the first in vivo trial in 2001 (Nelson et al., 2001). The progress
in the area has been evaluated recently by Fischetti (2010) and also in more detail elsewhere in
this publication.
Lysins are peptidoglycan hydrolases encoded by double stranded DNA phages and are expressed
at the end of the phage lytic cycle, facilitating host cell lysis and phage progeny release (Young
et ai, 2000). The name endolysin was first used by Jacob and Fuerst (1958) to designate a lytic
substance of protein origin, which was produced in bacterial cells during phage multiplication,
and which acted on the cell wall internally (Jacob and Fuerst 1958). The first lysins however
were only reported to be active against dead cells (Ralston et al. 1955), and it was not until the
1970s that a lysin (PAL) active against both live and dead S. aureus cells was identified
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(Sonstein et al, 1971). This early work stimulated the identification of lysins from phages of
Staphylococcus, Bacillus, Listeria and Clostridium in the 1990s, and in turn encouraged the
recent surge of interest in these naturally occurring phage enzymes as therapeutic agents
(Courchesne et al, 2009, Fenton et al, 2010a, Fischetti, 2010).
Today we know that lysins generally display a dual domain modular structure consisting of an
N-terminal catalytic domain and a C-terminal cell wall binding domain (Perez-Dorado et al.
2007; Fischetti, 2010). The N- terminal domain encompasses the catalytic activity of the enzyme,
which can be categorized into four types, depending on the cleavage site m the host
peptidoglycan (Fenton et al., 2010a). The C-terminal domain on the other hand is responsible for
non-covalently attaching the lysin to a specific moiety in the bacterial cell wall, which is usually
carbohydrate in nature (Loessner et al., 2002). Lysins accumulate in phage infected bacterial
cells during the latter stages of the phage lytic cycle and with the help of a phage-encoded holin
enzyme, which forms pores in the c>7oplasmic membrane, reach and digest the cell wall
peptidoglycan. This brings about release of progeny phages (Young and Blasi 1995; Wang et al.,
2000). Bacterial cells maintain a high internal pressure, which is maintained by the cross-linked
peptidoglycan cell wall. Disruption of this crosslinking by the lysin results in the leakage of the
cytoplasm of the cell and resulting hypotonic lysis and cell death (Perez-Dorado et al. 2007;
Fischetti 2010). Thus, while lysins require the help of the holin enzyme for their action on
peptidoglycan, they can also be applied exogenously to Gram-positive bacteria as recombinant
enzymes. In this approach termed “lysis from without”, the cytoplasmic membrane does not act
as a barrier (Loessner et al., 1995; Loessner 2005). It is important to note that this approach is
not as straightforward in Gram negative bacteria, given that they possess an outer membrane
which prevents access of exogenous lysin to the peptidoglycan. Nevertheless, for Gram-
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positives, lysins represent a viable Genus-specific antibacterial agent. Indeed the investigations
and studies conducted to date suggest that the advantages of the use of phage lysins for
therapeutic purposes far outweigh the disadvantages (Table 2).
Lysins possess several attributes as novel antibacterials. Nevertheless, several factors must be
taken into account if these enzymes are to realize their full potential; (1) Lysin preparations
should not pose a toxicity risk when used in animals or humans. To date the research reports
indicate that no toxicity or side effects have been observed in treatment of topical or systemic
infections in murine models (Loessner 2005, Fenton et al, 2010a). (2) Immunogenicity must be
considered, as lysins are capable of eliciting an immune response when administered mucosally
or systematically (Fischetti 2008). This could potentially be detrimental to their own activity.
Several in vitro and in vivo trials have been undertaken to investigate this and these generally
found that while lytic activity was diminished, it was not completely inhibited (Loeffler et al.,
2003; Fischetti 2005). Fischetti’s group have also shown that increased cytokine production in
lysin treatment of systemic infections can be reduced by administering regulated smaller doses of
enzyme (Entenza et al., 2005; Fischetti 2008). In addition, lysin can also be conjugated to
polyethylene glycol, reducing antibody binding and immunogenicity, and in the process
improving the enzymes pharmacokinetics, which could compensate for any slight reduction in
activity (Walsh et al., 2003). (3) Possible resistance to lysins must also be taken into account
when considering their potential therapeutic use. Since phages have evolved over millions of
years to utilize their lysins to kill their host bacteria, bacterial resistance to these enzymes is
improbable. Indeed research to date has indicated that the lysins have evolved to target specific
molecules in the peptidoglycan, which are essential for bacterial viability (Loessner 2005;
Fischetti 2008). An example of this is choline, which is essential for pneumococcal viability and
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which is the cell wall receptor for the pneumococcal lysin (Garcia et al, 1983; Lopez et ai,
2004). Other studies have shown that repeated exposure of B. cereus and S. pneumoniae to low
concentrations of lysin on both agar plates and in liquid culture did not give rise to resistant
mutants even after numerous challenges (Loeffler et al., 2001; Schuch et al., 2002). In addition,
a polysaccharide capsule of S. pneumoniae, which could potentially mask the peptidoglycan was
reported not to inhibit lysin activity (LoefQer et al., 2001; Schuch et al., 2002). In theory, the use
of lysins with two catalytic domains, each targeting different peptidoglycan bonds could
potentially act as a safe-guard against resistance to one enzymatic activity, if this arose (Fischetti
2008; Becker et al., 2008). (4) Lysins may be applied in synergy with other lysins or
conventional antibiotics; and this has been demonstrated in in vitro studies by several authors
(Jado et al., 2003; LoefOer and Fischetti 2003; Becker et al., 2008).
Most human infections begin at a mucous membrane site, either respiratory, intestinal, urogenital
or ocular (Fischetti 2010), and colonization in these areas is significant as it provides a potential
starting point for the establishment of infection. In addition the colonization acts as a reservoir,
which contributes to the spread of pathogenic bacteria within the community. These pathogenic
bacteria include staphylococci, streptococci, enterococci and pneumococci, of which many are
antibiotic resistant (Borysowski et ai, 2006; Fischetti 2010). Apart from polysporin and
mupirocin ointments, there are no approved antibacterial treatments for the control of mucous
membrane colonization by pathogenic bacteria and therefore lysins have increasingly been
investigated as potential agents for this purpose. Traditionally polysporin and mupirocin
ointments are applied prior to surgical interventions to reduce the incidence of nosocomial
infections, although several applications of these ointments may be necessary (Coates et al.,
2009). Several animal trials have revealed the ability of lysins to successfully prevent pathogenic
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colonization of mucosa (Nelson et ai, 2001; Loeffler et al, 2001; Locffler et al, 2003; Cheng et
c//.,2005; Entenza et al, 2005; McCullers et al, 2007; Fenton et al 2010b). A recent review from
our laboratory summarizes the effective use of lysins against a range of bacterial pathogens
including streptococci, S. aureus, enterococci, B. anthracis, and Clostridium (Fenton et al,
20i0a). In the context of dental earies, the use of lysins has also been explored by Yoshimura et
al. (2006) and Thanyasrisung et al. (2009) who demonstrated that N-acetyl-muraminidase
specific for S. sobrinus and S. mutans might be used to eliminate the causative agents of dental
caries and periodontal disease. This could be achieved by incorporation of the lysin into chewing
gum, mouthwash or dentifrice. Similarly a lysin eneoded by Actinomyces naeslundii phage Av-1
is capable of eliminating the causative agent of gingivitis and root surface caries (Courehesne et
al., 2009).
Fenton et al, (2010a) summarized the different lysins targeting pathogenic bacteria. In addition
to those, a number of additional lysin studies have appeared in the recent literature. Fischetti and
colleagues (Daniel et ai, 2010) construeted a chimeric lysin (ClyS) by fusing the N-tenninal
domain of the S. aureus phage Twort lysin with the C-terminal domain from a different S. aureus
phage lysin (phiNM3). This chimeric enzyme lysed all S. aureus regardless of antibiotic
resistance profile in vitro. In an in vivo murine study, it protected against MRSA induced septic
death when used in combination with oxacillin. Interestingly, the doses of ClyS and oxacillin,
which protected mice synergistically did not protect these mice when used alone (Daniel et al.,
2010). Subsequently, this chimeric lysin was formulated into an ointment and tested as a topical
skin decolonization treatment in a mouse model of infection. ClyS effected a greater log
reduction in S. aureus than the standard topical antibacterial agent mupirocin and in in-vitro tests
demonstrated a lower potential for the development of resistant bacteria than mupiroein (Pastagia

35

et al, 2011). The lysin LysGH15 was also recently investigated by Gu et al. (2011) and a single
intraperitoneal injection of lysin was sufficient to protect mice who had been administered
MRS A injections at double the lethal dose, highlighting that lysins can be effective therapeutics
even when administered at relatively low concentrations (Gu et al, 2011). In recent times
genetic screening strategies have also been increasingly used for the identification of novel
lysins. Fischetti and colleagues (Schuch et al, 2009) used this approach to successfully identify
the lysin PlyG from a B. anthracis phage. This method is technically applicable to the cloning,
expression, and analysis of lysins from any other phage. The group of Fischetti (Schmitz et al.,
2010) has also developed a two-step screening technique for the cloning of phage lysins from
uncultured viral DNA. When they applied this approach to a viral metagenomic library
constructed from animal faecal samples, 26 lysins were expressed and cloned. Interestingly these
included Gram positive-like enzymes. Gram negative-like enzymes and several additional
enzymes whose predicted structures were less similar to those from known phages. The genomes
of strains of C perfringens were also computationally screened for lysins and lysin like open
reading frames (ORFs) in resident prophages and several were identified. This study clearly
demonstrated that the field of genomics/metagenomics can serve as an abundant source of novel
lysins (Schmitz et al, 2011). It is also possible to engineer lysins with different combinations of
catalytic and binding domains, thus increasing their potential for application. O’Flaherty et al.
(2009) recently indicated the possibilities for engineering lysins and these can include (1) an
exchange of the binding and catal>^ic domains (2) construction of a chimeric lysin with two
distinct lytic activities and (3) construction of a chimeric lysin with two distinct genus
specificities. Indeed, in a recent study from our laboratory, it was shown that a truncated
derivative of the staphylococcal phage lysin (LysK) showed increased lytic activity against live
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S. aureus cells (Horgan et ai, 2009). This truncated derivative CHAPk was subsequently used
in murine decolonization trials (Fenton et al, 2010b).
In addition to their use for therapeutic purposes in animals and humans, lysins, like their parent
phages, also have many other potential uses including food safety, eontrol of phytopathogens,
veterinary applications and also as a diagnostic tool in pathogen detection. These applications
have been described in detail in Fenton et al. (2010a). More recent developments in the area
include exploring the possibility of using lysins as agents for the elimination of bacteria, which
have an outer membrane including mycobacteria and Gram-negative genera. Some lysins are
capable of killing Gram-negative bacteria by means of C-terminal membrane-active peptide
sequences (Borysowski et al., 2005). A recent patent termed Artilysin composes fusion proteins
composed of a cell wall degrading enzyme for Gram negative bacteria, and an additional peptide
stretch fused to the enzyme on the N or C-terminus. This invention also includes nucleic acid
molecules encoding the fusion protein, and veetors comprising these nucleic acids. Artilysin may
be used for treatment of Gram-negative infections, as a diagnostic means or cosmetic substance,
and also in the decontamination of work surfaces or devices in the food industry and medical
settings whieh are colonized by Gram- negative pathogens (Lavigne et al., 2010). Briers et al.
(2011) tested the combination ofP. aeruginosa endolysin EL 188 and several OM permeabilizing
compounds on P. aeruginosa strains and showed a 4-log reduction in the target bacterium.
Transgenic and cloning methods have also been exploited with eoliphage T4 lysin and phage
(pEalh lysin for the elimination of the Gram-negative plant pathogens Erwinia carotovora and
Erwinia amylovora from potatoes and pear surfaces respectively (During et al., 1993; Kim et al,
2004). The examples above suggest that the application of phage lysins need not be limited to
Gram-positive bacteria. The acid-fast Mycobacterium species present a similar problem for
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exogenous endolysins in that they must eircumvent a mycolic acid-rich outer membrane in order
to gain access to the peptidoglycan layer. Recent studies have shown that mycobacteriophages
encode a lipolytic enzyme (termed LysB) in addition to the cell-wall degrading lysin (Gill et al,
2008; 2010). A similar enzyme was also identified in other mycobacteriophage genomes
including Ardmore phage (Henry et al, 2010).

Genetically modified phages
In general, phage therapy exploits natural broad-host-range phages for the elimination of the
problematic bacteria. However another approach, which in recent times is becoming more
common, is the genetic manipulation of phages towards improved therapeutic characteristics
(Goodridge, 2010). There arc a number of approaches that can be used, and these are largely
based on events which can occur naturally in phage evolution. These include: (a) Broadening the
host range of therapeutic phages, which can be achieved by manipulations leading to novel or
multiple receptor recognition by phages, (b) Enabling phage to kill without bringing about cell
lysis and release of endotoxins. This involves using phages to deliver cither genes encoding
lethal agents or attaching lethal agents to the phage capsid, thereby presenting it to the cell, (c)
Temperate phages being genetically modified to render them exclusively lytic. This can be
achieved by inactivating genes involved in lysogeny, (d) Phages being modified to enable them
to survive longer in the mammalian circulatory system, a process which can be achieved by
altering amino acids in capsid proteins.
In the context of broadening the host range of individual phages, Morona and Henning (1984)
demonstrated that the T-even phage 0x2 can give rise to mutants with a broadened host range.
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These mutants were capable of using two bacterial receptors (OmpA and Ompc) rather than the
0x2 reeeptor used by the wild-type phage. Similarly, Moreno and Wandersman (1980) observed
that mutants of another T-even phage Tula recognized the receptors OmpC and LamB, while the
w ild-type phage employed the OmpF receptor for recognition. An interesting mechanism of host
range alteration has also been reported by Liu et al (2002), who reported that the Bordetella
phage BPP-1 could alter its tail fiber proteins using a reverse transcriptase enzyme. This resulted
in the display of different surfaee proteins depending on whether the phages were actively
infecting their host bacteria or surviving outside of their hosts. Tetart et al (1996) artificially
expanded the adsorption specificity of phage T4 by duplicating a segment of the tail fibre
adhesin gene, responsible for recognition of the bacterial surfaee receptor. This resulted in the
phage being able to adsorb to Yersinia in addition to E. coli / Shigella species.
Lethal agent delivery systems (LADS) utilize a recombinant phage expressing genes encoding
bactericidal agents to eliminate drug resistant bacteria. An example of this is the doc toxic
protein, which was derived from phage PL This was shown by Norris et al. (2000) to exhibit
bactericidal activity towards E. coli and bactericidal or bacteriostatic activity towards P.
aeruginosa, S. aureus, and E. faecalis. In another study, Westwater el al. (2003) developed
recombinant phages based on the Ml3 phagemid system and the post-segregational killing toxins
Gef and ChpBk encoded by the ge/ and chpBk genes which originated on the E. coli K12
chromosome. The recombinant phage was able to reduce target baeterial numbers by several
orders of magnitude in vitro and in an in vivo mouse model (Westwater et al, 2003). Fairhead
(2004) removed the lysis genes from phages and replaced them with genes encoding small acidsoluble spore proteins (SASP) from Bacillus. These were then used them to eliminate pathogenic
bacteria after phage infeetion. The SASP proteins concerned were DNA-binding proteins which
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when expressed halted all cellular activity. This system provided few opportunities for bacterial
resistance and has being investigated for the control of MRSA and C. difficile (Hanlon 2007).
Atsumi and Little (2004) replaced the Cro repressor of coliphage Lambda with a genetic module
containing the Lac repressor and several Lac operators, giving rise to mutant phages with
different regulatory behaviours, some of which behaved lytically under controlled conditions. Lu
and Collins (2007) engineered the E. coli phage T7 to express the molecule dispersin B
intracellularly during infection, and upon celt lysis to release it into the extracellular
environment, where it was effective in degrading bacterial biofilms. Subsequently they
engineered phage M13mpl8 to overexpress a repressor (lexA3) of the SOS response in bacteria.
Suppression of the SOS network in E. coli with this engineered phage significantly enhanced the
killing of these cells by quinolonc antibiotics (Lu and Collins 2009).
Lxploitation of phages for the elimination of bacterial cells without phage infection is also
possible, whereby the phage capsid is exploited for the delivery of inhibitory agents to bacterial
cells. This is generally achieved by eliminating lysis genes from lytic phages or by employing
filamentous phages whose progeny are chronically released from the cell. Hagens et al. (2004)
has described the successful utilization of the latter method for the elimination of Pseudomonas.
They replaced an export protein gene in the filamentous Pseudomonas phage Pf3 with a gene for
the restriction endonuclease BglW. Treatment oi Pseudomonas infections in mice with phage Pf3
and with a lytic phage resulted in higher survival rates and reduced inflammatory responses in
the mice treated with phage Pf3. The reduced inflammatory response was likely due to reduced
endotoxin release from the bacteria where the filamentous phage was employed. A similar
approach was used in E. coli (Hagens and Blasi, 2003). Zhang et al. (2000) reported that
quinolone antibiotic use had been implicated in shiga-toxin encoding phage induction, release
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and increased complications in treated patients. Employing a non-lytic phage could possibly be
an alternative treatment for patients with shiga toxin producing E. coli infections due to their
decreased endotoxin release upon infection. A study by Embleton et al. (2005) evaluated the use
of photosensitizers delivered by phages as bactericidal agents. 5. aureus phage 75 was covalently
cross-linked to the photosensitizer tin (IV) chlorin e6 (SnCe6), and IgG antibody was used as a
targeting molecule to direct the phage and deliver the SnCe6 to protein A in the cell wall of V
aureus cells. When exposed to red light, considerable reductions in MRSA and VISA titres were
achieved using as little as 1.5 pg/ml of the conjugated drug. Yacoby et al. (2006) exploited the
labile-linkage of toxins which are lethal to bacteria. In this case, filamentous phages were
genetically modified to display a targeting molecule on their surface, and deliver a high
concentration of chloramphenicol to the S. aureus target bacteria. They showed that drugs could
be linked to the phage by chemical conjugation. Therefore controlled release was possible by
mixing a constant ratio of chloramphenicol molecules per phage. The drug employed is devoid
of cytotoxic activity and is not activated until it dissociates from the phage at its intended target
site. This approach allows the drug to be brought specifically to the target bacterium, thus
avoiding the elimination of non-target bacteria. This technique may allow for the reintroduction
of non-specific drugs that may have been excluded from antibacterial use because of their
toxicity or low selectivity (Yacoby et al., 2006). This research group also addressed the
limitation regarding the low number of drug molecules, which could be attached to each phage
molecule (Yacoby et al. 2007). To this end, they designed a novel drug conjugation setup,
whereby they used hydrophilic solubility enhancing antibiotics as linker molecules, and also
introduced amino sugar based aminoglycosides. This allowed the conjugation of up to 40,000
chloramphenicol molecules to each phage, without compromising the phage’s integrity. A
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conjugation level of 10,000 drug molecules per phage, was suffieient to inhibit MRS A, S.
pyogenes and E. coli (Yaeoby et ai, 2007).
In the eontext of temperate phage being genetically modified to render them exclusively lytic, it
is noteworthy that temperate phages, since they reside in bacteria, are theoretically more
ubiquitous than virulent phages, and thus their exploitation and manipulation may prove useful in
some circumstances. Examples of this include the work of Rapson et al. (2003) who successfully
mutated the vir gene of a temperate phage which gave rise to a stable lytie phage. It is also
possible to engineer temperate phages to express genes toxic to bacteria only after integration
into the bacterial chromosome as shown by Schaak (2004), who used a recombinant phage
employing a gene for a toxin protein, which was bactericidal intracellularly but not
extracellularly. Similarly, .Vloradpour et al. (2009) engineered a non-replicating M13 phagemid
to express a lethal catabolite gene activator protein for the elimination of Zf coli 0157:117.
Modification of phages enabling them to survive longer in the mammalian circulatory system
can be veiy beneficial where phages are being exploited to eliminate infections. Merril and
colleagues identified long circulating phages with enhanced survival in blood, which resulted
from amino acid shifts in the major phage capsid (H) protein (Merril et al, 1996). This group
subsequently showed that the change of glutamic acid to a lysine at residue 158 of this major
capsid protein was sufficient to confer the "long-circulating" phenotype. This phage was
subsequently applied successfully in phage therapy studies by Vitiello et al. (2005).
Phage modification with the use of polyethylene glycol (PEG) has also been applied suceessfully
to improve the application of therapeutic phages. Examples of this were demonstrated by Kim et
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al (2008) who showed improved survival of Salmonella phage Felix-01 and Listeria phage A511
in miee after PEGylation.

In addition to modification to improve phages for direct therapeutic applications, phages may
also be modified for other applications. Li et al. (2010) adapted Ml 3 phage for cancer therapy.
Specifically, they chemically modified reactive groups on the surface of phage M13 allowing
attachment of molecules for targeting (folic acid) and also for imaging (a fluorescent probe) of
cancer cells. One such modified M13 phage had applications for image analysis of human KB
cancer cells. In addition, Pouillot et al. (2010) genetically engineered phage T4 with a view to
detection and possible eradication of threats from uncharacterized emerging bacterial pathogens,
which may be implicated in bioterrorism threats. They developed technologies allowing them to
(1) concurrently modify multiple regions within the coding sequence of a gene while conserving
intact the remainder of the gene, (2) reversibly interrupt the lytic cycle of an obligate virulent
phage (T4) within its host, (3) carry out efficient insertion, by homologous recombination, of any
number of engineered genes into the deactivated genomes of a T4 wild-type phage population,
and (4) reactivate the lytic cycle, leading to the production of engineered infective virulent
recombinant progeny. This allowed the production of very large, genetically engineered lytic
phage banks containing, in an E. coli host, a very wide spectrum of variants for any chosen
phage-associated funetion, including phage host-range. Screening of sueh a bank should allow
the rapid isolation of recombinant T4 particles capable of detecting (diagnosing), infecting, and
destroying hosts belonging to Gram-negative bacterial species far removed from the original E.
coli. Non-recombinant modification of phage genomes can also be useful for improving the
efficacy of phages in a therapeutie applieation. In a recent study, a serial passage technique was
used to generate r/m (restriction modification) modified derivatives of the S. aureus phage K.
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These modified phage circumvented the r/m systems of several S. aureus strains which were
previously impervious to lysis by the parent phage K. The combination of six modified phages in
a cocktail with phage K resulted in the lysis of 24 of 29 strains, which had been previously
resistant to phage K (Kelly et al., 2011). A bioinformatic study by Skiena (2001) suggested that a
large proportion of restriction sites could actually be removed without changing the phage
phenotype. This would be achieved by exploiting the triplet codes redundancy and searching for
the coding sequence which minimized the number of restriction sites while at the same time
coding for the desired phage proteins. This approach would render phages capable of avoiding
elimination by indigenous bacterial restriction modification systems.

As indicated by the examples above, genetic modification affords many opportunities to improve
phages and these modifications have the potential to address many of the natural shortcomings of
phages themselves.

Phages as delivery vectors
T he characteristics required of an ideal biological delivery vehicle include: (1) sufficient
packaging size for the intended molecule(s), (2) specificity for its target cell, (3) efficient
delivery of the cargo molecule(s), and (4) the ability to evade recognition by the host immune
system. Currently, viral and liposomal vectors show the most promise as delivery vehicles for
drugs to treat a wide range of diseases. However they have several limitations including limited
packaging capacity, low integration probability, reduced efficacy upon repeat administration,
risk of strong immune responses, inflammatory and toxicity risks, and insertional mutagenesis
risks (Seow and Wood 2009). To this end, alternative delivery vehicles are increasingly being
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investigated including phages, which have some significant advantages as delivery vectors.
These include (1) the ability to package RJMA, DNA, and antisense oligonucleotides, (2) relative
resistance to non-enzymatic degradation including high temperatures and pH extremes, (3)
targeting molecules can be readily engineered into phage capsid proteins, (4) cheap large scale
purification processes are generally available compared with cell-based mammalian systems.

In terms of stability, Jepson and March (2004) reported that phage lambda, could retain
infectivity and structural integrity for as long as 6 months at 4°C in water, which is longer than
any other biological delivery vehicle, including mammalian viruses. It is also stable over a pH
range of 3 - 11, making it a suitable candidate for delivery of drugs using the oral route (Jepson
and March 2004). Phage delivery vehicles can be of three different types, namely phagemid
vectors, phage display and vaccines.

Phagemid vectors arc plasmids with a phage origin of replication, which are packaged into phage
particles upon the addition of helper phages. These vectors have made the genetic manipulation
of phages as accessible as that in plasmids (Larocca et al, 2001). Use of phagemids allows for
more stringent control over the composition of wild type and modified coat proteins (Chatel et
al., 2008; Seow and Wood 2009) and also takes advantage of the fact that the phages have a
more substantial packaging capacity than other viral vectors (Greenstein and Brent 2001). In
addition, coat proteins of commonly used delivery phage vehicles such as lambda and M13 can
be successfully and readily engineered to incorporate many different ligands without
significantly affecting their structure (Seow and Wood 2009).

In relation to the use of phage as delivery vehicles for therapeutic applications, a common
technique, is that of phage display. This is a molecular diversity technology that allows the
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presentation of large peptide and protein libraries on the surface of fdamentous phage. Phage
display libraries permit the selection of peptides and proteins, including antibodies, with high
affinity and specificity for almost any target. The genes encoding the displayed protein are
incorporated into the phage genome. The technique also allows engineering of antibodies with
regard to size, number of bonds (valency), affinity and effector functions. Indeed the selection of
antibodies and peptides from phage-displayed libraries has led to isolation of both antibodies and
peptides for therapeutic and diagnostically relevant applications (Azzazy and Highsmith Jr,
2002; Bratkovic 2009; Pande et ai, 2010). Thie et al (2008) reviewed the development of a
plethora of human antibodies, which were generated by phage display and used for therapeutic
purposes. They described approved antibodies being taken through clinical trials for the
treatment of a range of human diseases including various cancers, inllammatory diseases, lupus,
autoimmune diseases, arthritis and Alzheimer’s disease, highlighting the progress which has
taken place in this area. Phage display has also recently been studied for stem cell delivery
(Staquicini et ai, 2010), as a possible immune-contraceptive agent for dogs (Samoylova et ai,
2010), and as a potential nasal therapeutic for the treatment of cocaine addiction (Dickerson et
ai, 2005).

Molenaar et al (2002) also demonstrated that phage display technologies which may fail due to
immune interference can be modified for better results. These authors demonstrated that the
uptake of phage Ml 3 in liver cells can be significantly increased when lysines on the surface of
phages are chemically conjugated to lactose. A recent study also reported the robustness of the
phage display workhorse phage Ml3 and its adaptability to large scale processing (Branston et
ai, 2011). Phage display is now considered the oldest biological display technique to be
developed (Bratkovic 2009), and its ease of implementation coupled with its low cost has made it
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a popular one also. Although the technique has undergone significant progression since its
inception over a quarter of a century ago, the technologies, innovation, and knowledge are now
highly sophisticated for further modification of displayed peptides and the optimization and
utilization of these peptides for clinical and therapeutic applications. The increase in the use of
peptide therapeutics, for instance the recent market release of the drug Romiplostim (Brown
2010), and also chemotherapeutic drugs for cancer treatment (Brown 2010; Wang et al, 2010)
suggests that novel peptides isolated from phage display libraries may have a significant role to
play in the future of therapeutic medical treatments. In the agrifood sector, phage display has
also recently been used for selecting peptides, which inhibit Campylobacter jejuni colonization
of chickens, a leading cause of zoonotic gastroenteritis in humans (Bishop-Hurley et al., 2010).

Phages can also be used as vaccines, and this can be accomplished in two main ways. Direct
vaccination involves the use of phages, which exploit phage display to carry vaccine antigens on
their surface. In contrast, phages can also be used to facilitate DNA vaccination (Clark and
March 2004a; 2004b), an indirect method involving the incorporation of a vaccine gene, which is
regulated by a eukaryotic expression cassette into the phage DNA. The vaccine proteins are
expressed following uptake of the whole phage and subsequent transcription and translation of
the vaccine DNA by immune cells. In the first method, phages can be constructed to display
specific antigens, or alternatively phages which display libraries of peptides can be screened with
antiserum sample to isolate novel peptide antigens (Folgori et al., 1994; Phalipon et al., 1997).
Patient serum samples can also be used for the identification of potential vaccines against
specific diseases by the screening of phage display libraries without any prior knowledge of
protective antigens (Meola et al, 1995). Phages displaying proteins as antigens in this way have
been used as vaccines in animal models of infection (Irving et al., 2001; Wang and Yu 2004). A
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recombinant phage based-vaccine was also developed for the vaccination of pigs against Taenia
solium induced cysticercosis, which is also the causative agent of neurocysticercosis in humans
(Manoutcharian et ai, 2004). This same author also reports that a filamentous phage vaccine trial
was earned out on a small group of multiple myeloma patients and demonstrated that phage
vaccination induced tumor-specific immune responses exerting beneficial effects on human
patients (Manoutcharian 2005).

The efficacy of the second approach, namely DNA vaccination using phage was demonstrated by
March et al. (2004) in mice and rabbits. These authors used phage lambda containing the DNA
vaccine cassette encoding either a hepatitis B surface antigen (lIBsAg) or a green fluorescent
protein antigen (EGFP). Upon delivery of the DNA using the lambda-EGFP phage in two
separate vaccinations, the uptake and expression of the cassette brought about specific antiiiGFP responses up to almost one month post-vaccination in mice. Similarly, two vaccinations
using the lambda-IlBsAg phage brought about high level anti-HBsAg responses, while a third
vaccination showed high level responses which persisted for more than 6 months. Interestingly
high anti-phage antibody levels were observed after the first immunization with lambda-1 IBsAg,
however these did not prevent subsequent immune responses against the DNA vaccine
components.
Clark et al. (2011) compared the efficacy of a phage delivered DNA vaccine and a commercial
recombinant protein vaccine against hepatitis B and found that in general antibody responses in
phage vaccinated rabbits were stronger than in those vaccinated with the recombinant protein
vaccine. They suggested that due to the stability of phage vaccines at a range of temperatures,
and their low cost of production that further studies into phage vaccination against hepatitis B
were indeed warranted (Clark et al., 2011). The stability and suitability of phage lambda as a
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workhorse for DNA vaccine delivery has also been reported (Jepson and March, 2004). It is clear
that phages possess undoubted potential as vaccine delivery vehicles. The fact that phages
themselves are natural stimulants of the immune system means that any antigen molecule
presented on the phage protein coat has natural adjuvant or synergistic activity and does not
require conjugation to any carrier molecules before immunization (Clark and March, 2006).
These authors have also reviewed the possibility of producing a hybrid phage vaccine for
targeting of both the cellular and humoral arms of the immune system. This type of vaccine
would be composed of a promoter driven DNA vaccine internally contained within a phage
particle and a phage display variant of the same antigen on the phage surface (Clark and March,
2004a).

Phages have also been used as vehicles for the delivery of labels for the detection of specific
bacteria as reviewed recently by Clark and March (2006) and Petty et al. (2006). An example of
the successful application of this approach is the use of bioluminescent phage for the diagnostic
detection of Yersinia pestis (Schofield et al., 2009).

Overall there are a number of benefits of using phages as delivery vehicles. These include their
potential to package novel functionalities into the particle, their significant packaging capacity,
their safety in humans and animals, and their ability to package non-DNA loads. Phages are easy
to purify and also stable, and have the capacity to cross the gastrointestinal tract and enter the
bloodstream. This suggests that oral phage vaccines may potentially be viable options as
vaccines for human and veterinary uses and also in the developing world (Clark and March
2004a). The low cost is also an important advantage as companies are investing less in expensive
conventional drug and vaccine developments, and thus phage-based technologies may indeed
offer novel strategies for vaccine and drug delivery.
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In the context of vaccination, it is worthy of mention that phages have also been used by
Fogelman et al. (2000) to test immune function. This study described the immunization of HIVinfected patients across all disease stages using phage phiX174 for measurement of CD4(-f) T
cell lymphocyte function. Function was evaluated by measuring the ability of T cells to provide
help to B cells in antibody production, amplification, and isotype switching. The patients'
responses regarding phage-spccific total antibody titers and IgG titers were quantitatively and
qualitatively inferior to the controls' responses. Phage phiX174 immunization therefore seemed
to be a useful tool for measuring immune function in vivo. Phages have also been used to
generate bacterial lysates, which in turn could be used as vaccines and this been used for
vaccination against bacterial diseases in animals and humans from the 1950s to the present day
(Kutter and Sulakvclidzc, 2005). Phage lysins can also be exploited to make bacterial ghost
vaccines. These enzymes compromise the bacterial cell wall releasing the cell contents but,
importantly, retain the cell wall for immune recognition. These “ghost vaccines” have been
shown to effectively immunize against bacterial infections, an example being the vaccination of
mice against Helicobacter pylori infection, using ghosts prepared with the phage lysis protein F
(Petty et al, 2006).

Overall it is clear that the use of phages, whether whole phage themselves, their lytic enzymes,
genetically modified phages, or phage delivery vehicles and derived vaccines have a
considerable array of applications as therapeutics in the modem medical and veterinary fields.
The continued antibiotic resistance problem coupled with the economic strain on global health
systems necessitates the exploitation of cheap, natural, readily-available, safe and efficient
therapeutic agents. Phages satisfy all of these criteria and their reintroduction as medical
treatment options in the western world is worthy of strong consideration.
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Table 1: Advantages and disadvantages of phage therapy.

Advantages

Disadvantages

Bactericidal agents

Not all phages make good therapeutics

“Auto dosing” agents

Narrow bactericidal spectrum

Minimal disruption to normal bacterial llora

Viral! virulent terminology could give them an
unfavorable public image

Low potential for inducing resistance

Possible safety concerns

Ease of discovery and isolation

Physiological barriers can prevent phages from reaching
target bacteria

Versatility in modes of formulation and application

Bacterial resistance

Active against biofilms

Possible risk of phage conversion of bacterial targets
where phage genome has not been characterized

Single dose potential

Potential cross infection to untreated subjects, either
from the environment or treated subjects

Capacity for low dosage use

Low environmental impact

Natural products

Relatively low cost
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Table 2: Advantages and disadvantages of phage endolysins.
Advantages

Disadvantages

Can be used both as a prophylactic and for treatment

Susceptible to inactivation due to their
protein nature

Can be considered protein therapeutics, as compared to viral nature

Costs related to production

of phages
Lysin resistance has not been reported to date

Immune response

Genus-specific antibacterial, which will not eliminate commensal
flora
Can be engineered and improved
Non-toxic
Can potentially be used in a range of environments (Human, animal,
food, biofilm).

71

Figure 1. Major timelines in the history of phage therapy.
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Chapter 2
Isolation and characterization of bacteriophages that inhibit strains of
Pediococcus damnosus, Lactobacillus brevis and Lactobacillus
paraplantarum that cause beer spoilage.

J Am Soc Brew Chem. (2011). 69(1), 8-12.
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Abstract
The aim of this study was to isolate and charaeterize bacteriophages against Pediococcus and
Lactobacillus strains that cause spoilage in brewing processes. A number of beer spoilage
bacteria were isolated from, breweries and characterized by 16S rRNA typing. Five distinct
Pediococcus damnosus (P. damnosus) phages and four Lactobacillus phages, which lysed both
Lactobacillus brevis (Lb. brevis) and Lactobacillus paraplantarum {Lb. paraplantarum) were
isolated from municipal sewage and fannyard slurry. A rapid DNA isolation method was used to
isolate DNA of sufficient purity for restriction endonuclease digestion from de Man, Rogosa and
Sharpe (MRS) phage broth cultures. Phages were analysed by restriction digest and transmission
electron microscopy and shown to be in the Siphoviridae family with genomes in the size-range
of 40-50 kb. Five Pediococcus and four Lactobacillus phages were isolated using beer spoilage
strains as target hosts. All phages were characterized and shown to be distinct. This study
identifies five novel phages against P. damnosus. Phages to this species are very rare in the
scientific literature. In addition four novel phages against Lb. brevis and Lb. paraplantarum were
also identified. These phages may have an application in the biocontrol of beer spoilage bacteria.
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Introduction
Beer has been recognized for centuries as a safe and microbiologically stable beverage. This is
due to a number of factors; the presence of ethanol, a low pi I, the presence of hop compounds,
the reduced content of oxygen and resulting raised carbon dioxide content, and the low level of
residual nutrients (2, 21, 24). However, in spite of these unfavorable conditions, a few bacterial
genera still succeed in growing in a beer environment, due in part to their resistance to hop
compounds (3, 23). These beer-spoilage microorganisms can cause visible turbidity and
unpleasant sensory changes in beer, affecting both the final product quality and the financial
profit of the brewing company. Members of the genus Pediococcus and Lactobacillus are
regarded as the most common beer spoilage organisms in modern breweries, and have been
reported to be responsible for approximately 70% of microbial beer-spoilage incidents (12, 24).
Lb. brevis and Lb. lindneri have been reported as the most common lactobaeilli causing spoilage
(21, 24), while P. damnosus is regarded as the most common of the pediococci (12, 22).
Lytic bacteriophages (phage) arc viruses that infect bacterial cells, disrupt bacterial metabolism
and lyse the bacterial cell, causing cell death. They possess attributes that are attractive in the
context of novel methods to control foodborne pathogens and spoilage bacteria (6, 10). Phages
have been used for many biocontrol applications in food and have successfully contributed to the
control of Campylobacter, Listeria monocytogenes. Salmonella and various spoilage organisms
in foods (11, 14). Indeed, the European Food Safety Authority recently published an extensive
review of the successful use of phages in dairy products, chicken, beef, pork, seafood, food
processing environments and on metallic surfaces (1). Regarding the stability of phages in food
systems, this review stated that phage persistence in or on foods tends to vary with each
bacteriophage, and also with the conditions of application of the phage including the dose, and
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with both physical and chemical factors relating to the food matrix. Hudson et al.{\\) suggested
that considerations for phage stability in foods are important because phages need to be stable
unde r the physiochemical conditions of the food to whieh they are applied to be useful as
biocontrol agents. These authors cited tolerance to pH, temperature, visible and UV light,
osmc')tic shock, osmotic pressure and the processing environment as the main factors to be taken
into aecount when considering phage stability. Phages are also natural and relatively inexpensive
to produce (9). Screening for bacteriophages, which kill problematic bacteria is thus very
worthwhile as they may have an application for control of these bacteria (4, 19, 20). In this
stud> , we describe the isolation and characterization of lytic phages active against bacterial
genera, whieh eause spoilage problems in beer. In addition, from a scientific point of view, very
limited if any work has been perfoiTned on phages of P. damnosus.

Materials and methods

Bacterial strains and growth media
All strains used in this study are listed in Table 1. All strains were isolated from breweries and
maintained in de Man, Rogosa and Sharpe (7) (MRS, Sigma Aldrich, UK) medium. They were
cultivated at 30°C in MRS broth or solid media containing 1.0% (w/v) bacteriological agar
(Merck, Darmstadt, Germany).
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Characterization of beer spoilage bacteria by 16S rRNA typing
DNA was extracted from overnight bacterial cultures (1% inoculum) using a QIA amp DNA
mini kit (Qiagen house, West Sussex, UK) according to the manufacturers instructions. PCR
amplifications of the DNA were carried out using a Bioline, Biotaq, Core kit (London, UK). For
the amplification of the target 16S rRNA gene sequence from DNA extracted from pure bacterial
cultures, universal primers (25) 16S-fl (AGA GTT TGA TCC TGG CTC AG) and 16S-r5 (ACG
GCT ACC TTG TTA CGA CTT) were used. The reaction mixture (50 pi) consisted of reaction
buffer (5 pi), a 2.5 mM concentration of each deoxynucleoside triphosphate (5 pi), 100 pmol of
each primer (1 pi each), 50 mM MgCl2(4 pi), sterile water (28.5 pi), bacterial DNA (5 pi) and 5
U/pl of Biotaq (Bioline, London, UK) DNA polymerase (0.5 pi). The following was used as the
amplification programme: After an initial “hot start” of 94°C for four min, the following cycle
was repeated 30 times: 94°C for 30 s, 61°C for 30 s, 72°C for 1 min and 72°C for 7 min. This
was followed by holding at 4°C. Amplified target sequences were purified with a QIA quick
PCR purification kit (Qiagen house. West Sussex, UK) and after sequencing (MWG Biotech,
Lbersberg, Germany), identifications were made using the BLAST database.

Bacteriophage isolation
All beer spoilage strains listed in Table I were used as hosts for phage isolation. A 10 g sample
of farmyard slurry or municipal sewage (Table II) was added to a 15 ml volume of MRS broth,
containing 100 pi of all target strains within the bacterial genus. In each propagation all strains
were included to increase the chance of amplifying phages. 50 pi of one mol f’ CaCl2 was also
added to the tube to aid phage adsorption to host cells, and this was then incubated at 30°C
overnight to allow specific phages to propagate if present. The culture was then centrifuged at
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3000 rpm for 10 min and the supernatant was filter-sterilized (0.45-pm filter) and stored at 4°C.
The supernatant was then subjected to plaque assay using each bacterial strain, which had been
used in that propagation, individually. Plates were then examined for plaque formation.

Phage assays
Phage propagations were perfonned as described by O’ Flaherty et <3/. (12). Briefly 100 pi of the
appropriate overnight culture and 20 pi of 1 mol f' CaCf were added to 10 ml volumes of MRS
broth. After incubation at 30°C for 2 h, 1 ml of purified phage solution was added and the sample
was incubated at 30“C until the phage cleared the broth. Samples were then centrifuged at 3000
rpm and filter sterilized (0.45-pm filter) and stored at 4°C. Phage plaque assays and spot tests
were performed as described previously (14). Bacteriophages were generally subjected to three
rounds of plaque purification prior to acquisition to experimental data.

Electron microscopy
o

Phage stocks were prepared from MRS broth lysates to achieve titres in excess of 10 PFU/ml.
Each sample was stained negatively with 2% (w/v) uranyl acetate on freshly prepared carbon
films. Grids were analyzed in a Tecnai 10 transmission electron microscope (FEI Company,
Eindhoven, The Netherlands) at an acceleration voltage of 80 kV. Micrographs were taken with a
MegaView II CCD-camera (SIS, Munster, Germany). Phage dimensions were calculated as
means of 8-22 measurements.
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Preparation of phage DNA from Pediococciis and Lactobacillus phages in MRS broth.
DNA was extracted from MRS broth phage stock solutions as follows. An aliquot of 750 pi of
Q

10 PFU/ml MRS phage suspension was incubated at 37°C for 10 min with RNase (50 mg/ml)
(Sigma-Aldrich, UK). Subsequently, 150 pi of lysis buffer (500 pi solution) containing the
following components; 10 % sodium dodecyl sulfate (50 pi), EDTA (0.5 M) (400 pi), Tris (pH
8.0, 1 M) (25 pi), sterile distilled water (25 pi) was then added, followed by 10 pi of proteinase
K (10 mg/ml) (Roche Diagnostics, Mannheim, Germany). The sample was incubated at 65°C for
30 min. Next, 750 pi of phcnol-chloroform-isoamyl alcohol (25:24:1) (Sigma-Aldrich,UK) was
added, the sample was shaken well and then centrifuged at 10,000 rpm for 5 min. This step was
repeated once and then the upper layer was transferred into a new microfuge tube. To the upper
layer, 50 pi of chloroform-isoamyl alcohol (24:1) (Sigma-Aldrich, Dublin, Ireland) was added,
and the sample was shaken well and then centrifuged at 10,000 rpm for 5 min. The upper layer
(600 pi) was then transferred into a fresh microfuge tube. Then, 6 pi of sodium acetate (pH 5.1, 3
M) and 350 pi of 100 % isopropanol were added. The sample was placed at -20°C for 2 h, after
which it was centrifuged at 10,000 rpm for 5 min, the supernatant removed, and the pellet dried
under vacuum. After 70 % ethanol washing, the DNA pellet was re-suspended in 100 pi of 10
mM Tris, ImM HDTA (pH 8). Typically 0.5 pg of DNA was used for restriction digests.

79

Phage host range tests
Most range for each phage was ascertained by the spot test technique and plaque assay technique
as described previously (14). The efficiency of plaquing (EOP) of each phage on each strain was
also -calculated as described previously (13).

Results

16S R\A typing of bacteria
.All bacteria used in the study were subjected to 16S RNA typing and compared to type strains to
confirm identity. The type strain for P. damnosns is P. damnosus strain DSM20331, the type
strain for Lh. brevis is Lh. brevis ATCC14869, and the type strain {or Lb. paraplantarum is Lb.
paraplantariim DSM10667. BLAST results in Table 1 indicate that both pediococci showed 99%
identity with their type strain DSM 20331, while the lactobacilli also showed 99% identity with
either L/?. brevis or Lb. paraplantarum. This confirmed the species identity (Table I).

Isolation of phages from farmyard slurry and municipal wastewater
After enrichment in the presence of a mixture of two strains of P. damnosus, nine of 19 farmyard
slurry and municipal sewage samples gave non-turbid plaques in lawns ofP. damnosus P 120.
These were also capable of forming plaques on P. damnosus P 82. After enrichment in the
presence of two strains o{ Lb. brevis and one strain of Lb. paraplantarum, 10 samples gave nonturbid plaques in lawns o{Lb. paraplantarum L913. These were also capable of forming plaques
on Lb. brevis. Phages were isolated from these plaques and prepared for extraction of phage
DNA for restriction analysis. A variety of restriction endonucleases were used, but HindlW gave
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the best quality digests with the discrimination between phages (Fig.la and b). Comparison of
digests indicated that there were five distinct Pediococcus phages and four distinct Lactobacillus
phages. All phages were named according to the geographical location where the samples were
sourced, and the host bacterium on which they were propagated. The genome sizes of the phages
were estimated from the different restriction digests and all were in the region of 40 - 50 kb,
which is typical of the Siphoviridae family (11).

Characterization of phages
The plaque-forming ability of all phages was compared. All phages fonned clear plaques of 0.5 1 mm in diameter on host strains, indicating that all phages were lytic on the host bacteria used.
Morphological analysis of phages by electron microscopy allowed each to be classified into its
respective viral family and order. All phages had obvious tails and hence belonged to the order
Caudovirales. The Pediococcus phages had non-contractile tails and isometric heads (Fig. 2).
Head dimensions ranged from 58 x 53 nm to 59 x 54 nm (Table III). Tail lengths ranged from
173 nm to 176 nm, while tail diameters ranged from 9 nm to 10 nm (Table 111). Differences in
plaque size were also observed, with phages mmPl, ctP2 and mmp2 having plaque diameters of
0.8 mm, and phages ckPl and clPl diameters of 0.9 mm and 0.7 mm respectively (Table IV).
As with the Pediococcus phages, the Lactobacillus phages had non-contractile tails and isometric
heads (Fig. 2). Dimensions for these phages were also similar, with head dimensions ranging
from 57 x 52 nm to 60 x 55 nm (Table III). Tails ranged in length from 166 to 178 nm, and tail
diameters were in the range of 11 nm. Tail tip appendices were visible for phages clLl, clL2 and
mmL2 and these ranged in length from 16 to 19 nm (Fig. 2, Table III). Phage mmLl also
revealed similar fine structures, albeit at a lower degree of resolution on the TEM micrographs.
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As with the Pediococcus phages, some differences in plaque diameter were also noted. Phages
mmLl and mmL2 had a plaque diameter of 0.5 mm, while phage clLl had 0.9 mm and clL2 had
1 mm (Table IV). All phages were classified into the Siphoviridae family based on guidelines of
the International Committee on Taxonomy of Viruses (11).

Bacteriophage host range
All Pediococcus phages were assessed for their ability to lyse the two beer spoilage Pediococcus
damnosus strains, and all Lactobacillus phages were assessed for their ability to lyse the three
beer spoilage lactobacilli used in the study as previously described (14). All Pediococcus phages
were found to lyse the two spoilage pediococci tested in-espective of the host strain on which
they were grown, while all Lactobacillus phages were similarly found to lyse the three spoilage
lactobacilli. HOP values and spot test results are shown in Table IV. In addition the ability of
Pediococcus phage clPl and Lactobacillus phage clL2 to survive in a beer environment was
o

investigated by inoculation of 10 PFU/ml of each into lleineken beer. This resulted in no
decrease in phage titrc for cither over a 3 month period (data not shown).
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Discussion
Bacteriophages have been found to have significant potential as antibacterial agents (13) and also
possess attributes that are useful to those looking for novel ways to control foodbome pathogens
and spoilage bacteria (11). The problematic spoilage bacterial strains used in the study were
hops-resistant beer bacteria found in German breweries in 2007. Our 16S rRNA typing results
confirmed the identity of the spoilage strains as P. damnosus (strains PI 20 and P82), Lb. brevis
(strains LI033 and LI 105) and Lb. paraplantarum (strain L913).
Five distinct Pediococcus phages and four distinct Lactobacillus phages were isolated from
farmyard slurry and municipal wastewater in different loeations in southern Ireland in 2008. All
phages were assigned to the Siphoviridae family based on morphology. All phages formed clear
plaques indicating that phages were undergoing a lytic cycle on these hosts. In the case of the
five Pediococcus phages, Hindlll digests indicated that there were apparent genotypic
similarities between them. While all five showed distinct banding patterns, phages mmPl, clPl,
clP2 and mmP2 had a number of electrophoretic restriction bands of identical molecular mass,
suggesting relatedness or perhaps a common ancestor. Phage ekPl showed less similarity with
the other four. Examination of electron micrographs of these five phages also indicated a similar
morphology, with minor differences in dimensions noted. In the case of the Lactobacillus
phages, analysis of HindXW digests showed that phages clL2, clLl, mmLl, and mmL2 showed
distinct banding patterns, but some similarities were apparent, indicating that these phages shared
a relatedness at the genotypic level. Electron micrographs also indicated a morphological
similarity, with all phages having similar head and tail dimensions. These phages were
interesting in that they lysed two distinct species of Lactobacillus, namely Lb. brevis and Lb.
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paraplantarum, suggesting that these species are closely related from a phage susceptibility point
of view.
It is worthy of mention that this is apparently the first report of isolation and characterization of
P. damnosus phages. Yoon et al.{26) isolated and characterized a lytic phage against a
Pediococcus starter culture used in cucumber fermentations. This phage, while also belonging to
the Siphoviridae family, had a smaller head diameter (51.2 nm), and a tail which was
significantly shorter in length (129.6 nm), yet slightly larger in diameter (11.6 nm) than the
Pediococcus phages isolated in this study. The phage of Yoon et al. (26) also had a smaller
genome size (24.1 kb) than the phages isolated in this work (40-50 kb). Overall this study
highlighted the relative abundance in sewage of phages for Pediococcus and Lactobacillus. Their
activity against prominent beer spoilage bacteria provides an opportunity for application in this
area.
In this context, phage are known to be stable at typical beer pH values which range from 3.8 to
4.7 (1). Indeed it is well known that phages of lactic acid bacteria frequently propagate and lyse
starter cultures in lactic acid dairy fermentations (5) and thus their activity in beer would not be
compromised by the pH of this environment. Indeed, inoculation of Pediococcus phage clPl and
Lactobacillus phage clL2 into beer resulted in no decrease in phage titres over a 3 month period.
With regard to genetic stability of Lactobacillus phages during this application, Desiere et al.{S)
reported that stringent barriers prevent the transfer of phage genes across Lactobacillus species.
While information regarding the genetic stability of Pediococcus phages is lacking (as they are
rare in the scientific literature), the situation is likely to be similar to that of the Lactobacillus
phages. Nevertheless, we are embarking on genome sequencing of the Pediococcus phages in
order to provide a more thorough knowledge on their genetic makeup.
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Tables
Table I. Beer spoilage bacterial strains used in this study and rRNA typing matches with
relevant type strains.
Strain name
16S RNA type BLAST result
Lb. brevis strain ATCC14869 16S rRNA gene, partial
Lb. brevis LI 105
sequence (99% l.D.)
Lb. brevis LI033
Lb. brevis strain ATCC 14869 16S rRNA gene, partial
sequence (99% l.D.)
Lb. paraplantarum L913
P. damnosiis P82
P. damnosus P120

Lb. paraplantarum strain DSM10667 16S rRNA, partial
sequence (99% l.D.)
P. damnosus 16S rRNA gene, strain DSM2033 1 (99%
l.D.)
P. damnosus 16S rRNA gene, strain DSM2033 1 (99%
l.D.)

I'able II. Sources of bacteriophages
Phage
Location
designation
Wastewater treatment plant, Carrick-On-Suir, Co.Tipperary, Ireland.
ckPl
mmPl
Farm slurry pit 1, Dunmarklum, Lissarda, Co. Cork, Ireland.
Wastewater treatment plant (post press machine sample), Clonmel, Co.
clPl
Tipperary, Ireland.
clP2
Wastewater treatment plant (post primary digestion sample), Clonmel, Co.
Tipperary, Ireland.
Farm slurry pit 2, Dunmarklum, Lissarda , Co. Cork, Ireland.
mmP2
clLl
Wastewater treatment plant (final tank and thickener sample), Clonmel, Co.
Tipperary, Ireland.
mmLl
Farm slurry pit 1, Dunmarklum, Lissarda , Co. Cork, Ireland.
clL2
Wastewater treatment plant (post primary digestion sample), Clonmel, Co.
Tipperary, Ireland.
mmL2
Farm slurry pit 2, Dunmarklum, Lissarda , Co. Cork, Ireland.
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Table III. Phage dimensions
Head dimension

Tail length

Tail diameter

(nm)

(nm)

(nm)

Tail tip
appendices
length (nm)

P. dam nos US
phage
ckPl

58.8±1.1 x53.6±2.7
(n=ll)

174.3±8.0
(n=ll)

9.8±1.2
(n=ll)

mmP 1

58.0±2.4 X 52.8±2.7
(n=ll)

175.7±5.3
(n=13)

9.5±0.9
(n=13)

elPl

59.0±2.9x53.4±2.6
(n-8)

174.5±5.3
(n=8)

9.6±0.8 (n=8)

./.

elP2

57.7±4.2 X 52.5±3.3
(n=9)

173.2±5.1
(n-9)

8.7±0.7 (n-9)

./.

mmP2

57.9±2.9x53.7±2.1
(n=ll)

176.0±4.7
(n-11)

9.7±0.9
(n-11)

./.

clLl

58.9±4.1 X 52.4±4.5
(n=12)

171.8±4.2
(n=13)

10.6±0.9
(n=13)

19.1±2.9(n-14)

mmLl

59.0±3.8x53.0±2.9
(n=8)

178.3±7.0
(n=9)

11.0±0.8
(n=9)

n.m.

clL2

56.8±4.9x52.0±3.9
(n=20)

173.3±3.7
(n=20)

11.1±1.2
(n=20)

16.2±3.0(n=16)

mmL2

59.7±3.7x54.8±3.4
(n=22)

166.3+6.9
(n=22)

11.2±0.8
(n=22)

17.5±2.2(n=22)

./.

/./>. phage

not present, n.m.; not measurable (low resolution)
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Table IV. Host range oiPediococcus and Lactobacillus phages showing efficiency of plaquing
(EOP) values and plaque diameter in brackets.
Bacterial strain
P. dam nos us PI 20
(propagating host strain)
P. damnosus P82

Lh. paraplantarum L913
(propagating host strain)

ckPl
1
(0.9 mm)
0.95
(0.9 mm)

clLl
1
(0.9 mm)

Lh. brevis LI 105

0.64
(0.9 mm)

Lb. brevis LI033

0.56
(0.9 mm)

Pediococcus bacteriophages
clP2
mmPl
clPl
mmP2
1
1
1
1
(0.8
(0.7
(0.8
(0.8 mm)
mm)
mm)
mm)
0.62
0.45
0.7
1.1
(0.8
(0.8
(0.7
(0.8 mm)
mm)
mm)
mm)
Lactobacillus bacteriophages
clL2
mm LI
mmL2
1
1
1
(0.5
(0.5 mm)
(1
mm)
mm)
0.90
0.76
0.45
(0.5
(0.5 mm)
(1
mm)
mm)
0.66
0.51
0.81
(0.5
(0.5 mm)
(1
mm)
mm)
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Figures
(a)

(b)

Figure 1. Phage DNAs digested with restriction endonuclease HindlW. Lane identification is as
follows: (a) Pediococcus phage DNAs. 1, lO-kb ladder (Bioline, London, England); 2, phage
ckPl; 3, phage mmPl; 4, phage clPl; 5, phage clP2; 6, phage mniP2.
(b) Lactobacillus phage DNAs. 1, lO-kb ladder (Bioline, London, England); 2, phage clLl; 3,
phage mniLl; 4, phage clE2; 5, phage mmL2.
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fliiWlnww)

Figure 2.Electron micrographs ot' Pediococcus and Lactohacilhis phages. Phages were
negatively stained with 2% uranyl acetate; (a) phage ckPl (b) phage mmPl (c) phage clPl (d)
phage clP2 (e) phage mmP2 (0 phage cl 1.1 (g) phage mmLl (h) phage clL2 (i) phage mmL2.
The arrows indicate appendices at the tail tips (obscured on phage mmLl micrograph g). Scale
bar represents 100 nm.
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Chapter 3
Genome sequence analysis of a novel virulent bacteriophage infecting
beer spoilage Pediococcus damnosus

Gene. (2011). Submitted.
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Abstract
Pediococcus damnosus (P. damnosus) phage clPl is a novel virulent phage isolated from a
municipal sewage sample collected in Southern Ireland. This phage infects the beer spoilage
strain P. damnosus P82 which was isolated from German breweries. Sequencing of the phage
has revealed a linear double stranded DNA genome of 38,013 base pairs (bp) with an overall GC
content of 47.6 %. Fifty-seven open reading frames (ORFs) were identified of which 30 were
assigned predicted functions based on their homology to previously sequenced proteins. The
majority of genes showed homology to those of the Lactobacillus plantamm phage OJL-1. All
genes were located on the same coding strand and in the same orientation. Morphological
characterization placed phage clPl as a member of the Siphoviridae family with an isometric
head (59 nm diameter) and non-contractile tail (length 175 nm; diameter 10 nm). Phylogenetic
analysis of the putative IINH homing endonuclease gene of this phage revealed similarities to
endonucleases of both phage and bacterial origin and it was assigned a DNA packaging function.
Interestingly, the phage elPl genome was found to share very limited identity with other phage
genome sequences in the database, and was hence considered quite unique. This was highlighted
by the genome organisation which differed slightly to the consensus pattern of genomic
organisation usually found in siphoviridae phages. To our knowledge, this study represents the
first report of P. damnosus phage genome sequencing.
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Introduction
Lactic acid bacteria (LAB) are heterogenous Gram-positive bacteria with a low percentage of
Guanine and Cytosine (G/C) in their genomes. They are non-spore forming, non-respiring, and
produce Lactic acid as the major end product of carbohydrate fermentation. They can have either
a coccoid or rod-shaped morphology (Klaenhammer et al.,2005). Members of this group of
bacteria are frequently used on an industrial scale for the production of fermented milk products
such as buttermilk, yoghurt, cheese and sauerkraut. These include Lactococciis lactis.
Streptococcus thermophilus, Leuconostoc, Lactobacillus and Pediococcus. (Klaenhammer et
ai,2005). However, despite this beneficial application of LAB, they are also a very prominent
cause of spoilage in alcoholic beverages such as wine, ciders and beer. This results mainly from
their growth and production of exopolysaccharides (LPS) and other metabolites (Gindreau et
al.,200\) in the beer environment making them predominant beer spoilers, reportedly causing
60-90% of spoilage incidents. (Back 1994). A genus which is prominent among beer spoilage
LAB is Pediococcus and in particular the species P. damnosus. (Sakamoto and Konings 2003;
Dobson et a/.,2002; Satokari et al.,\999\ Jespersen and Jakobsen, 1996). This genus is also
associated with a variety of other habitats, including plants, fermented foods, vegetable matter,
and modified atmosphere packaged meat products. (Dworkin et al.,2000\ Ray et al., 1995; Garrie
1986; Yoon et a/.,2007; Broadbent and Steele, 2010). Pediococci have been exploited for a wide
variety of applications including as probiotics (Reuter 1997), as silage additives to assist acid
production (Dworkin et al.,2006), and for food safety applications by pediocin production for the
elimination oiListeria and other Gram positive pathogens (Drider et al.,2006). They have also
been added as a nutritional supplement to animal feeds and used in polymer research for the
manufacture of biodegradable packaging materials (Reuter 1997; Dobson et al.,2002).
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Bacteriophages are viruses which infect and multiply within specific bacterial hosts. This
specificity is usually found at the strain or species level, and allows for direct targeting of
specific bacteria (Hagens and Loessner 2010). Research on bacteriophages of LAB dates back to
1935 when phages infecting L. lactis were first described (Whitehead and Cox 1935), and phages
of this species dominated the research for many decades (Coffey and Ross 2002). However in
more recent times this included phages of Lactobacillus and S. thermophilus. (Coffey and Ross,
2002; Desiere et a/.,2002; Villion and Moineau, 2009). In spite of this there has been very little
research on bacteriophages of Pediococci. These include a phage against P. halophilus from soysauce fermentation (Uchida and Kanabe 1993). Subsequently three temperate phages were
induced from F. acidilactici (Caldwell et ai, 1999), and two prophage gene clusters were
reported in P. pentosaceus (Makarova et 6?/.,2006). More recently, the isolation and
characterization of a lytic Pediococcus phage from fermenting cucumber brine was reported by
Yoon et al. (2007).
This study reports the sequence analysis of the complete genome of the first lytic phage infecting
P. damnosiis. It was isolated from a wastewater treatment plant in Southern Ireland using a beer
spoilage P. damnosus strain (P. damnosus P82) as host.
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Materials and Methods

Bacterial strains
The strain used for phage isolation and propagation in this study, P. damnosus P82 was one of
many strains isolated from German breweries where they caused beer spoilage. The strain was
maintained in de Man, Rogosa and Sharpe (De Man et al. 1960) (MRS, Sigma Aldrich,UK)
m.edium and cultivated at 30°C in MRS broth or solid media containing 1.0% (w/v)
bacteriological agar (Merck, Dannstadt, Germany).

Characterization of beer spoilage bacteria by 16S rRNA typing
DNA was extracted from an overnight bacterial culture (1% inoculum) using a QIA amp DNA
mini kit (Qiagen house. West Sussex, UK) according to the manufacturer’s instructions. PCR
amplifications of the DNA were carried out using a Bioline, Biotaq, Core kit (London, UK). For
the amplification of the target 16S rRNA gene sequence from DNA extracted from pure bacterial
cultures, universal primers (Weisburg et al. 1991) 16S-fl (AGA GTT TGA TCC TGG CTC AG)
and 16S-r5 (ACG GCT ACC TTG TTA CGA CTT) were used. The reaction mixture (50 pi)
consisted of reaction buffer (5 pi), a 2.5 mM concentration of each deoxynucleoside triphosphate
(5 pi), 100 p-mol of each primer (1 pi each), 50 mM MgCf (4 pi), sterile water (28.5 pi),
bacterial DNA (5 pi) and 5 U/pl of Biotaq (Bioline, London, UK) DNA polymerase (0.5 pi). The
following was used as the amplification programme: After an initial “hot start” of 94°C for 4
min, the following cycle was repeated 30 times: 94°C for 30 s, 61°C for 30 s, 72°C for 1 min and
72°C for 7 min. This was followed by holding at 4°C. Amplified target sequences were purified
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with a QIA quick PCR purification kit (Qiagen house, West Sussex, UK) and after sequencing
(MWG Biotech, Ebersberg, Germany), identifications were made using the BLAST database.

Phage isolation
A 10 g sample of municipal sewage was collected from a wastewater treatment plant (post press
machine sample) in Clonmel, Co. Tipperary, Ireland. This was added to a 15 ml volume of MRS
broth, containing 100 ul of target strain P. damnosus P82. Fifty pi of CaCl2 at 1 mol U' was also
added to the tube. This was incubated at 30'^C overnight to allow specific phages to propagate if
present. The culture was then centrifuged at 3000 rpm for 10 min and the supernatant was filtersterilized (0.45-pm filter) and stored at 4°C. The supernatant was then subjected to plaque assay
using P. damnosus P82 as host. Plates were then examined for plaque formation. Plaque assays
were performed as described previously (O’Flaherty et al 2005).

Phage propagation
Three rounds of plaque purification were performed to ensure a pure phage isolate. Briefly, a
plaque was aseptically picked from a plaque assay plate and added to a I ml culture of P.
damnosus P82 in MRS broth (1% inoculum from an overnight culture). The culture was
incubated at 30°C until clearing was noted relative to the positive control {P. damnosus P82
alone). It was then centrifuged at 3000 rpm for 10 min and the supernatant was filter-sterilized
(0.45-pm filter) and stored at 4°C. Further phage propagations and ultracentrifugation of phage
lysates were performed as described by O’Flaherty et al. (2004) to obtain high titre preparations.
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Host range of phage cIPl
The host range of the phage against a range

Pediococciis strains of brewing origin (Table 2)

was determined by the spot test technique and plaque assay techniques as described previously
(O’Flaherty et al.,2005).

Electron Microscopy
A phage stock was prepared from MRS broth lysate to achieve a titre in excess of 10^ PFU/ml.
The sample was stained negatively with 2% (w/v) uranyl acetate on freshly prepared carbon
films. Grids were analyzed in a Tecnai 10 transmission electron microscope (FBI Compan,
Eindhoven, The Netherlands) at an acceleration voltage of 80 kV. Micrographs were taken with a
MegaView II CCD-camera (SIS, Munster, Gennany). Phage dimensions were calculated as
means of 8-22 measurements.
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Analysis of phage structural proteins (SDS-PAGE)
Phage structural proteins were extracted from 30 pi of high litre ultracentrifuge lysate (10^
PFU/ml). 20 pi of sample buffer (containing 3.55 ml of deionized water, 1.25ml of 0.5M TrisHCl (pfi 6.8), 2.5ml of glycerol, 2.0 ml of 10% SDS and 0.2ml of 0.5% bromophenol blue) was
added to the phage lysate. (50 pi of P-mercaptoethanol was added to 950 pi sample buffer prior
to use). The sample was heated in a microfuge tube in a boiling waterbath for 5 min and proteins
were separated using a 7 % stacking gel and a 12 % polyacrylamide resolving gel at 150 V for 1
hour. Protein bands were visualised by staining the gel with Coomassie brilliant blue R250.
Excess dye was removed using a destaining solution (53% distilled Water, 40% ethanol, and 7%
acetic acid). Protein size was estimated using a protein molecular weight standard (Hyper page.
Bioline UK Ltd., London UK).
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Phage DNA preparation and analysis
DNA was extracted from MRS broth phage stock solution as follows: An aliquot of 750 pi of
high litre (10 - 10 PFU/ml) MRS phage broth or ultracentrifuge suspension was incubated at
37°C for 10 min with RNase (50 mg/ml) (Sigma-Aldrich,UK). Subsequently, 150 pi of lysis
buffer (500 pi solution) containing the following components; 10 % sodium dodecyl sulfate (50
pi), EDTA (0.5 M) (400 pi), Tris (pfl 8.0, 1 M) (25 pi), sterile distilled water (25 pi) was then
added, followed by 10 pi of proteinase K (10 mg/ml) (Roche Diagnostics, Mannheim, Germany).
The sample was incubated at 65°C for 30 min. Next, 750 pi of phenol-chlorofonn-isoamyl
alcohol (25:24:1) (Sigma-Aldrich, Dublin, Ireland) was added, the sample was shaken well and
then centrifuged at 10,000 rpm for 5 min. This step was repeated once and then the upper layer
was transferred into a new microfuge tube. To the upper layer, the same volume of chloroformisoamyl alcohol (24:1) (Sigma-Aldrich,UK) was added, and the sample was shaken well and
then centrifuged at 10,000 rpm for 5 min. The upper layer (600 pi) was then transferred into a
fresh microfuge tube. Then, 6 pi of sodium acetate (pi 1 5.1, 3 M) and 350 pi of 100 %
isopropanol were added. The sample was placed at -20X for 2 h, after which it was centrifuged
at 10,000 rpm for 5 min, the supernatant removed, and the pellet dried under vacuum. After 70 %
ethanol washing, the DNA pellet was re-suspended in 100 pi of 10 mM Tris, ImM EDTA (piI
8). This procedure was repeated in 9 other microfuge tubes and all samples were pooled and the
resulting pellet re-suspended in 100 pi of 10 mM Tris, ImM EDTA (pH 8). DNA concentration
was assessed using a Nanodrop spectrophotometer (Nanodrop ND 1000) and by agarose gel
electrophoresis. Phage DNA was digested with the restriction enzyme Hind 111 (Roche
diagnostics, GmbH, Mannheim, Germany) according to the manufacturer’s instructions.
Typically 0.5 pg of DNA was used for restriction digests. The genome size of the phage was
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estimated from the digest pattern (Fig 2b). The test for the presence or absence of cohesive ends
was determined as previously described (Forsman and Alatossava, 1991) using the restriction
enzymes EcoRV, Hindlll, and Sail (Roche diagnostics, GmbFI, Mannheim, Germany) (Fig 3).
Briefly, phage DNA samples were divided into two parts after restriction digestion. The first part
was loaded onto a gel as normal, whereas the second part was heated at 70°C for 10 min prior to
loading. All samples were then immediately separated by DNA electrophoresis in the usual
manner and band patterns were analysed.

DNA Sequencing
50 pi of 196 ng/pl DNA was sent for pyrosequencing (twenty fold sequencing coverage) at
Cogenics Genome Express using a 454 GS-FLX NextGen sequencing platform (Roche
Diagnostics, GmbH, Mannheim, Germany) as described by Henry et al. (2010).

Genome annotation
The assembled genome was annotated using the software package GAMOLA (Altcrmann and
Klaenhammer, 2003). The gene model was determined with GLIMMER 3.02 (Gene locator and
interpolated Markov ModelER (Delcher, 2007),
http://www.ncbi.nlm.nih.gov/genomes/MlCROBES/glimmer 3.cgi and sequence similarity
analyses were performed with the gapped BLASTp algorithm (Altschul et al, 1997) against the
non-redundant database provided by NCBl (ftp://ftp.ncbi.nih.gov/blast/db). The genome
annotation was then manually verified using the ARTEMIS package (Carver et a/.,2008)
www.sanger.ac.uk . Start positions, stop positions, and all putative genes were then manually
identified and confirmed with the aid of ARTEMIS and Blastp outputs (Table 1). A tRNA scan
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was carried out using tRNA scan SE (Lowe and Eddy, 1997) http://lowelab.ucsc.edu/cgibin/tRNAscan-SE.cgi. A search for tRNA and tmRNA was also undertaken using the ARAGON
tool (Laslett and Canback, 2004) http://l30.235.46.10/ARAGORN/. Both strands were searched
against the standard genetic code, assuming a linear topology.

Comparative analysis
A comparative analysis of the genome of Pediococcus phage clPl with its closet relative,
Lactobacillus plantarum phage OJL-1 was carried out with the Artemis Comparison Tool (ACT)
viewer (Eig 5) (www.sanger.ac.uk). Similarities between the genomes were determined through
BLAS'fn comparisons on the online program Double act (www'.sanger.ac.uk), and the resulting
alignment was visualized with the ACT package (Carver et a/.,2008).

Phylogenetic analysis
The putative llNll homing endonuclease gene (GRF 12) of phage clPl was selected for
phylogenetic analysis in an effort to provide further insight into its probable function for this
phage. PSl-BLAST (Altschul et <3/., 1997) search analysis of the non-redundant (nr) database was
used for population of multiple alignments. Seven PSl-BLAST iterations were used, after which
no new relevant sequences were identified. In total, forty three protein sequences were selected
for multiple alignment (Table 3) which were aligned using ClustalW (Thompson et (3/., 1994),
and trees were drawn using the neighbour-joining method in Mega 4 (Tamura et <3/.,2007). The
resulting phylogenetic tree was visualised using DENDROSCOPE (Huson et <3/.,2007) (Fig 6).
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Nucleotide sequence accession number
The genome sequence of phage clPl has been deposited in the Genbank database under
accession number JN051154.

Results and Discussion

Phage isolation
After enrichment in the presence of P. damnosus 82, phage clPl was isolated from a municipal
sewage plant sample in Clonmel, South Tipperary, Ireland. The phage gave non-turbid plaques
of diameter 0.7 mm in lawns of P. damnosus P82, indicating that it was undergoing a lytic
infection cycle on this host. It was also capable of fonning plaques on P. damnosus PI20 (Table
2). Phage were isolated from these plaques and propagated for extraction of phage DNA for
restriction analysis and also for sequencing. The phage was named according to the geographical
location where the sample was sourced (Clonmel) and the host bacterium on which it was
propagated (P. damnosus).

Phage host range
Analysis of host range results suggested that phage clPl had a narrow host range and was
restricted to infection of the species P. damnosus. No lysis was evident when phage clPl was
tested against a range of other pediococci which had been isolated from brewing
ingredients/environments (Table 2).
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Phage morphology
An electron micrograph of negatively stained phage clP 1 was obtained by transmission electron
microscopy (Fig 2 b). Morphological analysis of this image indicated that phage clPl had an
obvious non-contractile tail and hence belonged to the order Caudovimles. Tail length was 175
nm, while tail diameter was 10 nm. The phage also had an isometric head of dimension 59 nm x
53 nm. These morphological features suggested that phage clPl was a member of the
Siphoviridae family (Murphy et al. 1995) corresponding to group B as defined by Bradley
(1967).

Analysis of phage structural proteins (SI)S-PAGE)
SDS-PAGE was used to separate the structural proteins of phage clPl to enable further
characterization. Eight proteins were visualised on the gel, ranging in molecular mass from 22
kDa to 91 kDa (Fig. 4). Three major proteins of 22.7 kDa, 28.2 kDa and and 30.9 kDa were
identified as the putative major tail protein (ORF 57), a putative structural protein (ORF 7) and
major head protein (ORF 5) respectively. Three minor proteins of sizes 58.4 kDa, 75.6 kDa and
90.5 kDa were also observed and these were the minor head protein (ORF 8), putative minor tail
protein (ORF 51) and a putative structural protein (ORF 52). Two unidentified minor proteins in
the region of 40 kDa and 50 kDa were also evident on the gel.
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DNA Sequencing, analysis, and Genome annotation
The sequencing run resulted in 24,946 reads of which 98.7% was used for assembly into one
contig. The genome was found to be composed of 38,013 base pairs of linear double stranded
DNA, which includes 0.02% repeats. The GC content of the genome was 47.6%, which is higher
than the reported GC content (37.8% - 41.2%) of pediococci themselves, as determined by
physicochemical methods (Bohacek el al, 1969). Restriction digestion of phage DNA with the
enzymes EcoR V, Hindlll, and Sail revealed the same band patterns in heated and unheated
samples (Fig. 3) indicating that the genome of phage clPl was likely to be terminally redundant
and circularly permuted, and that the phage had a pac or “headful packaging” method of DNA
packaging into phage heads (Clokie and Kropinski, 2009; Forsman and Alatossava 1991). All
putative genes (ORFs) were located on the same coding strand and in the same orientation
(reverse). In total, fitly seven ORFs were identified of which twenty were assigned a putative
function based on their similarities to proteins with known functions. Start codons varied, with
the majority (43) of genes beginning with ATG, while seven began with both GTG and TTG. No
obvious tRNA or tMRNA genes were identified in the clPl genome sequence after both strands
were searched against the standard genetic code.
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Comparative analysis
Comparative BLASTn analysis of the clPl genome with its closest relative Lactobacillus
plantarum phage OJL-1 revealed that the phage indeed appears significantly novel and unique in
comparison to phages previously characterised. While the analysis gave a total score of 130, an E
value of 8e-25, and 77% identity, the query coverage spanned only a minute distance over the
genome length (0% equivalent value). Fig. 5 highlights this distant homology across both
genomes.

Phylogenetic analysis
The phylogenetic tree constructed from multiple alignment of the protein sequence of the
putative IINH Homing endonuclease of phage clPI with its forty three closest relatives (Table 3)
as determined by PSl-BLAST analysis is shown in Figure 6. Phylogenetic analysis revealed that
the closest relatives to the target protein were HNll endonuclease family proteins of bacterial
origin from Pseudomonas syringae pv. Tomato max 13 and Burkholderia glumae BGRl. Initial
BLAST’ analysis of the entire clPl genome had matched the putative IINH Homing
endonuclease with that

Streptococcus phage PH 15 (Table 1). Interestingly conserved

NUMOD4 domains were found in all four of these putative proteins. These are putative DNA
binding motifs found in homing endonucleases and related proteins (Sitbon and Pietrokovski
2003).
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Genome overview and general features
The majority of genomes of lactic acid bacteria (LAB) phages analysed consist of linear doublestranded DNA with a GC content consistent with that of the host chromosome. In addition, the
majority of genomes are 18-40 kb in length (Mcgrath et a/., 2004). Here we present the
nucleotide sequence of the novel virulent P. damnosus phage clPl. The phage has a linear
double-stranded DNA genome consisting of 38,013 bp (~38kb) and a GC content of 47.6%
which is higher than the reported GC content of its Pediococcus host (Bohacek et al., 1969;
Broadbent and Steele, 2010). Bioinformatic analyses revealed fifty seven putative ORFs, of
which thirty were assigned putative functions based on their homologies to previously
characterised proteins (Table 1). All ORFs were on the same coding strand and oriented in the
same direction (Fig. 1 A). This coding of genes on the same strand (Fabric et «/.,2008) and in the
same orientation (Lu et a/.,2005; Dupuis and Moineau, 2010) has also been reported recently for
phages ofL. lactis (Fabric et c^/.,2008; Dupuis and Moineau, 2010) and Lb. plantarum (Lu et
c?/.,2005). A total of twenty two ORFs showed homology to genes found in the Lb. plantarum
phage (hJL-1, making this phage the closest homologue to phage clPl (Fig 5). For the majority
of the remainder of the putative genes, homologies were found to genes in phages of lactic acid
bacteria or in lactic acid bacteria themselves. Twenty seven ORFs could not be assigned putative
functions highlighting the unique nature of this novel genome (Table 1).
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Genome organization.
Phages of the Siphoviridae family have previously been reported to have a conserved modular
organisation (Lucchini et a/., 1999; Desiere et al.,2001; Brussow and Desiere, 2001). This
organisation is illustrated in Figure lb. While the phage clPl genome was also modularly
organised, containing DNA-packaging, head and tail morphogenesis, host cell lysis, and DNA
replication modules, the actual order of these modules differed slightly from the consensus
organisation mentioned above (Fig la). In addition all genes were coded on the reverse strand
and in the reverse orientation. Botstein (1980) has suggested a theoi^ of modular evolution for
phages. He proposed that a family of interchangeable genetic elements, which he termed
modules were the product of phage evolution rather than the whole phage itself. He also
proposed that evolution acts at the level of these modules and not at the level of the intact phage.
Thus, phages are found to be modularly organised in a manner which enables them to adapt to
their particular niche and life cycle. In addition module exchange through recombination occurs
among phages in an interbreeding population (Botstein 1980). In developing this theory, Flendrix
et al. (1999) proposed a model whereby all double-stranded phage genomes are considered
mosaics with access to a large common genetic pool by horizontal exchange, but in which access
is not uniform for all phages. It is therefore possible that the unusual genome organisation of the
phage clPl may result from a lack of horizontal exchange with more commonly occurring
phages or indeed that the genome organisation, which the phage presents is the one that leaves it
best adapted for survival in its own particular niche. In addition, the absence of any previous
Pediococcus phage genome data in the scientific literature highlights the possibility that this may
simply be a norma) genome arrangement for this phage genus which has not been previously
identified.
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DNA packaging and Head assembly
The DNA packaging and head morphogenesis genes comprise the early gene cluster in the
genome (Figla). ORFs 1 -9 exhibited homology to hypothetical proteins of the Lb. plantanim
phage (FJL-l (Lu et al.,2005). These included the head to tail joining protein (ORF’ 1), the DNA
packaging protein (ORF 3), Scaffold protein (ORF 6) major head protein (ORF 5), minor head
protein (ORF' 8), and the putative large terminase subunit (ORF 9). The product of ORF 1
encoded a conserved phage protein HK 97 gp 10 family domain. This family is related to a
morphogenesis family involved in tail completion. It also encoded a DUF646 conserved phage
protein domain, which is present in caudovirales and may be a tail component (Marcher-Bauer et
al.,20 \ 1). The protein encoded by ORF 3 also contained conserved domains, a gp6- like head to
tail connector protein domain (Cardarelli et al.,2010), and a gp 15 head to tail connector protein
found in SPPl like phages (Lhuillier et al.,2009). This suggested that ORF 3 had a dual role in
DNA packaging and head to tail joining. Interestingly, the product of ORF 8 encoded phage
portal protein conserved domains similar to gp 6 of the SPPl superfamily (Lurz et al.,200\).
Perhaps ORF 8 had a dual role also in this phage genome. The large subunit terminase function
of ORF 9 was confirmed by the presence of conserved PBSX, XtmB, and Terminase 3
superfamily domains (Marcher-Bauer et al.,20\ 1). The derived protein product of ORF 10 was
homologous to the small terminase subunit of the temperate Lb. plantarum phage phi-gle
(Kodaira et al., 1997). In tailed phages, the small terminase subunit, specifically binds DNA,
while the large subunit cleaves phage DNA into genome units and allows prohead binding
(Black 1989). A terminase 2 small subunit conserved domain (Black 1989) was also found
encoded by this ORF. The location of the small and large terminase genes beside each other in
the genome as was found for phage clPl has been reported previously (Rao and Feiss, 2008).
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The general rule that the cos or pac DNA interaction sites of the terminases are located close to
or within the structural genes (Black 1989) was also found to be true for phage clPl (Fig la).
After restriction of phage clPl DNA with restriction enzymes, no alteration in the banding
pattern was seen after heating the restricted DNA to 70°C (Fig. 3). This suggested that phage
clPl exploited the pac DNA packaging mechanism. In pac phages a specific site (pac site) is
recognised by the terminase in multiple phage genomes made in the host cell prior to packaging
(DNA concatemer) and the DNA is cleaved at this site. Packaging then begins into each phage
head. When the first phage head has its full DNA load, the DNA is cleaved and the next empty
phage head is filled and so on. Importantly, apart from the initial cleavage at the pac site,
cleavage does not occur at a specific site for the remainder of the packaging event but only when
the phage head is full. Hence, pac phages contain DNA which has not been cleaved accurately
and may have the same sequence at either end of one genome. Upon infection of a host cell these
direct repeated termini can undergo homologous recombination to generate a circular genome for
replication. As a consequence, pac phages usually have genomes which are circularly permuted
and terminally redundant. Cos phages on the other hand employ a packaging method whereby
the DNA is cleaved at a specific site (cos site) before packaging into each phage head, and hence
phage DNA has cohesive ends in these genomes (Clokie and Kropinski, 2009). Another lytic
Pediococcus phage was found to employ this pac method of packaging also (Yoon et a/.,2007).
Portal proteins are typically found in the packaging module of phages and have a molecular mass
of between 40-90 kDa. They form a hole (portal) which facilitates passage of DNA into the
phage head during packaging (Leiman et a/.,2003). Despite the fact that no obvious putative
portal protein was found in the genome sequence, the position of ORFs 2, 4, and 7, close to both
putative packaging, and head genes suggests that one of these ORFs may be the phage portal
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protein, although their molecular masses are considerably lower than the values usually
associated with these proteins (Table 1). In addition, the product of ORF 7 was found to contain
a conserved putative head morphogenesis protein of the SPPl gp 7 superfamily, and a conserved
phage Mu F like protein which are both involved in head morphogenesis (Marcher-Bauer et
al.,20\\). The gene product of ORF 12 shared homology (33% identity) to the HNH
endonuclease of the Streptococcus gordonii phage PH 15 (Van Der Ploeg 2008). HNH homing
endonucleases are DNA-cleaving enzymes that mobilize their own reading frames by generating
double strand breaks at specific sites in target genomes. These endonucleases are found in
microbes from all biological kingdoms as well as in phages and other viruses (Stoddard 2011).
They can exist as free-standing ORFs between genes or within introns or inteins, driving the
mobility of their own genes or of the introns / inteins in which they reside (Chevalier and
Stoddard, 2001). In phages these HNH endonucleases arc known to have many potential roles
and these include functions in replication, repair, recombination, maturation and packaging of
DNA (Crutz-Le Coq ct <7/.,2002). They have also been known to cleave the DNA of foreign
phage in mixed infections, thus conferring an evolutionary advantage on their phage host
(Stoddard 2011). Edged et al. (2010) has extensively reviewed phage encoded homing
endonucleases and stated that an evolutionary strategy utilised by these enzymes is that they
insert themselves within or near genes which are functionally critical to the phage such as DNA
enzymes. This was indeed the case with the putative HNH homing endonuclease of phage clPl
which was positioned close to the putative terminase genes (Figl A). The position of this ORF in
the genome suggested that the HNH endonuclease is involved in DNA packaging. This theory is
further enhanced by the fact that the putative HNH endonuclease of phage clPl also encoded a
conserved NUMOD4 DNA binding domain, which is known to initiate highly specific DNA
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binding (Sitbon and Pietrokovski 2003). Potential roles that the endonuclease may play in
packaging include acting as a cleaving subunit of a terminase, or in the clearing of branched
replicative DNA before packaging is initiated (Crutz-Le Coq et a/.,2002). Phylogenetic analysis
of the putative HNH endonuclease of phage clPl revealed that the protein shared closest
homology to HNII endonucleases of bacterial origin after PSl-BLAST iterative searches (Fig 6),
highlighting the diverse and adaptable nature of these enzymes.

DNA Replication
The DNA replication module of phage clPl is situated upstream of the lysis genes (Figla). This
arrangement differs to the consensus Siphoviridae genome where the replication module is most
commonly the late cluster module of the genome (Fig lb). Putative functions were assigned to
ORFs 33 (Ilelicase), 34 (DNA binding protein), 38 (Replication protein), 42 (Primase), and 43
(NTP-binding I lelicase). The predicted gene product of ORF 33 shows strong similarity to the
putative DNA helicase

Lactobacillus phage T>JL-1, while ORF's 42 and 43 display homologies

to the primase and NTP-binding helicase respectively of this same phage (Lu et al.,2D^5).
I lelicases unwind duplex DNA, providing a single strand for replication (Lionnet et ^7/.,2007),
while the primase enzyme catalyses the synthesis of short RNA molecules used as primers for
DNA polymerases (Frick and Richardson, 2001). ORF 34 showed homology to a DNA binding
protein of Enterococcus faecalis TX0104. These binding proteins usually regulate transcription
by binding to DNA sequences and activating or inhibiting the transcription of genes (Myers and
Komberg, 2000). A replication function has been assigned to ORF 38 which shares homology to
a putative replication protein of the Bacillus phage SPPl (Alonso et al, 1997). This replication
protein had conserved NUMOD4 and NUMODl domains, representing DNA binding, and helixtum-helix functions respectively in the replication process (Marcher-Bauer et al.,2011). The
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remaining ORFS in the predicted replication module could not be assigned predictive functions
and hence it could only be deduced that they play some role in the replication process of phage
clPl (Table 1).

Host cell lysis
The lysis module of phage clPl is embedded between the replication and tail modules (Figla),
and consists of ORf s 47 and 48, which encode a putative lysin and putative holin respectively.
This dual holin-lysin systcmi is responsible for host cell lysis and progeny release in double
stranded DNA phages (Daniel et <3/.,2007). ORF 47 shares a strong sequence similarity (79%
identity) with the putative lysin oi'Lactobacillus phage (hJL-l (Lu et al.,2005) (Table 1). This
protein was found to encode a characteristic G1I25 Murarnidase superfamily domain (MarcherBauer et al.,20 \ 1) involved in bacterial cell wall degradation. ORF 48 displays a more distant
homology (39%) to its closest match, which was predicted to be the putative holin of the L. casei
temperate phage OATS (Chun lo et al.,2005) (Table 1). This putative protein also encoded a
conserved domain termed the holin LLM superfamily domain found in phage and prophage
regions of gram positive bacteria (Marcher-Baucr et al.,20\\).

Tail assembly and structural protein analysis
The tail morphogenesis module was situated downstream of the lysis module and most likely
encompasses ORFS 49-57 (Fig la). The products of ORFs 51 and 53 showed homology to two
putative minor tail proteins oi Lactobacillus phage OJL-1 (Lu et al.,2005) (Table 1). The
putative best match for ORJ^' 51 was found to encode a conserved DUF2479 domain, a domain of
unknown function found in phages of several bacterial genera, which has been postulated to be a
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long tail fibre protein (Marcher-Bauer et al.,2Q \ 1). Similarly the product of ORF 53 was found to
have similarity to a minor tail protein which had a conserved Sipho tail superfamily domain. This
superfamily consists of Siphoviridae and other phage tail components as well as bacterial
proteins of unknown function (Marcher-Bauer et al.,2Q \ 1). The best match obtained for the ORF
54 of phage clPl was the putative tape measure protein of Lactobacillus phage OJL-1 (Lu et
a/.,2005) (Table 1). These proteins determine the length of the phage tail, which is directly
proportional to the size of the tape measure protein (Katsura 1987). They are found in almost all
Siphoviridae phages (Pcdulla et al.,2DQ2)) and are usually 800 - 5006 amino acids in length
(Minakhin et ti/.,2008). The putative tape measure protein of phage clPl was 1084 amino acids
in length, and is therefore certainly most likely to be the phage tape measure protein. This was
further enhanced by the presence of a conserved tape measure TP901 family domain core region
(Pedersen et al.,2i)00) and also a conserved phage related minor tail protein, often found in phage
tape measure proteins (Marcher-Bauer et al.,2i) \ 1). The final ORF in the tail morphogenesis
module which could be assigned a putative function was ORF 57 which again showed homology
(66%) to a protein from Lactobacillus phage OJL-1 (Lu et a/.,2005), on this occasion the major
tail protein (Table 1). This protein contained a phage tail 2 superfamily domain, characteristic of
phage major tail proteins (Marcher-Bauer et al.,2^ \ 1). The remaining ORFs in the tail
morphogenesis module could not be assigned putative functions although ORFs 50 and 55
displayed homology to proteins in Lb. reuteri and Lb. paracasei, perhaps suggesting that this
phage may have evolved some genes from phages of other species. Interestingly, the putative
head to tail joining protein of phage clP 1 which displayed homology to the head to tail joining
protein of Lactobacillus phage OJL-1 (Lu et <3/., 2005), was located at ORF 1 of the genome
before the head morphogenesis genes and at the opposite end of the genome to the tail genes.
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Perhaps this phage has evolved a meehanism to circularize its genome at some point during
replication hence leaving this gene conveniently located between the genes for head and tail
morphogenesis.
Structural protein coding ORFs were confirmed by separation of a purified phage sample by
SDS-PAGE. Eight structural proteins were identified and most of the molecular masses obtained
from the SDS-PAGE analysis correlated well with the correspondent masses determined from
genome sequencing (Fig 4). Three major proteins were identified, which is typical of a pac type
phage. The major tail protein (ORE 57) had a molecular mass of 22.7 kDa and was most similar
to the major tail protein

Lactobacillus phage OJL-1 (Lu et t//.,2005). This had an estimated

molecular weight (MW) of 28 kDa (Lu et <3/.,2005). The major head protein of phage clPl (ORF
5) also showed homology to one of the major head proteins oiLactobacillus phage OJL-1 and its
MW of 30.9 kDa agreed well with that of the protein of phage OJL-1 (Lu et a/.,2005). The
function of the third major protein was not determined although its location at ORF 7 in the
genome suggested it was a structural protein involved in head assembly (Table 1). Two of the
minor proteins identified at ORFs 8 and 51 were determined to be the putative minor head
protein and putative minor tail protein respectively. Both of these proteins again showed closest
homology to proteins of Lactobacillus phage cDJL-1 (Lu et <3/., 2005).
Their molecular masses of 58.4 kDa and 75.6 kDa agreed well with the molecular masses of 61
kDa and 76 kDa respectively for the corresponding proteins of phage OJL-l (Lu et <3/.,2005).
The location in the genome close to tail morphogenesis genes of the minor stmctural protein
deduced from ORF 52 (Table 1) suggested that it was a structural protein involved in phage tail
assembly (Fig lA). Two unidentified minor structural proteins were also evident on the SDS gel
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and no probable function could be assigned to these based on their estimated molecular masses
(Fig 4).

Conclusion
In conclusion, phage clPl is a novel virulent phage whose evolution has led to its infection of the
beer spoilage species P. damnosns. While the overall genome organisation satisfies all
requirements for the completion of a virulent life cycle, the order of the modules in the genome
differs slightly to the consensus genome arrangement of the Siphoviridae family. The
morphological features of phage clPl were very similar to those observed for Pediococcus
phages previously reported in the literature (Uchida and Kanabe 1993; Caldwell et a/., 1999;
Yoon et aL,2001). Nucleotide sequence analysis of the genome of phage clPl indicated that this
phage was not closely related to any phages previously characterized, highlighting the large level
of diversity associated with this novel phage. However the large number of putative ORF
matches to genes in phages of lactobacilli, and in some cases of lactobacilli themselves suggest
that this phage may possibly be derived from a phage infecting lactobacilli. This is perhaps not
surprising as lactobacilli often occupy similar niches to pediococci. This phenomenon has
previously been reported between phages of Lactococcus and Listeria (Dupuis and Moineau,
2010). Phylogenetic analysis of the putative HNH endonuclease of phage clPl indicated that it
most likely encompassed a DNA packaging function. In keeping with the virulent nature of the
phage as determined phenotypically, no lysogeny module was found in the genome suggesting
that phage clPl did not evolve from a temperate ancestor. In addition, no definitive anti-receptor
gene was observed in the genome and hence phage clPl may possibly have evolved a novel
method for host binding. Anti-receptor genes include those encoding lower baseplate proteins
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(Vegge et al, 2006). Also interestingly BLAST analysis of ORF 24, a putative phage protein
located in the middle of the genome and flanked on both sides by genes of unknown function,
indicated that this gene encoded a VRR NUC superfamily domain. This family is considered a
restriction endonuclease -like fold family present among hypothetical proteins (Kinch et
a/.,2005). Thus it is possible that the phage may have evolved this protein as a protective
mechanism or possibly to cleave the DNA of competing phages as is often carried out by phage
homing endonucleases (Stoddard 2011).
Pediococci themselves arc found at many stages in the brewing process and pose a spoilage
threat from the wort to the final beer product (Sakamoto and Konings 2003). An interesting
recent study has suggested that hops resistant Pediococcus isolates which grow in beer tend to
encounter no selective pressures to express genetic mechanisms for antimicrobial resistance.
Consequently, it has been reported that these beer spoilers tend to be more susceptible to
common antimicrobial compounds than isolates which do not grow in beer (Ilaakensen et
a/.,2009). This suggests that phages are a viable option for the treatment of these Pediococcus
isolates and perhaps of beer spoilage bacteria in general (Kelly et al.,2{) \ 1). Ironically phages of
lactic acid bacteria have commonly been problematic in the infection of lactic acid bacteria
starter cultures which are used in the manufacture of fermented foods. However in this study we
have referred to their beneficial use for the eradication of spoilage bacteria in the brewing
industry. The sequencing of the phage clP 1 genome has highlighted some unusual properties in
its organisation. This opens up opportunities for further studies on phage evolution. Ln general,
the application of phages for bio-control requires that the genome is characterised to ensure that
it is exclusively lytic for the above application.
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Table 1. Gene eoordinates and predicted protein sizes and functions for the
clPl genome. Details of best matches obtained from BLASTn analysis along
with accession numbers are also shown.
Stop

F/R

Size
(aa)

MW
(kda)

Start
codon

Predicted function

Best match

%
ID

E value

709

335

R

125

980

705

R
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ttg

Head to tail joining protein

Phage phiJL-1

65

10.2

atg

Hypothetical protein

Phage phiJL-1
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1324

980

R

1604
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R
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13.1
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Putative DNA packaging protein

Phage phiJL-1
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Hypothetical protein

2512

1655

R

Phage phiJL-1

286

30.9
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Major head protein

Phage phiJL-1
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putative scaffold protein
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Hypothetical protein
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Phage phiJL-1
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R
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Putative large suhunit terminase

R
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Putative terminase small subunit
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Unknown protein
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putative PfNH homing endonuclease
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Unknown protein
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Unknown protein
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Accession number
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YP_223 893.1
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286

Phage phiJL-1
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ttg
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Lactobacillus
phage phiJL-1
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l.OOE-173

YP_223915.1

467

DNA binding protein

Enterococcus
faecalis
TX0104
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ZP 03949595.1
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11.8
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18623
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Hypothetical protein
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ttg

Unknown protein
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Unknown protein
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Unknown protein
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atg

Unknown protein
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atg

Primase
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R
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atg
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Hypothetical protein
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atg

Hypothetical protein
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Unknown protein
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25712
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413
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atg
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atg

Putative holin

27433
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ttg

Unknown protein

27822

27454

R
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14

atg

Hypothetical protein

29942

27837

R

702

75.6

atg

Putative minor tail protein

32415

29926

R

830

90.5

gtg

Hypothetical protein

33248

32430

R
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30

ttg

Putative minor tail protein

36515

33264

R

1084
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atg

Putative tape measure protein

36758

36522

R
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8.7

atg

Hypothetical protein

37240

36839

R

134

15.2

atg

Hypothetical protein

37897

37274

R

208

22.7

atg

Putative major tail protein
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Lactobacillus
plantarum
phage phiJL-1

48

2.00E-29

YP_223913.1

153

Bacillus phage
SPPl

38

l.OOE-04

NP_690858.1

163

43

l.OOE-137

YP_223911.1

637

77

2.00E-94

YP_223910.1

224

50

4.00E-59

YP_223909.1

246

36

5.00E-11

YP_223908.1

134

79

0

YP_223905.1

398

39

6.00E-14

YP_025044.1

129

44

4.00E-24

ZP 03973563.1

126

34

9.00E-26

YP 223901.1

749

58

l.OOE-146

YP 223900.1

738

55

2.00E-48

YP 223899.1

441

45

0

YP 223898.1

1133

43

2.00E-07

ZP 03964229.1

89

46

3.00E-24

YP 223896.1

139

66

2.00E-72

YP 223895.1

199

Lactobacillus
plantarum
phage phiJL-1
Lactobacillus
plantarum
phage phiJL-1
Lactobacillus
plantamm
phage phiJL-1
Lactobacillus
plantamm
phage phiJL-1

Lactobacillus
plantamm
phage phiJL-1
Lactobacillus
phage phiAT-3

Lactobacillus
reuteri CF483A
Lactobacillus
plantamm
phage phiJL-1
Lactobacillus
plantamm
phage phiJL-1
Lactobacillus
plantamm
phage phiJL-1
Lactobacillus
plantamm
phage phiJL-1
Lactobacillus
paracasei subsp.
paracasei
ATCC 25302
Lactobacillus
plantamm
phage phiJL-1
Lactobacillus
plantamm
phage phiJL-1

Table 2. Host range oiPediococcus phage clPl.

1
2
3
4
5
6
7
8
9
10
11
12

Strain name
Pediococcus damnosus P82
Pediococcus damnosus P120
Pediococcus acidilactici DSM 20284
Pediococcus claussenii DSM 14800
Pediococcus ethanolidurans DSM 22301
Pediococcus inopinatus DSM 20285
Pediococcus inopinatus DSM 20287
Pediococcus pentosaceus DSM 20280
Pediococcus pentosaceus DSM 20283
Pediococcus pentosaceus DSM 20336
Pediococcus stilesii DSM 18001
Pediococcus cellicola DSM 17757

Origin
German brewery
German brewery
Barley
Spoiled beer
Walls of a distilled spirit fermenting cellar
Brewery yeast
Beer
Brewery yeast
Barley
Dried American beer yeast
White maize grains
Distilled spirit fermenting cellar

128

Phage lysis ( + / -)
+
+
-

Table 3. Predicted protein functions and corresponding Genbank accession numbers for HNH
homing endonuclease of phage clPl and its closest relatives.
Number

Predicted protein

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

HiNH endonuclease. Pediococcus phage clPl
Putative eiidodeoxyribonuclease. Lactobacillus phage phiAT3
Putative endodeoxyribonuclease. Lactobacillus phage A2
HNH endonuclease. Bacteroides sp. 3 1 33FAA
HNH endonuclease protein. Prophage LambdaSa2. Bacteroides sp. 20 3
HNH endonuclease protein. Prophage LambdaSa2. L. rhamnosus HNOOl
Putative HNH homing endonuclease. Streptococcus phage PH 15.
Phage-related HNH endonuclease. Lactobacillus rhamnosus Lc 705
Endonuclease. Lactobacillus phage Lrml
HNH endonuclease protein. Prophage LambdaSa2. 5. agalactiae 2603V/R
HNH endonuclease protein. Prophage LambdaSa2. L. rhamnosus HNOOl
HNH endonuclease protein. Prevotella buccalis ATCC 353 10
Homing nuclease. Bacteroides sp. 3 1 33FAA
Hypothetical protein. LP65 gpl43. Lactobacillus phage LP65
Putative HNH endonuclease. Lactobacillus phage Lc-Nu
HNH endonuclease family prophage LambdaSa2. Lactobacillus vaginalis ATCC
49540
HNH endonuclease protein. Enterococcus phage EFRM31
Homing nuclease. Lactobacillus amylovorus GRL 1112
Putative HNH endonuclease. Lactobacillus phage Lc-Nu
Putative HNH endonuclease, Phage associated. S. carnosus subsp. Camosus
rM300
HNH endonuclease. Deep-sea thermophilic phage D6E
ORF 027. Staphylococcus phage 88
HNH endonuclease. Staphylococcus epidermidis .VI23864:W1
Cjp33. Mycobacterium phage Ramsey
Putative endonuclease. Lactobacillus phage phiAT.3
NUMOD4 domain protein. Sinorhizobium meliloti AK83
HNH endonuclease domain protein. Bacteroides fluxus YIT 12057
Putative HNH endonuclease. Lactococcus phage CFH4
Replication protein. Bacillus phage SPPl
Putative DNA endonuclease. Bacillus cereus AH 1134
GP51. Mycobacterium phage Omega
HNH endonuclease family protein. Gramella forsetii K'r0803
Homing nuclease. Lactobacillus gasseri ATCC 33323
Putative HNH homing endonuclease. Lactobacillus phage phiJL-1
HNH endonuclease family protein. Pseudomonas syringae pv. Tomato Maxi 3
GP42. Mycobacterium phage Ardmore
YL247 .MIMIV' RecName: Full uncharacterized HNH endonuclease L247
Uncharacterized HNH endonuclease. Acanthamoeba polyphaga mimivirus
HNH endonuclease family protein. Gramella forsetii KT0803
HNH endonuclease protein. Prophage LambdaSa2. Bacillus cereus G9241
Putative HNH homing endonuclease. Lactococcus phage Bill 70
HNH endonuclease protein. Prophage LambdaSa2. Blautia hansenii DSM 20583
GP 31.2. Bacillus phage SPOl
HNH endonuclease family protein. Burkholderia glumae BGRl

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
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Genbank Accession
number
JN05n54
YP 025078.1
NP 680539.1
ZP 06090618.1
ZP 07216293.1
ZP 03212364
YP 001974337.1
YP 003173557.1
YP 002117719.1
NP 688865.1
ZP 03212345.1
ZP 06288160.1
ZP 06090620.1
YP 164778.1
YP 358806.1
ZP 03960649.1
YP 004306639.1
YP 004031905.1
YP 358789.1
YP_002633 575.1
ADE87501.1
YP 240718.1
ZP 04818974.1
YP 002241820.1
YP 025062.1
ZP 07596591.1
ZP 08300506.1
ACU46908.1
NP 690858.1
ZP 03232611.1
NP 818352.1
YP 862450.1
YP 814436.1
YP 223875.1
ZP 07230506.1
YP 003495183.1
Q5UPT4.1
YP 003986743.1
YP 862519.1
ZP 00240331.1
NP 047162.1
ZP 05854223.1
YP 002300418.1
YP 002911398.1
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Figure 1. (a) Map of phage clPl genome. Each arrow represents an open reading frame (ORE)
and numbering refers to Table 1. Arrows are orientated according to the direction of
transcription. The 57 ORES which were identified are shown, and predicted functions
determined by bioinformatics analyses are indicated for the main genes, (b) Conserved modular
organizational pattern usually found in the genome of phages of the Siphoviridae family.
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(a)

(b)
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Figure 2. (a) Phage DNA digested with HindiU restriction endonuclease, lane 1, 10-kb
ladder (Bioline); lane 2, Phage elPl. (b) Electron micrograph oiPediococcus phage clPl. The
sample was negatively stained with 2% uranyl acetate. Scale bar represents 100 nm
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Figure 3. Restriction endonuclease analysis of phage cl PI DNA to determine packaging
mechanism. The phage DNA was digested with EcoKW, HindXW, and Sail restriction enzymes.
Lanes 1 and 8: (M) 10 kb DNA ladder (Bioline). Lanes labeled 1 and 2 indicated that digests for
each enzyme were heated and unheated prior to electrophoresis respectively.
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Protein
size in kDa

Functional
assignments

90.5
75.6
58.4

Structural protein (ORF 52)
Putative minor tail protein (ORF 51)
Minor head protein (ORF 8)

Q9
30.6

Major head protein (ORF 5)
Structural protein (ORF 7)

3

22.7

Putative major tail protein (ORF 57)

Figure 4. SDS-PAGE electrophoresis protein profile for phage clPl and functional assignments
of proteins. The sizes (in kDa) of the proteins in the molecular mass standard are indicated on the
left of the gel, while protein sizes (in kDa) and functional assignments of visualized protein
bands are shown on the right of the gel.
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Figure 5. Alignment of the phage clPl genome with its closest homologue, Lactobacillus
plantanim bacteriophage PhiJL-1 using the ACT software. Lines between the genomes represent
DNA:DNA similarities (BLASTn) between both sequences. The entire genome lengths were
used for the BLASTn scan. Red lines represent corresponding regions that are oriented similarly,
while blue lines represent regions of similarity oriented in opposite directions.
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Endonuclease. Lactobacillus phage phiAT3 (2)
Endonuclease. Lactobacillus phage A2 (3)
Endonuclease. Lactobacillus phage Lrmi (9)
Prophage HNH endonuclease. L. rhamnosus (11)
Prophage HNH endonuclease. L. rhamnosus (6)
Phage-like HNH endonuclease. L. rhamnosus (8)
Endonuclease. Lactobacillus phage Lc-Nu (15)
Endonuclease Lactobacillus phage phiJL-1 (34)
gp143. Lactobacillus phage LP65 (14)
Endonuclease. Lactobacillus phage phiAT (25)
Homing nuclease. Bacteroides sp. (13)
Homing nuclease. L. amylovorus (18)
HNH endonuclease. Bacteroides sp. (4)
Prophage HNH endonuclease. Bacteroides sp. (5)
HNH Endonuclease. P. buccalis (12)
Prophage endonuclease. L vaginalis (16)
Homing nuclease. L.gassed (33)
HNH endonuclease. Streptococcus phage PH15 (7)
Prophage HNH endonuclease. S. agalactiae (10)
-Phage associated endonuclease. S. carnosus (20)
HNH endonuclease. S. epidermidis (23)
ORF027. Staphylococcus phage 88 (22)
Replication protein. Bacillus phage SPP1 (29)
Endonuclease. Lactobacillus phage Lc-Nu (19)
Endonuclease domain protein. B. fluxus (27)
DNA endonuclease. B. cereus (30)
Prophage endonuclease. B. cereus (40)
HNH endonuclease. Lactococcus phage CBM (28)
Endonuclease. Lactococcus phage blL170 (41)
Uncharacterized HNH endonuclease L247 (37)
HNH endonuclease A. polyphaga mimivirus (38)
Endonuclease. Enterococcus phage EFRM31 (17)
gp31.2 Bacillus phage SP01 (43)
NUMOD4 domain protein. S. meliloti (26)
Prophage endonuclease. B. hansenii (42)
Endonuclease. Deep-sea thermophilic phage D6E (21)
HNH endonuclease protein. G. forsetii (32)
Putative HNH endonuclease. Pediococcus phage cIPI
HNH endonuclease protein. P. syringae (35)
HNH endonuclease protein. B. glumae (44)
HNH endonuclease protein. G. forsetii (39)
-gp42. Mycobacterium phage Ardmore (36)
gp33. Mycobacterium phage Ramsey (24)
gp51. Mycobacterium phage Omega (31)
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Figure 6. Phylogenetic analysis of the putative HNH Ploming Endonuclease of phage clPl with
its closest relatives by the neighbour-joining method. Bootstrap values represent the number of
times a node was supported in 1000 sampling replications

136

Chapter 4
Development of a broad-host-range phage coektail for biocontrol

Bio engineered Bugs. (2011). 2(1), 31-37.
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Abstract
The aims of this study were to investigate the incidence of different resistance mechanisms to
phage K in a bank of Irish Staphylococcus aureus (S. aureus) hospital strains; and to develop a
broad host-range phage cocktail with enhanced lytic activity against those strains which were
previously phage resistant. A bank of 180 S. aureus strains, which included a diverse range of
the sequence types currently in circulation in Ireland, were tested for sensitivity to phage K.
Twenty nine strains were identified, which did not permit plaque formation. The phage
resistance systems in the 29 strain were investigated and it was found that restriction
modification (r-m) was evident in 24, an adsorption inhibition mechanism was evident in three,
while two were resistant by an unidentified mechanism. Seventeen modified derivatives of phage
K were developed which could circumvent all the r-m systems. Nevertheless, six of the modified
phage were considered superior in terms of their individual host ranges. These six were pooled as
a cocktail with phage K, which then lysed 24 of the 29 resistant strains (97.2% of the entire
staphylococcal bank). In conclusion, phage resistant systems affecting phage K are common in S.
aureus but it is possible to significantly broaden the host-range of this phage for biocontrol
applications.
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Introduction
The emergence of pathogenic bacteria which are resistant to the majority of currently available
antimicrobial therapies, along with the increase in numbers of immunosuppressed hospital
patients has become a major problem in the modem medical world.^ Antibiotic resistant S.
aureus in particular is now considered one of the most common causes of both communityacquired and nosocomial infections which are difficult to eliminate. ’ This trend of increasing
antibiotic resistance, combined with the financial burden on health systems has led to a renewed
interest in the use of alternative antibacterial agents, including phages.Phages had been
utilised as antibacterial agents for decades in phage therapy for the elimination of pathogenic
bacteria, including staphylococci in humans ^, but this practice disappeared in the Western world
since the 1940s with the introduction of antibiotics. As a result of the antibiotic resistance issue
primarily, recent years have seen a renewed research interest in phage therapy.One of the
main challenges and prerequisites for phage therapy is for the candidate phage to have a
relatively broad host range and also to be exclusively virulent to avoid the risk of transmission of
bacterial DNA by transduction. Previous work by our group has indicated that phage K fulfils
both of these characteristies. ’

Generally, it is considered that the use of single phages is usually

ineffective as many phage have a limited host range when used alone. ‘ Thus while narrow
host range is useful for phage typing, it is undesirable in phage therapy and biocontrol
applications.’^ The most common approach for circumventing this limitation is the development
of phage mixtures composed of a variety of phage isolates and several studies have detailed the
development and use of phage mixes, each containing a number of phages for biocontrol
purposes. '

Related to phage host-range is the existence and prevalence of phage resistance

systems in target bacteria.
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In this study we describe the incidence of different systems of phage resistance to phage K in
180 strains of S. aureus. We also describe the development of modified phages from a single
phage isolate, by multiple passage on phage resistant strains. This is followed by the pooling of
these phages as a cocktail with extended host-range capabilities against a bank of phage resistant
Irish S. aiirms hospital strains.

Materials and Methods

Bacterial strains, phage and growth media
All microbial strains used in the study are listed in tables 1 and 4 Strains were grown at 37°C in
Brain-Heart Infusion (Bill) broth (Sigma Aldrich,UK). Solid media contained 1.0% (w/v)
bacteriological agar (Sigma Aldrich,UK). All strains were stocked at -8()°C in Bill broth
containing 40% glycerol in the Cork Institute of Technology (CIT) culture collection. Filtersterilised phage K was stored at 4°C in Bill broth.
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Antibiotic sensitivity by disk diffusion method
All strains used in the study were tested to determine their antibiotic resistance profiles according
to the Performance Standards for Antimicrobial Disk Susceptibility Tests, published by the
Clinical and Laboratory Standards Institute

using 12 common antibiotics: Vancomycin (VA

30pg), Ciprofloxacin (CTP 5pg), Erythromycin (E 5pg), Gentamycin (CN lOpg), Oxacillin (OX
Ipg), Fusidic Acid (FD lOpg), Methicillin (MET 5pg), Tetracycline (TE lOpg), Ampicillin
(AMP lOjLig), Teicoplanin (TEC 30pg), Mupirocin (MUP 5pg), Trimethoprim (W 5pg). The
resulting zones of inhibition for respective isolates were measured and compared to the standards
given by the CLSl, and the resistance profile of each strain interpreted as Resistant (R),
Intermediate Resistance (1), or Sensitive (S), accordingly.

Incidence of phage resistance
The incidence of phage resistance in S. aureus was defined by plaque assay as previously
described. 23

Bacteriophage propagation
Phage K was routinely propagated in BHI broth on S. aureus DPC5246 as described
previously.^"^ Typically three rounds of plaque purification were carried out before phage K was
used for experimental work.

141

Modified phage preparation
A multiple passage method was used for the development of modified derivatives of phage K on
previously resistant strains. 100 pi of an overnight culture of each phage resistant strain (grown
from a 1% inoculum) was added to 10 ml of Bfll broth in a test-tube. After two hours, 1 ml of
o

high-titre (>10 PFU/ml) phage K in Bill broth was added to each strain and incubated under
conditions suitable for phage propagation (37°C with shaking). Positive and negative control
tubes were also included and these were composed of 5. aureus DPC5246 in the presence and
absence of phage K respectively. When clearing was observed in the phage sensitive sample, all
phage resistant strain samples were centrifuged and filter sterilised to remove cells. One ml of
this supernatant was then added to a fresh culture of the same strain as used in the first
propagation. This provided an opportunity for modified phage to propagate to high numbers.
Rounds of propagation were repeated for each phage resistant strain until clearing was observed
in broths, indicating a high titre of modified phage. Modified phages were plaque purified and
named according to the propagating host used.

Modified phage cocktail preparation
The phage cocktail was composed of modified phage with the broadest host range and also the
original phage K. This was prepared either from high titre broth preparations of the individual
phages or ultra-centrifuged phage preparations. Ultracentrifugation was performed as described
previously.*’
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Bacteriophage host range tests
The plaque assay technique and the spot test technique were used as previously described to
ascertain host-range. The efficiency of plaquing (EOF) of phage on each bacterial strain was
calculated as phage titre of test strain/phage titre of host strain on which phage K was
propagated. McNemers test^^ was used to examine the null hypothesis (Ho) and alternative
hypothesis (Ha), and hence deduce whether the probability of sensitivity of the Staph aureus
strains to phage K and the modified phage cocktail was either the same or different. A P-value of
< 0.05 was considered to be statistically significant.
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Bacteriophage adsorption assays
Adsorption assays were carried out for strains which were not eliminated by the phage cocktail
to investigate whether or not they possessed an adsorption inhibition mechanism. Test strains
were grown at 37°C in BHI broth overnight (1% inoculum) for use in the assay. BHI broth alone
was used as a negative control. One ml from the test strain was added to a sterile 2 ml microfuge
tube and the samples were centrifuged at 9,300 x g for 3 minutes. The pellet of cells was re
suspended in 1ml of fresh BHI broth, and 5pl of 1M Calcium chloride (CaCl2) was then added to
each sample. One ml of phage K dilution (10^ PFU/ml) was added to each sample and the tubes
were mixed (vortex). The samples were left at room temperature for 10 minutes to allow the
phage to adsorb to the cells, and then centrifuged for 5 minutes at 9,300 x g to remove adsorbed
phage. The supernatants were removed and diluted down to 10'^ and tested in a plaque assay
using a phage sensitive host (DPC 5246) to determine the number of un-adsorbed phage
remaining in the supernatant. The negative control sample (broth + phage) was treated in an
identical fashion. This represented the total titre of phage present. The percentage of phage
adsorbed by each test strain was calculated using the following formula:
Phage titre (negative control) - Phage titre (test strain)

X 100 = % adsorbed

Phage titre (negative control)
Adsorption assays were earned out in triplicate and % adsorption values were calculated as
average values based on these counts.
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Results
Selection of phage sensitive and phage resistant S. aureus strains and establishment of
antibiotic resistance profile.
Phage K has been previously shown to have a broad host range where Irish S. aureus hospital
strains are coneemed in that the vast majority of isolates allowed elear plaque formation.^
Nevertheless, over the course of our studies, with 180 S. aureus isolates, which included all Irish
sequence types (ST) from the National MRSA reference laboratory. Veterinary laboratories, and
various hospitals, 29 strains were identified that did not readily permit plaque formation with
phage K. These strains, with their origin and antibiotic resistance profile are included in Table 1.

Identification of R-M in phage resistant strains
Phage resistant strains were initially assessed for restriction modification. When all 29 strains
were analysed by plaque assay with phage K, plaque fonnation did not occur (Table 2). I'o
explore the presence of R-M in these strains, phage K was added to each strain and incubated
under conditions suitable for phage propagation. In the case of most strains, broth culture
clearing was observed after two to three exposures to culture supernatant from the previous
exposure, indicating that modified phage had developed. In some cases up to five exposures to
phage had to be carried out before plaque formation was observed, indicating the presence of a
potent R-M system(s). Seventeen distinct modified phages were generated in all. These were
then evaluated for their host range on all 29 phage resistant strains. Using the 17 phage isolates,
24 of the 29 phage resistant strains were successfully lysed. On analysis of individual host ranges
of the seventeen modified phages, it was observed that six in particular had a superior host range
on the 29 strains. These six, highlighted in Table 2 were selected for further study.
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Host range of modified phage
The efficiency of plaque formation of the six modified phage was determined for all phage
resistant S. aureus strains and it was evident that using the six modified phages it was possible to
eliminate the 24 strains mentioned above. Following this, the modified phages were combined to
make a phage cocktail, which also included phage K. The host range of this seven-phage mixture
(as compared to that of phage K alone) is shown in Table 3. As expected, the phage cocktail hit
24 of the 29 phage resistant strains, while five of the strains were still resistant to lysis. The level
of phage resistance to phage K was 16.1%, while the level of phage resistance to the cocktail was
2.8%, which is a significant improvement. This improvement was quantified by McNemers test
and the P-value was found to be < 0.0001.

Investigation of incidence of adsorption resistance in S. aureus
Analysis of host range results for the phage cocktail indicated that five strains were resistant to
lysis by the phage cocktail (Table 3). These five strains were subjected to assays to investigate
whether they possessed an adsorption inhibition mechanism. Three of the isolates showed a
reduced ability to adsorb phage in comparison to the control S. aureus DPC5246. These were the
strains 3581ST 2471A, ()104ST239I11, and 0.1345ST8IIV, which permitted 59.65%, 32.52% and
5.49% phage K adsorption respectively when compared to the phage K sensitive strain DPC5246
(97.88% adsorption). This indicated that phage adsorption was compromised in the three strains
compared with strain DPC5246.Two phage resistant strains, namely ST45ISA54 and M2493 18
showed no reduction in phage adsorption in that they adsorbed 99.77% and 99.32% respectively.
It is likely that while these strains did adsorb phage K efficiently, they did not permit phage
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replication even using the phage cocktail, and therefore it is likely that another as yet undefined
phage resistance mechanism is present in these cases.

Investigation of the role of capsule production in phage adsorption inhibition
It has previously been reported that adsorption inhibition in bacteria can result from either the
loss of phage receptor molecules on the host, or the presence of physical barriers which mask
these receptor molecules, such as capsules.

To help clarify which may be involved in S.

aureus, 10 known capsule (Type 5) producing S. aureus strains

’

were tested for their phage

sensitivity. These strains, and their designated ST types are listed in table 4. Interestingly, it was
found that all capsule producers were successfully lysed by phage K, giving normal plaque sizes
and plaque titres. In summary it appeared that EPS production does not play a role in phage
adsorption resistance.
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Discussion
In recent years, an increase in the incidence of antibiotic resistance has been noted in several
medically important bacteria including S. aureus. The problem has escalated to the point that it
has been described as a clinical super-challenge.

Moreover, the cost of treating antibiotic

resistant infections, combined with the decrease in the discovery and development of novel
antibiotics has led to an increase in demand for alternative therapeutic agents with attributes such
as low cost, ease of availability, minimum side effects and high potency.

Indeed the World

Medical Association (WMA) recently lodged an appeal for increased research funding in aid of
the development of new antimicrobial agents and vaccines.^ Phages are known to kill bacteria
irrespective of their antibiotic sensitivity, and they possess all the attributes mentioned above.
1 lence they are a viable option for use as therapeutic or prophylactic agents to reduce antibiotic
resistant infections. ’ ' Consequently phages have increasingly become a focus of research
interest for the elimination of pathogenic bacteria in recent years, and phage related therapies
may w ell be utilised to a greater extent in the future.^ This study defines the incidence of phage
K resistance in 180 strains of .S. aureus. The phage resistance could be divided into R-M (24
strains, 13.3%), adsorption inhibition (3 strains, 1.7%), and undefined phage resistance (2 strains,
1.1%). Restriction modification systems which comprise of restriction endonucleases and
methyltransferases, recognize and modify specific DNA sequences, protecting “self’ DNA from
restriction while eliminating potentially harmful foreign (e.g. bacteriophage) DNA which lacks
appropriate modification.^"^ The three well-characterized types of classical R-M systems have
been documented in S. aureus which differ from each other in terms of enzyme structure,
reaction mechanisms, and in the types of DNA sequences that they recognise.They include
type I such as the Saul type I system, which is widely distributed in sequenced S. aureus isolates
148

and type III systems such as that reported previously.The well known type II systems cut
within specific recognition sequences and are therefore widely used as molecular biology tools
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and in S. aureus, these include the Sau961 and Sau3AI type II systems present in isolates of
specific lytic groups,and the Sau42I Bcgl-like system expressed by S. aureus (j) 42
lysogens."^' Indeed as far back as 1978, it was reported that most strains of .S’, aureus cany' several
R-M systems."^" Our findings indicate that phage K is unaffected by many of these resistance
systems. Significantly, we previously observed that the genome of this phage contains no GATC
sites rendering it impervious to the Sau3AI R-M system.." Our findings, namely that 83.9% of 5*.
aureus strains are apparently phage K-sensitive suggest that this phage may also be unaffected
by some other inherent S. aureus R-M systems. The different host ranges of the seventeen
modified deriviatives of phage K suggests that a variety of R-M systems are active in the twenty
four staphylococcal strains exhibiting R-M activity in this study.
In addition to the above phage resistance systems. Clustered Regularly Interspaced Short
Palindromic Repeats (CRISPRs) are also worthy of mention. These are loci containing multiple
short direct repeats and are found in the genomes of approximately 40 % of bacteria and 90 % of
archaea. They function as a prokaryotic immune system, conferring resistance to exogenous
genetic elements such as plasmids and phages.This CRISPR system provides a forni of
acquired immunity as short segments of foreign DNA called spacers are incorporated into the
genome between CRISPR repeats and serve as a memory of past exposure, with spacers
recognising and silencing exogenous genetic elements.CRISPRs were first described for E.
coli in 1987,"^^ and similar clustered repeats were discovered in additional bacteria and archaea in
2000. In addition a set of genes, some encoding nuclease and helicase proteins were discovered
which were associated with CRISPR repeats and these were termed CRISPR-associated genes
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(cas).'^^ CRJSPR repeats range in size from 24 to 48 base pairs and are separated by spacers of
similar length.

Some of these spacer sequences have identity to sequences from plasmids and

phages,"^^ and new spacers can be added rapidly as a response to phage infection.More than
forty different Cas protein families have been described and combinations of Cas genes and
repeat structures have been used to define 8 different CRISPR subtypes. More than one subtype
may occur in any single genome and the sporadic distribution of CRISPR/Cas subtypes indicates
that the system may be subject to horizontal gene transfer during microbial evolution. 48
Exogenous DNA is processed by proteins encoded by Cas genes into elements of around 30 bp
in length and these are then inserted into the CRISPR locus near its leader sequence. RNAs from
the CRISPR loci are constitutively expressed and processed by Cas proteins to small RNAs
composed of individual exogenously-derived sequence elements with some Hanking repeat
sequence. The RNAs then guide other Cas proteins to silence exogenous genetic elements at the
RNA or DNA level.CRlSPRs are evolutionarily conserved and through this mechanism
bacteria may acquire immunity against certain phages and prevent further transmission of
targeted phages.

They have been shown to limit horizontal gene transfer in S. epidermiciis,

and have been exploited for the generation of bacteriophage-insensitive mutants (BlMs) of A
thennophilus starter cultures.The only known report of CRISPR systems in S. aureus was
described recently^^ in an Australian S. aureus isolate MSMRl 132, where it was predicted to
impact accessory genome acquisition. The spacer sequences in this CRISPR system revealed
attempted invasion by known S. aureus mobile genetic elements. 55

With regard to phage adsorption, it has been reported that in S. aureus, phage adsorb to part of
the cell wall teichoic acids.When phage adsorption does not occur, it is normally caused by
either lack of a phage receptor, a mutation in a receptor or a production of a capsule which masks
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a receptor. From our findings with extracellular polysaccharide-producing S. aureus, it is clear
that in the case of phage K, the presence of the capsule does not prevent adsorption. The
incidence of compromised adsorption of phage K in the bank of staphylococci in this study was
quite low at three strains out of 180 (1.7%).

All of the R-M systems, which were apparent in 24 of the 180 strains, could be circumvented by
making modified derivatives of phage K on seventeen R-M-positive strains. Ultimately, six of
these modified phages were able to lyse all 24 strains. The pooling of these six modified phage
(and phage K) resulted in a cocktail, which had a significantly broader host range than the parent
phage K alone among the 180-strain bank of staphylococci. The cocktail lysed 97.2% of the
bank, while phage K alone only lysed 83.9%, brought about by the fact that it eliminated 24 of
the original 29 phage resistant strains. This improvement in the host range of the cocktail
compared to phage K was shown to be statistically significant, with strong evidence against the
null hypothesis (the probability of sensitivity of A aureus strains would be the same for phage K
and for the phage cocktail) and in favour of the alternative hypothesis (the probability of
sensitivity of A aureus strains is different for phage K and for the phage cocktail). The F-value
calculated by McNemers test was less than 0.0001, which is considered to be statistically
significant.

It is important to state that the initial bank of staphylococci were random human

and veterinary isolates collected over a 10-year period, which were subsequently supplemented
to ensure that all the Irish ST types in existence were represented in the collection. It is worthy of
mention that while all experiments were done with fresh phage preparations, a shelf life study
was performed on phage K and modified phage suspensions used in the study. In this shelf-life
analysis, they were stored at 4°C in a refrigerator and the titres were found to remain constant
over an eight-month period when tested by plaque assay. Such a phage cocktail may be used in
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the future for various applications including biofilm removal on devices and elimination of
infections in humans or animals. The work described here also highlights the importance of
phage resistance when designing phage for biocontrol applications.
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Origin and antibiotic resistance profiles of phage-sensitive S. aureus DPC5246 and
phage resistant strains used in this study.
Table 1.

S. aureus strain
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DPC5246 *
W64352 **
W69939 **
M249678 ***
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W73365 ***
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ST 39 ISA 108 t
ST 22 ISA 67 t
ST 39 ISA 82 f
ST 30 ISA 58 t
ST 15 ISA 88 t
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ST 22 ISA 59 f
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R= Resistant, S= Susceptible, 1= Intermediate resistance
* = Dairy Products Research Centre, Teagasc, Fermoy, Cork, Ireland (1998).
** = Cork Institute of Technology bacterial culture collection, Cork, Ireland (2001).
*** = Waterford Regional hospital, Waterford, Ireland (2001).
J = Cork University hospital, Cork, Ireland (2003).
t = Athlone Institute of Technology collection, Athlone, Ireland (2007).
£ = National MRSA Reference laboratory, St James Hospital, Dublin (2008).
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Table 2. Sensitivity of .S’, aureus strains to phage K and six individual modified phages on the
basis of plaque formation. EOF values are given for each phage.

S. aureus
strain

CD
K

CDK.W7336
5

DPC5246 **
W64352
W69939
M249678
M249180
M249318
M251955
W73365
M255039
W65216
M254959
MS811
M255409
M253164
M249671
ST45 ISA 54
ST391SA10
8
ST22 ISA 67
ST39 ISA 82
ST30 ISA 58

1
★
_*

Phage K and six modified phages
(PK.ST39ISA10
<DK.MS81
<DK.ST22ISA6
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** = Positive control strain (sensitive to phage K).
- = no plaque formation or clearing.
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Table 3. Sensitivity of S. aureus strains to phage K alone and phage cocktail.
S. aureus
strain
DPC5246 **
W64352
W69939
M249678
M249180
M249318
M251955
W73365
M255039
W65216
M254959
MS811
M255409
M253164
M249671
ST45 ISA 54
ST391SA 108
ST22 ISA 67
ST39 ISA 82
ST30 ISA 58
ST15 ISA 88
ST8 ISA 76
ST30 ISA 53
ST30 ISA 80
ST22 ISA 57
ST22 ISA 59
ST8 ISA 60
0.1345 ST 8 IIV
3581 ST 247 lA
0104 ST 239 III

Sensitivity to
phage K
+
_*

-

-

Sensitivity to
phage cocktail
+
+
+
+
+
-

Phage titre
(PFU/ml)
9.5 X 10“
1.63x10'
2.24 X 10“
2.51 X 10“
1.29 X
-

+
+

+
_*
-

_*
_*
-*
-

+
+
+

+
+
+
+
+
+
+
+
+
+
+
+
+

3.04 X
3.2 X
1.63X
1.43x
1.40 X
5.4 X
1.25x
1.45X
3.1 X

10“
10“ '
lO''
10'
10'
10“
10'
10'
10“

1.84
8.0

X
X

10'
10“ 1

6.4
2.36

X
X

10“
10“ I

-

1.51 X 10“
1.38x10“
1.33 X 10“ I
7.7 X 10“
9.0 X 10'
5.1 X 10“
2.36 X 10“
-

+

-

+ = Clear plaque formation.
* = no plaque formation, but clearing evident on plates with in excess of x 10' PFU/ml of phage.
- = no plaque formation and no clearing.
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Table 4. Exopolysaccharide (EPS) producing S. aureus strains used in the study (Intervet
International BV, Boxmeer, Netherlands) and phage K plaque assay data against these strains.
S. aureus
strain
BMA/GE/032/412
Newbould 305
BMA/UK/032/106
BMA/GE/032/384
BMA/G E/032/411
BMA/FR/032/366
BMA/GE/032/385
BMA/FR/032/088
BMA/NE/032/163
BMA/FR/032/091

Sequence type
(ST)
1306
115
97
45
97
71
1229
97
71
97

phage K titre
(PFU/ml)
8x 10'

2.9 X 10“
2.6 X 10“
9.2 X 10“
4.8 X 10'
4.0 X 10“
1.63 X 10“
1.78 X 10“
1.08 X 10*
9.9 X 10'^
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Figures

I I Sensitive to phage K (83.9%)
§ R-M activity for phage K (13.3%)
(ilHl Reduced phage K adsorption (1.7%)
B Undefined phage resistance (1.1%)

Figure 1. Proportion of 180 S. aureus strains exhibiting resistance to plaque fonnation by phage
K (inset).
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Appendix to Chapter 4
Multilocus Sequence Typing (MLST) of Exopolysaccharide (EPS)
producing Staphylococcus aureus strains
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Introduction
In the course of the work described in chapter 4, a variety of new S. aureus strains were obtained
from different labs in the UK, Germany, France and The Netherlands. Consequently it was
necessary to type these strains in order to assign a sequence t>pe number consistent with all the
other bacteria used in this chapter.

[Materials and Methods
Multilocus Sequence Typing (MUST)
The MLST typing method was perfomied as previously described (Enright et ai, 2000) in order
to assign a sequence type (ST) number to the ten un-typed EPS producing S. aureus strains used
in this study. Briefly, chromosomal DNA was extracted from overnight cultures (1% inoculum)
of all strains using a QIA amp DNA mini kit (Qiagen Mouse, UK) according to the
manufacturer’s instructions. S. aureus strains encode seven housekeeping genes {aroE, arcC,
gmk, glpE, pta, tpi and yqiL) and the sequences of the internal fragments of each of these genes
(~ 450 bp in length) were amplified by polymerase chain reaction (PCR). PCR amplifications of
the DNA were carried out using a core kit (Biotaq, Bioline), and sequences of primers for each
of the seven housekeeping genes {aroE, arcC, gmk, glpF, pta, tpi and yqiL) and the PCR
conditions required for their amplification were obtained from the MLST database
(www.saureus.mlst.net) (Enright et ai, 2000). Amplified internal fragments were sent for
sequencing (MWG-Biotech) in forward and reverse orientations, and resulting sequences were
manually trimmed to the exact length of a specific internal fragment region within each gene.
The completed seven housekeeping gene trimmed sequences for each of the ten EPS producing
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S. aureus strains were then submitted to the online S. aureus MLST database
(www.saureus.mlst.net). A specific ST number was then generated for each strain based on a
comparative analysis between the allelic profile of the sequences of the seven housekeeping
genes for each strain compared to that of all S. aureus strains previously deposited in the
database (Enright et al, 2000).

RESULTS AND DISCUSSION
Multilocus Sequence Typing (MUST)
MUST analysis was successfully performed and ST numbers were assigned to all ten EPS
producing S. aureus strains. These ST numbers along with the allelic profiles of the seven
housekeeping genes for each strain which led to their assignment arc shown in Table 1. Six
different sequence types were found among the ten strains, with ST97 being the most common.
Interestingly, a novel sequence type (ST) number (1306), which had not previously been
deposited in the MEST database was assigned to S. aureus strain BMA/GE/032/412.

References
Enright, M.C., Day, N.P., Davies, C.E., Peacock, S.J., and Spratt, B.G. (2000). Multilocus
sequence typing for characterisation of methicillin-resistant and methicillin-susceptible clones of
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Table 1. Exopolysaccharide (EPS) producing S. aureus strains used in the study (Intervet
International BV, Boxmeer, Netherlands), assigned sequence type (ST) numbers, and allelic
profiles for each of the seven housekeeping genes of each strain.

S. aureus
Sequence type arcC aroE glpF gmk pta tpi
strain
(ST)
BMA/GE/032/412
72
1
52 160
1306 *
6
43
1
1
Newbould 305
115
3
1
1
5
BMA/UK.032/106
1
1
1
1
97
3
5
BMA/GE/032/384
14
45
10
8
6
10
3
BMA/GE/032/411
97
3
1
1
1
1
5
BMA/FRy'032/366
18
1
1
1
1
71
5
189
4
4
BMA/GE/032/385
1229
3
159
1
1
1
BMA/FRy032/088
97
3
1
1
5
1
1
1
BMA/NE/032/163
71
18
1
5
BMA/FRy032/091
1
97
3
1
1
1
5
= New sequence type not previously deposited in the MLST database.

166

yqiL
59
53
3
2
3
3
3
3
3
3

Chapter 5
Prevention of Staphylococcus aureus biofilm formation and reduction in
established biofilm density using a combination of phage K and
modified derivatives

Journal of Applied Microbiology. (2011). Submitted.
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Abstract
The aim of this study was to investigate the ability of a mixture of phage K and six of its
modified derivatives to prevent biofilm formation by S. aureus, and also to reduce established
biofilm density. The bioluminescence producing S. aureus Xen29 strain was used in the study,
and incubation of this strain at 37°C for 48 h confirmed its strong biofilm forming capacity.
Subsequently, removal of established biofilms of S. aureus Xen29 with the high titre phage
combination was investigated over time periods of 24 h, 48 h, and 72 h. Results suggested that
these biofilms were eliminated in a time dependant manner, with biofilm biomass reduction
significantly greater after 72 h than after 24 - 48 h. In addition initial challenge of X aureus
Xen29 with the phage cocktail resulted in the complete inhibition of biofilm formation over a 48
h period with no appearance of phage resistance. In general our findings demonstrate the
potential use of a modified phage combination for the prevention and successful treatment of X.
aureus biofilms, which are implicated in several antibiotic resistant infections.
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Introduction
Staphylococcus aureus {S. aureus) is a commensal bacterium colonizing the skin and mucosal
membranes of healthy humans and animals (Van Belkum 2006). These bacteria typically have a
benign relationship with their hosts, and development to pathogen status only occurs due to
damage of the natural skin barrier (Otto 2008). However, antibiotic resistant S. aureus has
become a major cause for concern with up to 40% of S. aureus strains reported to be resistant to
methicillin (Durai et ai, 2010), and is now regarded as one of the most common causes of both
community-acquired and nosocomial infections which are difficult to eliminate with traditional
antimicrobial treatments (O’Flaherty et ai, 2005a; Mann 2008). The particular threat posed by
antibiotic resistant S. aureus has arisen due to its natural intrinsic virulence, its ability to adapt to
varied environmental conditions, and its implication as the causative agent of a range of life
threatening infections including endocarditis, sccpticemia, pneumonia, phlebitis, meningitis, and
toxinoses (Lowy 1998; Noble 1998; Lowy 2003). It is also a problematic pathogen in bovine
infections leading to bovine mastitis in cattle (O’Flaherty et al, 2005b). These increasing
problems associated with the antibiotic resistance of S. aureus, in addition to the corresponding
financial burden on health systems necessitates the identification of alternative, and more
effective antibacterial agents (O’Flaherty et al., 2009; Gorski et ai, 2009; Durai et ai, 2010).
A biofilm is a sessile community of bacterial cells which are attached to a substratum, interface,
or to each other. These cells are typically embedded in a self-produced matrix of extracellular
polymeric substances, and they exhibit an altered phenotype with respect to growth rate and gene
transcription (Donlan and Costerton, 2002). Microscopic examination of in vitro formed biofilms
has indicated that rapid attachment of bacterial cells to the colonizing surface is followed by an
accumulation of growth to form multi-layered clusters which are surrounded by a slimy matrix
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(Gotz 2002). Microorganisms embedded in a biofilm are known to exhibit a significantly greater
tolerance to antibiotics (often up to 1000 fold greater) and other antimicrobial agents such as
disinfectants and germicides, than their planktonic counterparts (Donlan and Costerton 2002;
Cerca et al, 2005; Hoiby et al, 2010). This resistance has been attributed to: decreased
penetration of antimicrobials through the biofilm matrix, low metabolic activity of bacteria found
in the inner layers of the biofilm, and the presence of hibernating persister cells which are
protected from the effects of the drug (Donlan and Costerton 2002; Keren et al, 2004).
Consequently, effective elimination of biofilms is often compromised and the physical removal
of infected medical devices from patients may be necessary, thus increasing health-care costs
(Jansen et al., 1992). S. aureus is considered to be one of the most clinically significant
pathogens involved in biofilm formation (Gotz 2002; Parsek and Singh 2003; Ando et al., 2004;
Otto 2008; Smith et al., 2008) on the surfaces of several implanted medical devices. These
include catheters, cerebrospinal fluid shunts, heart valves, and prosthetic joints (Ziebuhr 2001).
Several publications have detailed the mechanisms of biofilm formation (Tu Quoc et al., 2007;
Otto 2008; Schroeder et al., 2009; Sharma-Kuinkel et al., 2009). The implication of S. aureus in
these infections may be attributed to the easy access of these skin inhabitants into wounds
associated with implanted devices, and subsequently onto the device. It has also been reported
that biofilm associated infections caused by S. aureus result in devices needing removal and
replacement more frequently than is the case with other staphylococcal infections (Jones et al.,
2001). Biofilm infections of 5”. aureus are also a problem in contagious bovine mastitis in the
mammary glands of ruminants (Vasudevan et al, 2003; O’Flaherty et al., 2005b; Oliveira et al.,
2006). Conventional antimicrobial therapies are often less than 50% effective (Gill et al., 2006)
and this results in major economic losses in the dairy industry.
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Virulent bacteriophages (phages) are viruses which specifically target and kill bacteria
irrespective of their antibiotic sensitivity (O’Flaherty et ai, 2009; Gupta and Prasad, 2011).
Thus, in recent times there has been a major interest in their use as prophylactic and therapeutic
agents (Gorski et ai, 2009). Several recent reviews have documented studies describing the
interaction of phages with biofilms and also biofilm treatment. (Sutherland et al, 2004; Azeredo
and Sutherland, 2008; Donlan 2009; O’Flaherty et al, 2009). Phages have potential in the
control of biofilms due to two main attributes: they replicate at the site of the infection,
increasing in number and producing progeny where they are most required, and also some
phages possess polysaccharide degrading enzymes, known as depolymerases which enable them
to penetrate the exopolysaccharidc (liPS) matrix of the biofilm (Hughes et al, 1998; Hanlon et
ai, 2001). Phage K is a polyvalent phage which kills a broad spectrum of pathogenic
staphylococci (O’Flaherty et ai, 2005a). We have previously reported that modified derivatives
of phage K can be isolated by multiple serial passage of this phage through strains harbouring
potent restriction modification (r-m) systems (Kelly et al, 2011). This gives rise to phages with
broader host ranges than the parent phage. In this study we describe the utilisation of the mixture
of modified phages and phage K for the prevention of biofilm foiTnation, and the treatment of
established biofilms of S. aureus.
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Materials and Methods

Bacterial strains and growth media
The strains used in the eurrent study were S. aureus Xen29 (Caliper Lifescienees, Cheshire, UK),
and S. aureus DPC5246 (Moorepark Food Researach Centre, Teagase, Femioy, Cork, Ireland).
S. aureus Xen29 is a biofilm producing strain, derived from the parental strain S. aureus 12600,
which itself was isolated from a sample of fluid from a space that surrounds the lungs known as
the pleura. S. aureus Xen29 possesses a stable copy of the modified Photorhahdiis luminescens
luxABCDE operon at a single integration site on the bacterial chromosome. This opcron affords
the strain the ability to emit luminescent light when metabolically active (Kadurugamuwa et ai,
2003a; Kadurugamuwa et al., 2003b; Kadurugamuwa et ai, 2004). S. aureus DPC5246 is a
bovine mastitis isolate which has previously been used as a propagating host for phage K
(O’Flaherty et ai, 2005a; Kelly et al, 201 1), and has not been characterised as a biofilm forming
strain. Both strains were stocked at -80°C in broth containing 40% glycerol, and grown at 37°C
in Tryptic Soy Broth (TSB), or on Tryptic Soy Agar (TSA) (Sigma Aldrich, UK). Selective
growth of X aureus Xen29 in TSB, or on TSA was achieved by addition of 200 pg/ml of
Kanamycin (Sigma Aldrich, UK).
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Phage propagation and cocktail preparation
Phage K was routinely propagated on S. aureus DPC5246 as previously described (O’Flaherty et
al, 2005b). Briefly, a plaque of phage K was aseptically picked from a lawn of S. aureus
DPC5246 on a Brain Heart Infusion (Bill) (Sigma Aldrich, UK) plaque assay plate. Three
rounds of plaque purification were carried out and subsequently the pure phage K suspension
was propagated to higher titres by the following procedure; 100 pi of S. aureus DPC5246 was
added to 10 ml of BHl broth. After two hours growth at 37°C, I ml of Phage K in B111 broth was
added to the tube. When clearing of the culture was noted, the sample was centrifuged and filter
sterilized to remove cells, and stored at 4°C. Generation of modified derivatives of phage K was
carried out as previously described (Kelly et al., 2011), and concentrated preparations of Phage
K and its modified derivatives were obtained by polyethylene glycol (M.W.8000) (Sigma
Aldrich, UK) precipitation followed by Cesium Chloride (CsCl) (Sigma Aldrich, UK) density
gradient ultracentrifugation of phage lysates. Ultracentrifugation was performed as described by
Sambrook et al. (2001). One ml of concentrated phage K and the same volume of six of its
modified derivatives at the highest titres (10^ - 10**^ PFU/ml) obtained (Kelly et al., 2011) were
combined to make a phage mixture which was stored at 4°C and used for biocontrol
experiments. Individual phages making up the cocktail were added at the highest titres as
infecting phage titre has previously been reported to be an important factor in biofilm dismption
(Carson et al., 2010).
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Bioillm formation
Static microtitre plate assays based on a previous study (Cerca et ai, 2007), but with
modifications to optimize the assay, were used to investigate biofilm formation and phage
treatments in this study. Briefly, pure colonies of S. aureus strains DPC5246 and Xen29 were
grown overnight in TSB. A standard plate count was then used to determine the titre of an
overnight culture of each strain. Strains were then appropriately diluted in Ringer’s solution to a
titre of 10^ CFU/ml. TSB broth supplemented with 1% D-(+)-glucose (TSBg) (Sigma Aldrich,
UK) was used in these assays as this aids in biofilm formation (Eftekhar and Speert, 2009).
Briefly, a 1:100 dilution was performed by adding 2pl of a cell suspension of 10^ CFU/ml of
each culture to 198 pi of TSBg in wells of a sterile 96-well microtitre plate (Sarstedt, UK). This
gave a starting inoculum of 10^ CFU/ml. 200 pi of TSBg was added to a set of wells as a
negative control. All wells were seeded in triplicate. Microtitre plates were then incubated at
37°C for 48 h to allow biofilm formation to occur. After the incubation period, medium was
poured off and wells were washed twice using 200 pi of sterile Phosphate Buffered Saline (PBS)
(Sigma Aldrich, UK) solution to remove any planktonic cells. Microtitre plates were then
inverted and dried in an incubator for 1 h at 60°C. Staining to determine total biofilm biomass
was then performed by addition of 100 pi of 1% crystal violet solution (Sigma Aldrich, UK) to
wells for 10 min. The wells were then washed and dried as described previously and biofilm
formation was determined by visually comparing the intensity of staining in the wells. In
addition endpoint spectrophotometric readings at 590nm using a microtitre plate reader
(Molecular Devices, Spectra Max 340, USA) were also determined.
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Established biofilm treatment with phage mixture
Biofilm formation was carried out as described above. After biofdms were established, and
washed with PBS for the first time, 100 pi of phage in 10 mM Tris (pH 7) (Sigma Aldrich, UK)
was added to one set of microtitre plate wells in triplicate, while 100 pi of 10 mM Tris (pH 7)
was added to the other set of wells, also in triplicate. 100 pi of 10 mM Tris (pH 7) was also
added to a set of wells which had been inoculated with TSBg alone. Optical density readings
were taken at 590nm (OD590) in plates incubated for 24 h, 48 h, and 72 h at 37°C. After
incubation for each time period, plates were removed and gently washed twice with PBS, and
stained with 1% crystal violet as described previously to determine the final biofilm biomass.

Biofilm prevention with phage mixture
The ability of the phage mixture to prevent biofilm formation was also investigated. This was
carried out as described for biofilm formation above with the following modifications. At the
beginning of the assay, 20 pi of the phage mixture in 10 mM Tris (pH 7) was added to 200 pi of
10^ CFU/ml of .S', aureus cells in one set of wells in a sterile microtitre plate. 20 pi of 10 mM Tris
(pH 7) was added to a second set of wells also eontaining 200 pi of 10^ CFU/ml of .S’, aureus,
while 220 pi of 10^ CFU/ml of S. aureus cells alone were inoculated into a third set of wells.
Plates were incubated at 37°C for 48 h and were also monitored spectrophotometrically at 590nm
as described above. The biofilm prevention ability of the phage cocktail was also assessed using
the biolumineseent S. aureus Xen29 strain and the in-vitro imaging system (IVIS) (Xenogen,
California, USA). Plates were inoculated as described above and incubated at 37°C, and

175

subsequently the wells were photographed every hour and examined for bioluminescence using
the IVIS.

Results
Biofilm formation
Static microtitre plate assays were used to investigate biofilm fomiation by S. aureus strains
DPC5246 and Xen29. Incubation of plates at 37°C for 48 h, and subsequent staining using 1%
crystal violet solution allowed direct visual comparsions to be made. They confirmed that strain
Xcn29 was a strong biofilm producer while the negative control strain DPC5246 was incapable
of biofilm formation as expected (Fig. 1).

Established biofilm treatment with phage cocktail
After confirmation of biofilm formation by S. aureus Xen29, the ability of a combination of
phage K and its modified derivatives to disrupt these established biofilms was determined.
Biofilms of the strain were grown for 48 h at 37°C, after which they were challenged with the
phage mixture for separate periods of 24 h (Fig. 2a), 48 h (Fig. 2b), and 72 h (Fig 2c). Overall it
was clear that the cocktail was capable of biofilm disruption. A reduction in OD590 of the
cocktail treated wells relative to untreated control wells was evident over all time periods (Figs 2
a, b, c). The main reduction in OD appeared to be initiated around 15- 20 hours post inoculation
of the cocktail (Figs. 2 a, b, c). Results also indicated that treatment of biofilms for 72 h (Fig. 2c)
resulted in a significantly greater decrease in biofilm biomass than treatment for 24 h (Fig. 2a) or
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48 h (Fig. 2b). Crystal violet staining of phage treated and untreated microtitre plate wells was
also perfonned, and visualization of the degree and intensity of staining in the wells correlated
well with the OD590 results mentioned above. Wells treated with the phage mix showed a
reduction in the intensity of staining, corresponding to a reduction in biofdm biomass in
comparison to untreated controls. In addition it was clear that cocktail treatment of biofilm wells
for 72 h (Fig. 2c) resulted in a more efficient disruption of biomass and reduction in intensity of
staining than those treated for 24 h (Fig. 2a) or 48 h (Fig. 2b). Faint residual staining seen in
treated wells is likely to be due to the presence of persister cells or biofilm debris after phage
treatment.

Biofilm prevention with phage cocktail
Initial attachment of bacteria to a solid surface is the first step in biofilm formation, fherefore,
the effect of the modified phage preparation on prevention of biofilm formation by S. aureus
Xen29 was also investigated. Static microtitre plate biofilm assays were used and the assay was
monitored both spectrophotomctrically, and also using the 1 VIS. A typical growth profile of S.
aureus Xen29 in TSBg indicated that log phase growth was initiated roughly 3 h post
inoculation, while stationary phase was reached at 7-10 h post inoculation (1%). Monitoring of
the biofilm assay by the IVIS confirmed that bioluminescence production by S. aureus Xen29
began at 3 h post inoculation. Reduction in light emission was seen after 9 h, and no
bioluminescence was detected at 48 h post inoculation (Fig. 3). This data corresponded well with
the growth profile of the strain and confirmed that light production is only seen when S. aureus
Xen29 is metabolically active. Analysis of images taken using the IVlS system showed that no
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growth of the S. aureus Xen29 strain occurred in wells inoculated with the phage mixture, while
strong bioluminescenee was seen in control wells (Fig. 3). In addition, when microtitre plate
wells were stained with 1% crystal violet after 48 h incubation at 37°C, no biofilm formation was
seen in wells inoculated with the phage combination, while typically strong biofilm formation,
and subsequent staining intensity was observed in control wells (Fig. 4). This confirmed the
complete inhibition of biofilm formation by the phage cocktail.

Discussion
Biofilm associated infections have been implicated in a plethora of human diseases, and are often
associated with complications arising from the colonization of medical devices used to treat
these diseases (Donlan and Costerton 2002). The widespread failure of antibiotic therapy to
eliminate biofilm associated infections has accelerated the search for alternative therapeutic
agents. It has previously been reported that in contrast to several other biofilms which are
implemented in medical problems, biofilms associated with staphylococci are usually of a
singles species nature, and in addition it is rare to find more than one strain causing the infection
(Arciola et ai, 2005). Thus, in this study we utilized the biofilm forming strain S. aureus Xen29
as a model single species biofilm. hitervention strategies generally used for the control of
infectious biofilms include: prevention of device contamination, minimizing any subsequent
microbial attachment, penetration and elimination of the biofilm matrix using antimicrobial
agents, and ultimately the potential removal of the contaminated medical device (Donlan and
Costerton, 2002). Therefore, in the hope of eliminating the costly need for device removal,
phages have been considered as novel biofilm treatment agents (Azeredo and Sutherland, 2008;
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Donlan 2009). In this study we investigated the potential of a combination of the polyvalent
phage K (O’Flaherty et al, 2005a) and six modified derivatives for the prevention of biofilm
formation, and also the treatment of established biofilms of .S', aureus. Initial static microtitre
plate assays confirmed that strong biofilms were formed by S. aureus Xen29 after 48 h. In
addition to its ability to adhere to surfaces, S. aureus also has a broad array of cell wallassociated compounds such as murein, polysaccharides, teichoic acids, and binding proteins for
tissue and plasma factors (Gotz 2002). These compounds readily interact with, and bind to blood
components in the blood environment of implanted medical devices, affording this pathogen an
added opportunity for adherence. Consequently disruption of biofilms caused by S. aureus is of
critical importance. Phage K. has previously been shown to reduce S. epidermidis biofilrn
biomass after 24 h of challenging (Cerca et al., 2007). Nevertheless, this phage has never been
evaluated for the treatment of .S. aureus biofilms and thus this is worthy of investigation.
It is notable that phage resistance is commonly encountered in S. aureus (Sjostrom et al., 1978;
Tock and Drydcn, 2005) and thus the use of modified derivatives with expanded host ranges is
worthwhile. Recently Kelly et al. (2011) quantified the incidence of phage K resistance in a bank
of Irish S. aureus and showed that 16.1% of strains were resistant to phage infection. The
resistance in strains harboring r-m systems could be overcome by serial passage of phage K
through these strains, generating modified phage derivatives with broader host ranges. In
general, phage mixtures or cocktails are considered to be more effective in phage therapy studies
than single phages (Kutter and Sulakvelidze, 2005a). While the composition of effective phage
cocktails can often be undefined (Kutter and Sulakvelidze, 2005b), this study uses a defined
mixture where the individual host ranges of the component phages on highly phage resistant
strains is known (Kelly et al., 2011). The use of this eocktail based on sueh broad host range
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phages (O’Flaherty et ai, 2005a; Kelly et ai, 2011) is particularly applicable for multispecies
staphylococcal biofilms due to its broader host range against resistant bacterial strains.
We investigated the ability of phage K and six modified derivatives to disrupt biofilms of S.
aureus Xen29 over 24 h, 48 h, and 72 h periods. During the 24 h treatment a reduction in biofilm
biomass relative to the control was initiated around 15 h post phage inoculation. Further
treatment of S. aureus Xen29 biofilms for 48 h and 72 h resulted in a significant increase in
biofilm biomass removal. Optical density (OD590) readings indicated that biofilm biomass was
reduced to levels comparable with negative controls at a period of around 40 h post phage
inoculation. In addition analysis of crystal violet stained wells showed that only very faint
staining was visible in phage treated wells 72 h post phage treatment when compared to
untreated control wells. We propose that this minimal staining is likely to be due to the presence
of biofilm debris from lysed staphylococcal cells (Wu et ai, 2003), or perhaps represents some
highly resistant hibernating persister cells (Keren et ai, 2004) or the emergence of phage tolerant
subpopulations (Lacqua et ai, 2006). Nevertheless our cocktail was highly efficient in disrupting
biofilms of X aureus, and this effect was increasingly evident over a period of 72 h. This
observation that biofilm cells are killed more slowly than planJktonic cells has previously been
shown for S. epidermidis (Cerea et ai, 2007) and also for P. fhiorescens (Sillankorva et ai,
2004). In addition, it has been reported that certain phages possess a polysaccharide
depolymerase enzyme which can aid in the elimination of biofilms by degradation of the EPS
matrix (Hughes et ai, 1998). Previous work by our group has shown that the genome of phage K
does not encode such an enzyme (O’Flaherty et ai, 2004), and therefore it appears that phage
lysis of cells alone is responsible for biomass reduction in this study. This suggests that biofilms
of X. aureus Xen29 may possess water-filled channels which provide access for the phages to the
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inner layers and matrix of the biofilm, an architecture which has been reported for many biofilms
(Sutherland et al, 2004).
The nature of biofilms, the ability of staphylococci to adhere to surfaces and the problems
associated with their treatmient and removal indicates that biofilm prevention is preferable to
biofilm disruption and removal. Thus, we also investigated the potential of the phage mixture for
prevention of .S. aureus Xen29 biofilm formation, and found that it was very effective in that no
biofilm development was detected for up to two days post treatment. Monitoring of the assay by
the IVIS confinPied the absence of any biofilm growth in phage treated wells. These results
suggest that the phage mixture could potentially be used as a coating agent on medical devices to
prevent staphylococcal adherence and biofilm formation as previously demonstrated by Curtin
and Donlan (2006) who coated catheters with phages for the successful reduction of X
epidermidis biofilms. A similar study described the successlul use of P. aeruginosa phage for
pretreatment of catheters (Fu et ai, 2010). Indeed phage K has been previously shown by our
group to retain its lytic activity in a bismuth-based cream (O’Flaherty et al., 2005), suggesting
that the cocktail would be amenable to such applications.
In conclusion, we have demonstrated the potential of a mixture of phage K and modified
derivatives for the prevention and / or removal of X aureus biofilm. This phage mix can
overcome some of the most important obstacles to biofilm treatment, including antibiotic
resistance, presence of the EPS matrix, and the protective effect of biofilm age, and hence may
have future applications as a stand-alone treatment or in combination with antibiotics (Verma et
al., 2009) for elimination of problematic biofilms and associated infections. It has the added
advantage of being effective for elimination of many phage resistant strains (Kelly et al, 2011).
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Figures

B

Figure 1. Biofilm formation by S. aureus after 48 h incubation in a microtitre plate at 37°C. (A)
Negative control wells, which were inoculated with TSBg alone; (B) Absence of biofilm
formation by S. aureus strain DPC5246 in TSBg, indicated by faint staining in wells with 1%
Crystal violet; (C) Confirmation of strong biofilm fonnation by S. aureus strain Xen29 in TSBg,
indicated by intense crystal violet staining in wells.
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Figure 2. Reduction of established S. aureus Xen29 biofilm after (a) 24 h, (b) 48 h, and (c) 72 h
challenge using phage mixture. Absorbance readings at 590nm were taken in a microtitre plate
reader. (■) = Xen29 ^ 10 mM Tris; (A) = Xen29 + phage cocktail in 10 mM Tris; (♦) = TSBg
+ 10 mM Tris. Microtitre plate wells stained with 1% crystal violet and displaying the biofilm
disrupting effect of the phage cocktail are also shown. (A) Xen29 + 10 mM Tris; (B) Xen29 +
phage cocktail in 10 mM Tris; (C) TSBg + 10 mM Tris. Assays were performed in triplicate and
OD590 data was expressed as the mean ± standard deviations.
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Figure 3. Biofilm prevention using phage cocktail against S. aureus Xen29. Images of microtitre
plates were taken using the IVIS system (Exposure: 15 seconds, Binning; medium, Colour scale
31 - 200) over a 10 hour period post inoculation of wells. Colours indicate signal intensity with
red to blue respresenting high and low bioluminescent signals respectively.. An image of wells
taken after 48 hours is also shown. A= Xen29 + phage cocktail in 10 mM Tris; B=Xen29 alone;
C=Xen29 + Tris 10 mM.
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Figure 4. S. aureus Xen29 biofilm prevention with phage cocktail. Microtitre plates were
photographed after 48 h at 37°C and wells were stained with 1% crystal violet. Wells containing
TSBg were initially inoculated as follows; (A) Xen29 + phage in 10 mM Tris. (B) Xen29 alone.
C-Xen29 + Tris 10 mM.
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Appendix to chapters 4 and 5
Ex - vivo studies using bacteriophage K
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Introduction
The work presented in chapters 4 and 5 highlighted the potential for broadening the host range of
phage K, and subsequently utilising these broad host range modified derivatives for therapeutic
applications. As the immunostimulatory activity of phages has been well documented, and is an
important consideration when phages are to be used for therapy, it is worthwhile to investigate
the ability of phage K to induce an inflammatory response. In this study this assay was carried
out using primary human umbilical vascular endothelial cells (I lUVECs) in which induction of
the adhesion molecules Inter-Cellular Adhesion Molecule 1 (ICAMl), Vascular Cell Adhesion
Molecule 1 (VCAMl), endothelial-leukocyte adhesion molecule 1 (E-selectin), the
transcriptional activator Cyclooxygenase-2 (Cox-2), and the cytokines Chemokinc (C-X-C
motif) ligand 1 (CXCLl), Interleukin 32 (IL32) or Interleukin 8 (IE8) in response to phage K
stimulation was investigated. Tumor Necrosis Factor-alpha (TNF-(x), a cytokine involved in
systemic inflammation, and Lipopolysaccharidc (EPS), a molecule found in the outer membrane
of Gram-negative bacteria which acts as an endotoxin and elicits strong immune responses in
animals, were included as controls.

[Materials and Methods
Chemicals /Reagents
EPS and Human TNFa were included as controls in the assays. EPS (Sigma, Dorset, UK) was
reconstituted in sterile PBS used at 100 ng/ml. Human TNFa (R&D Systems, Abingdon, UK)
was reconstituted in sterile PBS containing 1 % BSA, and used at a concentration of 10 ng/ml.
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Cells and Cell Culture
IIUVECs (Promocell, Heidelberg, Gemiany) were maintained at 37°C from passage number 2- 7
in EGM-2 media (EGM-2 growth supplements to Findothelial Basal medium (EBM-2), (Lonza,
Cambridge, UK). Cells were seeded at lx 10^/ml for all assays unless otherwise stated. The
compounds Phage K (10^^ PFU/ml, 10^ PFU/ml, 10^ PFU/ml), EPS and TNFa were added to the
IIUVECs for 6 Hrs.

Direct cell Real-time polymerase chain reaction (qRT-PCR)
After stimulation with phage K in 10 mM tris buffer, 10 mM tris buffer alone, EPS and
TNFa, Sidestep™ lysis buffer was used to lyse IIUVECs and cDNA synthesis was performed on
the lysates by reverse transcription using RT reagents (Roche). Hydrolysis real time RT-PCR
reactions (PCRs) were performed using primers designed for the Universal Probe library (Table
I) on a Roche LC480 (Roche Diagnostics, West Sussex, UK) to test for inllammatory gene
induction and expression. Relative mRNA expression was calculated by the AACt method (Livak
etal., 2001).

Results and Discussion
In relation to IIUVECs, the induction of adhesion molecules and cytokines suggests
inflammatory insult and this is used to traffic leukocytes to the site of injury for repair and
defence. Thus, significant mRNA expression of the adhesion molecules ICAMl, VCAMl, Eselectin, the transcriptional activator Cox-2, or the cytokines CXCLl, IL32 or 1L8 after
stimulation with phage K would suggest inflammatory induction of the IIUVECs by phage K.
Relative mRNA expression of each of these molecules after stimulation with phage K is
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illustrated in Figure 1 (a-f). In relation to the control samples, TNFa induced a significant
inflammatory response in all HUVECs, while LPS did not. This may be due to the high purity of
the LPS sample used or the common tolerance shown by HUVECs to LPS. Phage K at titres of
10-10 did not induce significant mRNA expression of any of the HUVECs. Expression levels
for phage K were similar to those induced by the lOmM Tris buffer (Fig 1. a-l). Overall it is
clear from the results obtained that ultracentrifuge preparations of purified phage K at titres of
10 - 10

PFU/ml do not appear to induce a functional inflammatory gene response. This data

gives an initial indication that phage K may indeed be applicable to systematic infection control
without inducing a significant immune response. Future assays with phage K and functional
primary human blood monocytes (PBMCs) may further contribute to findings on its suitability
for such applications.

References
Livak, K.J. and Schmittgen, T.D. (2001). Analysis of relative gene expression data using real
time quantitative PCK and the 2(-Delta Delta C(T)) Method. Methods 25, 402-408.

195

Table 1. Primers used for RT-PCR of inflammatory genes.
Gene

Gene

symbol

description

ACTB
CXCL1

ICAM1
IL32
IL8

PTGS2

SELE

VCAM1

beta actin
(House
keeper
control)
CXCL1 ,
chemokine
ICAM1
adhesion
molecule
IL32,
Interleukin 32
IL8 Interleukin
8
PTGS2, Also
known as
Cox-2,
inflammatory
intermediary
SELE, or Eselectin,
,adhesion
molecule
VCAM1,
adhesion
molecule

Primer forward sequence

Primer reverse sequence

GGCCAGGTCATCACCATT

GGATGCCACAGGACTCCAT

TCCTGCATCCCCCATAGTTA

CTTCAGGAACAGCCACCAGT

CCTTCCTCACCGTGTACTGG

GGTAAGGTTCTTGCCCACTG

CATGTGCTTCCCGAAGGT

TCTATGGCCTGGTGCATTC

TAGCCAGGATCCACAAGTCC

CTGTGAGGTAAGATGGTGGCTA

CGCTCAGCCATACAGCAA

TCATACATACACCTCGGTTTTGA

CCTCCTGACATTAGCACCATT

AGCTGCTGGCAGGAACAA

GAAGTTTAACACTTGATGTTCAAGGA

GGATGCAAAATAGAGCACGAG
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Figure 1. Relative mRNA expression of the adhesion molecules ICAMl (a), VCAMl (b), IL8
(c), 1L32 (d), CXCLl (e), Cox-2 (f) after stimulation with phage K (10^, 10^, lO’® PFU/ml) in
10 mM tris buffer. 10 mM Tris buffer alone, LPS (100 ng/ml) and TNFa (10 ng/ml) were
included as controls.
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Discussion and Conclusions
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In recent times, there has been an increase in the prevalence of antibiotic resistant pathogenic
bacteria worldwide, with perhaps the best known and problematic genus being S. aureus, and in
particular methicillin resistant S. aureus (MRSA). This antibiotic resistance, combined with the
decreased investment in the development of novel antibiotics by the major pharmaceutical
industries due to financial constraints has intensified the need for the exploitation of alternative
and cost effective antimicrobial agents. In addition, the presence of food pathogens in or on
various foods, and their subsequent alteration of the sensory qualities, and ultimate spoilage of
these food products leads to very significant financial losses in the food industry. Recently,
bacteriophages (phages) have emerged as antibacterials with considerable promise in the
elimination of pathogens of concern in both the medical/veterinary and the food sectors
(O’Flaherty et ai, 2009; Coffey et al., 2010). This thesis describes the isolation and
characterisation of phages with applications in the elimination of bacteria causing problems in
both of the above areas.
Chapter 1 reviewed the extensive literature research on the applications of bacteriophages and
their lytic enzymes (lysins). Both have been exploited as powerful antibacterial agents due to
their target specificity (and thus their minimal effects on surrounding microflora), bactericidal
activity, low cost, widespread availability, safety and efficacy, and the low probability of
resistance development when compared to the use of antibiotics. In addition, the genetic
modification of phage genomes and phage protein coats towards improved drug delivery and
subsequent disease treatment is described. Finally, recent advances in the use of phages as
delivery vectors are reviewed. These include delivery of several drugs by phage display and also
the delivery of vaccines, either as antigens on the phage surface or DNA vaccination, whereby
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the vaccine gene is incorporated into the phage DNA. In addition, several other applications of
phages, including biocontrol in the food sector are also presented.
Chapter 2 describes the isolation and characterisation of five novel virulent phages which lyse P.
damnosus and four novel phages which lyse both Lb. brevis and Lb. paraplantarum. These
strains are responsible for a large percentage of beer spoilage incidents in breweries (Sakamoto
and Konings, 2003). All phages were assigned to the Siphoviridae family based on moiphology.
In the case of the five Pediococcus phages, IlindlU digests indicated that there were apparent
genotypic similarities between them. While all five showed distinct banding patterns, phages
mmPl, clPl, clP2 and mmP2 had a number of electrophoretic restriction bands of identical
molecular mass, suggesting a common ancestor. In addition these phages had a narrow host
range, limited to P. damnosus. Ln the case of the Lactobacillus phages, analysis of 1 lindlll
digests showed showed distinct banding patterns, but with some similarities, indicating that these
phages had some relatedness at the genotypic level. Interestingly, these phages lysed two distinct
species of Lactobacillus, namely Lb. brevis and Lb. paraplantarum, suggesting that these species
are closely related from a phage sensitivity point of view. This study also described the first
incidence of P. damno.sus phage isolation in the scientific literature. Comparison of the
morphological characteristics and genome size of these phages with a previously isolated lytic
Pediococcus phage (Yoon et al, 2007) indicated that they had larger heads, tails, and genome
sizes than this phage. Overall, the work presented highlighted the rich abundance of phages of
Pediococcus and Lactobacillus in sewage. It proceeded to characterise their lytic activity against
prominent beer spoilage bacteria and demonstrated their survival in a beer environment. This
provides an opportunity for their exploitation as agents for beer spoilage control. Ironically
phages of lactic acid bacteria are generally considered problematic as they frequently inhibit
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lactic acid bacteria starter cultures whieh are used in the manufaeture of fermented foods.
However, this study highlights a beneficial application.
The isolation of novel P. damnosiis phages in chapter 2 and the aforementioned rarity of these
phages in the literature encouraged us to embark on genome sequencing to provide an insight
into the genetic makeup and evolution of these phages. The work presented in Chapter 3 thus
focuses on analysis of the sequenced genome of the novel P. damnosus phage clPl. Nucleotide
sequence analysis indicated that this phage was not closely related to phages previously
characterized, highlighting the unique nature of this phage. F^utative matches which were noted
after bioinformatics analyses were mostly to genes of phages of lactobaeilli, or their host
bacteria. This suggested that this phage may possibly have evolved from a phage infeeting
lactobaeilli. This is perhaps not surprising as lactobaeilli often occupy similar niches to
pediococei providing an opportunity for genetic exchange. Indeed, this phenomenon has
previously been reported between phages

Lactococcus and Listeria (Dupuis and Moineau,

2010). The overall genome organisation in clPl satisfied all requirements for the completion of a
virulent life cycle, however the order of the modules in the genome differed slightly to the
consensus genome arrangement usually seen in phages of the Siphoviridae family (Lucchini et
ai, 1999; Desiere et ai, 2001; Brussow and Desiere, 2001). This may possibly be a novel
genome arrangement not yet noted in sequenced phages of laetic acid bacteria.
The putative FINH Floming endonuelease gene in the clPl genome was selected for phylogenetic
analysis as these genes are often interesting in phages and have been known to confer an
advantage to some phages in mixed infeetions, affording them an evolutionary advantage
(Stoddard 2011). However the position of this gene elose to the putative terminase genes
suggested that the HNH endonuclease was involved in DNA packaging. This theory was further
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supported by the fact that the putative HNH endonuclease of phage clPl also encoded a
conserved NUMOD4 DNA binding domain, which is known to initiate highly specific DNA
binding (Sitbon and Pietrokovski 2003). Potential roles that this endonuclease may play in
packaging include acting as a cleaving subunit of a terminase, or in the clearing of branched
replicative DNA before packaging is initiated (Crutz-Le Coq et al, 2002). Phylogenetic analysis
of the putative I INH endonuclease of phage clPl revealed that it shared closest homology to
MNfl endonucleases of bacterial origin highlighting the diverse and adaptable nature of these
enzymes.
Interestingly, BLAST analysis of ORF 24, a putative phage protein located in the middle of the
genome and flanked on both sides by genes of unknown function, indicated that this gene
encoded a VRR NUC superfamily domain. This family is considered a restriction endonuclease like fold family present among hypothetical proteins (Kinch et al., 2005). Thus it is possible that
phage clPl may have evolved this protein as a protective mechanism in response to bacterial r-m
systems, or possibly to cleave the DNA of competing phages in a mixed infection and hence
drive its own evolution, as is often earned out by phage homing endonucleases (Stoddard 201 1).
No lysogeny module was found in the genome suggesting that phage clPl did not evolve from a
temperate ancestor, while no definitive anti-receptor gene was observed in the genome and hence
phage clPl may possibly have evolved a novel method for host binding. The sequencing of the
phage clPl genome has highlighted some unusual properties in its organisation and provides
opportunities for further studies on phage evolution. In general, the application of novel phages
for biocontrol applications requires that the genome is characterised to ensure that it is
exclusively virulent to avoid giving rise to transduction of undesirable genes among bacteria.
Chapter 4 moves the thesis to the medical/veterinary sector and focuses on S. aureus and the
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broad-host-range phage K. It speeifieally describes the investigation of the incidence of phage K
resistance mechanisms in strains of clinically important S. aureus including MRSA. Antibiotic
resistant S. aureus is now regarded as one of the most common causes of both communityacquired and nosocomial infections which are difficult to eliminate with traditional antimicrobial
treatments (O’Flaherty et al, 2005; Mann 2008). 83.9% of S. aureus strains tested in the study
were sensitive to lysis by phage K suggesting that this phage is unaffected by many inherent S.
aureus r-m systems. This phage has previously been shown to contain no GATC sites rendering
it impervious to the Sau3Al r-m system (O’Flaherty et ai, 2004). The phage resistance
mechanisms in the remaining strains were divided into r-m (24 strains, 13.3%), adsorption
inhibition (3 strains, 1.7%), and undefined phage resistance (2 strains, 1.1%). Restriction
modification (r-m) systems which comprise of restriction endonucleases and methyltransferascs,
recognize and modify specific DNA sequences, protecting “self’ DNA from restriction while
eliminating potentially harmful foreign (e.g. bacteriophage) DNA which lacks appropriate
modification (O’Sullivan et al, 2000). All of the r-m systems, which were apparent in 24 strains,
could be circumvented by making modified derivatives of phage K on seventeen r-m-positivc
strains. Six of these modified phages were then able to lyse the full complement of 24 previously
resistant strains. The pooling of these six modified phage (and phage K) resulted in a cocktail,
which had a significantly broader host range than the parent phage K itself amongst the initial
bank of staphylococci. The cocktail lysed 97.2% of the bank, while phage K alone only lysed
83.9%. This improvement in the host range of the cocktail compared to phage K was shown to
be statistically significant by McNemers test (Samuels and Witmer, 2003). With regard to phage
adsorption, it has been reported that S. aureus phage adsorb to cell wall teichoic acids (Barnard
and Seaman, 1981). Inhibition of adsorption is normally caused by either lack of a phage
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receptor, a mutation in a receptor or a production of a capsule which masks a receptor.
Interestingly, from results obtained against extracellular polysaccharide (EPS) producing S.
aureus strains in this study, it is clear that in the case of phage K, the presence of a capsule does
not prevent adsorption. The incidence of compromised adsorption of phage K in the bank of
staphylococci in this study was quite low (1.7%). Overall this chapter highlighted the lowincidence of resistance to phage K. in S. aureus. The majority of strains which were resistant to
phage K encoded r-m systems, which could be circumvented to generate modified derivatives of
phage K with a broader host range than the parent phage K. The work described here highlights
the importance of considering phage resistance when designing phages for biocontrol
applications.
Chapter 5 describes the utilization of the above modified phage cocktail for the prevention of
biofilm fonnation and the disruption of established biofilms of lV. aureus Xen29, a known
biofilm forming strain. Microorganisms in a biofilm are known to exhibit a tolerance to
antibiotics, disinfectants, and germicides of up to 1000 fold greater than their planktonic
counterparts (Donlan and Costerton 2002; Cerca et ai, 2005; Hoiby et ai, 2010). Consequently,
effective elimination of biofilms is often compromised and the physical removal of colonised
medical devices from patients may be necessary (Jansen et ai, 1992). Results showed that the
phage combination used in this study completely prevented biofilm formation over a 48 h period.
Also, this cocktail had the ability to lyse and disrupt mature established biofilms of X aureus.
This killing of biofilm cells and subsequent reduction in biofilm biomass occurred in a time
dependant manner, with a significant increase in biofilm removal noted after 72 h in comparison
to that noted after 24 h and 48 h. These results indicate that the phage cocktail developed in
chapter 4 may have considerable potential as a coating agent for medical devices for biofilm
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prevention. It is worthy of mention that phage K has been previously shown by our group to
retain its lytic activity in a bismuth-based cream (O’Flaherty et ai, 2005), suggesting that the
cocktail would be amenable to such applications.
In addition, preliminary inflammatory response assays using primary human umbilical vascular
endothelial cells (HUVHCs) were performed. Stimulation of these cells with phage K at litres
ranging from 10 - 10

PFU/ml did not promote expression of the genes for the adhesion

modeculcs Inter-Cellular Adhesion Molecule 1 (ICAMl), Vascular Cell Adhesion Molecule I
(VCAMl), endothelial-leukocyte adhesion molecule 1 (Fi-selectin), the transcriptional activator
Cyclooxygenase-2 (Cox-2), or the cytokines Chcmokine (C-X-C motif) ligand 1 (CXCLl),
Interleukin 32 (1L32) or Interleukin 8 (IL8). Interestingly, this finding indicates that
ullracenlrifuge preparations of purified phage K did not stimulate an immune response in these
cells, and hence that phage K may indeed be applicable to systematic infection control without
inducing a significant immune response. Future assays with phage K and functional primary
human blood monocytes (PBMCs) may further contribute to findings on its suitability for such
applications.
In summary, this thesis describes the successful isolation and characterization of novel phages
with applications in the medical/vcterinary sector and also in the food and beverage industry.
Whether for elimination of problematic spoilage bacteria, or pathogens, phages can be
considered excellent alternatives to current antimicrobial strategies. It is likely that their
exploitation will increase in the future, and thus this thesis contributes to their understanding and
successful application.
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